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1
HisTory
In 1935, Edward Derrick described a series of cases with a febrile, probably infectious, 
illness among abattoir workers in Brisbane, Australia. He believed it was a distinct clinical 
entity, because blood cultures remained negative in every case. Therefore, he chose to 
name it, ‘Q’ fever (from Query) ‘until fuller knowledge should allow it a better name’ [1]. 
To date, although knowledge about this illness has evolved tremendously, this Q has not 
been replaced by any other name, as ‘Query’ still holds true. 
bacTeriology
The causative agent of Q fever is Coxiella burnetii, a small coccobaccillus of approximately 
0.4-1 µm in size that has the cell wall characteristics of a Gram-negative bacterium. It is 
an obligate intracellular organism in vivo and it has a tropism for myeloid cells [2]. Phylo-
genetically, it is classified in the order of Legionellales and the group of γ proteobacteria 
[3]. Coxiella burnetii has several distinctive characteristics that enable its survival. The first 
feature, its high transmissibility, is partially due to the two morphological forms in which C. 
burnetii exists. The Small Cell Variant (SCV) is a metabolically inactive spore-like form that 
can resist harsh environmental conditions and spreads easily [4]. The SCV can survive on 
clothing, meat, and in milk and SCV’s have sporadically been isolated from formaldehyde 
stored tissues [5]. Upon the acidic but relatively safe environment of the phagocytic cell, 
the SCV transforms into the metabolically active Large Cell Variant (LCV) with the capacity 
to replicate. In-vitro, the generation time is estimated to be 20-45 hours [5]. Another 
noticeable feature is the antigenic (or phase) variation of its lipopolysaccharide (LPS) [6]. 
In nature, phase I with a smooth LPS is found, which acts as a virulence factor. Cultur-
ing multiple passages under laboratory conditions results in an antigenic shift driven by 
chromosomal deletions in the genes for LPS, which becomes truncated of the O-antigen. 
This phase variation results in a less competent phase II bacterium, which is easily recog-
nized and killed by host cells. These features, transmissibility, environmental stability and 
virulence, have led to the classification of C. burnetii as a category B biological threat agent 
[7]. Even though it is unlikely to be associated with life-threatening disease on a large scale, 
a bioterrorism attack would cause significant disability. 
epidemiology
Q fever is a zoonosis and is transmitted from animals to humans. Although many animals, 
including ticks, cats and birds can become infected, domestic small ruminants (sheep and 
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goats) are the main source of human infection [8]. Q fever is prevalent world-wide, except 
for New Zealand [9]. Many countries are either endemic for Q fever or experience local 
outbreaks. In countries where Q fever is endemic, cases occur after risk activities, mostly 
related to contact with livestock [10]. High seroprevalence is known in Australia [11, 12], 
Africa [13] and in French Guiana [14], which potentially puts travelers at risk [15]. Out-
breaks can occur after dissemination of spores from infected livestock farms by the wind 
to urban areas, usually during lambing season [16, 17]. An interesting Q fever outbreak 
occurred after intramuscular injection of fetal sheep cells by a German doctor as part of a 
controversial “live cell therapy” advertised to treat various health problems [18]. Because 
of the non-typical presentation and the diagnostic issues, many smaller Q fever outbreaks 
may go unrecognized. 
In 2007-2010, the Netherlands experienced the largest Q fever outbreak in the world [19, 
20]. More than 4.000 cases were reported and it was estimated that approximately 40.000 
individuals have been infected [21]. Although every province has faced Q fever cases, the 
epidemic was concentrated in the South-East part of the country, where large-scale dairy 
goat farms in densely-populated areas were eventually identified as the source of the 
epidemic [22, 23]. The epidemic came to an end after the implementation of hygienic 
measures, culling of pregnant goats and mandatory vaccination of other dairy goats [24]. 
In 2011, almost 1400 individuals at risk for developing chronic Q fever living in the high 
incidence area were vaccinated with the Australian ‘Q-vax’ vaccine that is not approved for 
regular use in the Netherlands [25]. Pre-vaccination screening was required as a previous Q 
fever infection increases the risk for adverse events. Among the individuals at risk screened 
for Q fever, 389 individuals had serological evidence of a previous Q fever infection but 
were apparently cured without any intervention [26]. A large group of these individuals 
participated in our studies on risk factors for progression to chronic Q fever [27-30]. 
clinical manifesTaTions
acute Q fever
Following the inhalation of infected particles, about 60% of individuals develop an as-
ymptomatic infection. The incubation period ranges from one to three weeks. In most 
symptomatic cases, individuals present with either flu-like illness, pneumonia or hepatitis 
[31]. Typical symptoms are fever, headache and cough, but they probably depend on 
region, infective strain and host factors. In reality, symptoms and signs often remain 
non-specific and acute Q fever cannot be differentiated from other febrile illnesses based 
solely on symptoms and signs [32]. In the first days of the infection, the bacterium may be 
identified by PCR in serum or may rarely be cultured, which requires stringent laboratory 
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culture conditions [33, 34]. After two weeks, anti-C. burnetii phase II IgM can be detected 
in serum. Usually, phase II IgG is detectable around the same time, after which phase I 
IgM and phase I IgG follow quickly. IgM may remain detectable for a long time after the 
acute infection and is thus insufficient to diagnose acute Q fever [35]. The diagnosis can 
be made using two consecutive serum samples with a two-week interval, showing either 
seroconversion or a fourfold rise in antibodies [2, 35]. More rare clinical phenotypes have 
also been described, including lymphadenitis, myocarditis and pericarditis. Acute Q fever is 
usually self-limiting and the mortality rate is less than 1% [36, 37]. 
chronic Q fever
Chronic Q fever or persistent focalized C. burnetii infection is characterized by persistence 
of C. burnetii mostly at specific predilection sites. Both symptomatic and asymptomatic 
acute infection may progress to chronic Q fever in 1-5% of cases and the persistence of the 
bacterium depends on bacterial factors (such as virulence) and host factors [8]. Risk factors 
for chronic Q fever can be divided into general host factors that harbor a slightly increased 
risk; focalized risk factors, which are almost conditionally present; and immunological 
factors that contribute to the susceptibility and may provide a ‘tipping point’ to develop 
chronic Q fever in individuals who are otherwise immunocompetent. 
As for general risk factors, it has been known for a long time that men are more suscep-
tible to chronic Q fever. A history of smoking is a risk factor, as is renal insufficiency and 
age above 60 years [38, 39]. The strongest predictors for progression to chronic Q fever 
are focalized risk factors such as valvulopathy and vasculopathy related to the preferred 
localization of persistent C. burnetii infection. In France, preexisting cardiac valvulopathy, 
and especially prosthetic valves, have been estimated to lead to chronic Q fever in 39% 
of cases [38, 40]. In the Netherlands, the risk of progression to chronic Q fever in infected 
individuals with preexisting cardiac valvulopathy appeared to be only 7% and degenerative 
valvular disease (without the presence of prosthetic valves) was not found to be associ-
ated with the progression to chronic Q fever [41]. In contrast, aortic aneurysms or aortic 
prostheses posed, with a 30% chance of developing chronic infection, a greater risk than 
foreseen [42]. Prostheses, both valvular and vascular proved to be strongly associated with 
the risk of chronic Q fever [38, 40]. Pregnancy, which may be both a focalizing and im-
munological risk factor, has been reported to be associated with chronic Q fever and poor 
fetal outcome in France [43-46], although the risks were limited during the Dutch Q fever 
outbreak [47, 48]. The difference in preferred localization of persistent C. burnetii infec-
tion in France and the Netherlands could be related to transmission and microbiological 
factors. Genome comparison of the predominant strain in the Dutch outbreak, NL3262 of 
the CbNL01 genotype, with several other C. burnetii strains, suggests increased genome 
plasticity and mutations in genes related to the evasion of the host immune system [49].
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An immunocompromised state is regarded as a risk factor for chronic Q fever, a specific 
definition of the immunocompromised state and the type of immunosuppressive drugs 
are not apprehended [50]. Anti-TNF-α therapy does not increase the risk for development 
of chronic Q fever in rheumatoid arthritis patients, although the conversion to chronic 
Q fever is higher in rheumatoid arthritis patients with and without immunosuppressive 
therapy (9%) compared to the general population [51, 52]. Long-term corticosteroid use 
may increase the risk for progression to chronic Q fever [53]. These risk factors have only 
been studied in very small groups, including patients with high dose of prednisone use, 
TNF-α inhibitors, methotrexate, mycofenolate mofetil, a patient with splenectomy [39] and 
a patient with myelodysplastic syndrome [54]. Cases of chronic Q fever have been reported 
in patients with leukemia, cancer [55], human immunodeficiency virus infection (HIV) [56] 
and renal transplants [57]. 
Other immunological factors can predispose to chronic Q fever, in the presence of traditional 
focalized risk factors such as valvulopathy and vasculopathy. It is therefore worthwhile to 
investigate which processes explain that some individuals, despite their risk factors and C. 
burnetii exposure, do not progress to chronic Q fever. Immunological factors related to C. 
burnetii immune response may be both protecting and risk-inferring. Previously, several 
genetic host factors related to immune response have been associated with increased risk 
of chronic Q fever. Small variations in genes responsible for the recognition of C. burnetii 
by pattern recognition receptors conferred an increased risk of progression to chronic Q 
fever [27]. Variations in a gene, IL12B, a driver of the interferon pathway also showed 
an association with chronic Q fever [29]. It is conceivable that other yet unidentified im-
munological factors predispose to chronic Q fever. 
symptoms
Less than half of the chronic Q fever patients recall an episode of acute Q fever infec-
tion [54]. During the persistent infection, fever is the most common presenting symptom 
(23-100%), followed by weight loss (11-100%), hepatosplenomegaly (11-90%) and night 
sweats (26-100%). Abdominal pain and lumbar pain have been described as well [50]. The 
persistent infection may very well remain asymptomatic (6-78%) until a life-threatening 
complication such as aortic rupture occurs [50]. 
diagnosis
The diagnostic approach for chronic Q fever is based on risk factors, symptoms, imaging, 
immunological and microbiological findings [50]. Yet, in many patients, these findings 
do not lead to a definite diagnosis. Anti-C. burnetii phase I IgG ≥1:1024, determined by 
immunofluorescence assay (IFA), indicates a possible chronic Q fever infection [58]. In the 
presence of risk factors, such as valvulopathy, aneurysms, or aortic prostheses or an im-
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munocompromised state, the clinical likelihood of a persistent chronic Q fever infection is 
higher, even though imaging techniques may not show signs of an infection. Symptoms of 
a chronic infection, such as fever, weight loss and night sweats also add to a higher clinical 
suspicion of a chronic infection. Therefore, patients with either risk factors or symptoms 
in addition to high serological titers have a probable chronic Q fever infection. Infection 
can be proven if endocarditis or vascular infection are visualized by imaging techniques. 
18F-FDG-PET/CT has recently proven its usability in the diagnosis of chronic Q fever [59]. A 
definite diagnosis can also be made when a PCR for C. burnetii is positive in blood or tissue 
in the absence of an acute infection. 
Early treatment and thus early diagnosis is paramount. All current diagnostic tools for 
microbiological evidence have important shortcomings, for instance the limited sensitivity 
of the PCR in serum, multiple cut-off values for serology titers and high interlaboratory 
differences [33]. PCR on serum and culture directly demonstrate the presence of the bac-
terium. However, PCR on serum is troublesome with intracellular bacteria. Culture has 
its difficulties as C. burnetii is slow-growing and requires stringent conditions in a BSL3 
facility. By determining anti-C. burnetii antibodies, ongoing infection with C. burnetii is 
demonstrated by measuring the output of the humoral adaptive immune system, assuming 
that the higher the output, the more likely it is that an infection persists. Apart from techni-
cal difficulties, it is debatable that the activity of the humoral adaptive immune response 
adequately reflects persistent infection with an intracellular bacterium in (resident tissue) 
macrophages. With this in mind, the IFNγ production assay was developed, measuring the 
specific C. burnetii induced IFNγ response in ex-vivo stimulated whole blood. Sensitivity 
and specificity of this test are very promising with regard to detecting a previous Q fever 
infection [28]. The C. burnetii specific IFNγ/IL-2 production ratio had a sensitivity of 79% 
and a specificity of 96% to diagnose chronic Q fever [60]. The place of these tests in the 
diagnosis of previous or chronic Q fever still needs to be investigated. Despite these recent 
promising developments, new diagnostic markers are necessary and the IFNγ production 
assay has paved the way for new immune markers. 
Treatment, complications and outcome
Immediately after diagnosing a patient with chronic Q fever, a regimen of doxycycline 
(100mg, 2 times daily) and hydroxychloroquine (200mg, three times daily) should be 
started [61-64]. Achieving a doxycycline serum concentration of 5mg/L is associated with a 
better outcome [65]. This is the preferential therapy, although recent studies show that the 
replacement of doxycycline by moxifloxacine may have equal results [64]. The addition of 
hydroxychloroquine is paramount, as it increases the pH of the Coxiella Containing Vacu-
ole, improving the efficacy of doxycycline which is then able to exert bacteriocidal effects 
[62, 66]. Therapy needs to be continued for at least 18 months or 24 months in case of the 
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presence of prosthetic material, as recurrence of the bacterium can occur at shorter therapy 
duration [63]. Generally, reaching a fourfold decrease in specific anti-C. burnetii IgG phase 
I titers after the minimal treatment duration is assumed to be sufficient as is reaching the 
cut-off for a chronic infection: phase I IgG of 1:1024 [63] in combination with absence 
of active infection on imaging. Treatment duration must be tailored personally as some 
individuals fail to reach the described stop criteria. Usually, an offensive treatment strategy 
is adopted to avoid recurrence of this life-threatening infection. In some individuals, long 
term suppressive antibiotic therapy rather than curative therapy is conducted. As in other 
chronic infections [67], antibiotic therapy failure promotes an alternative approach, aug-
menting the immune response to the specific pathogen. Supplementary immunotherapy 
seems logical in individuals with genetic deficiencies for certain cytokines, but may also 
aid individuals with more subtle immunodeficiency or a non-productive immune response 
which may be present in chronic Q fever. 
Chronic Q fever has a poor prognosis, with a mortality up to 38% in the Dutch chronic Q 
fever cohort [68]. This can be attributed to the high rate (61%) of devastating complica-
tions, occurring mostly within 6 months after diagnosis of chronic Q fever, but sometimes 
years after the diagnosis. Complications that occur most frequently are acute aneurysms, 
heart failure, abscesses, aorto-enteral fistula, and spondylodiscitis [69]. The presence of 
prosthetic material or a positive PCR in blood are risk factors for complications (data from 
the nationwide Q fever cohort). Surgical intervention is therefore often necessary, either to 
treat complications in an acute setting [69], or to remove the infectious tissue or prosthesis 
to aid antibiotic therapy [61, 70]. 
Qfs
In about 20% of cases with symptomatic acute Q fever infection, the symptoms of infection 
such as fatigue, muscle ache and malaise do not resolve after more than 6 months. This 
condition, in which the immune system has successfully eradicated the bacterium, is named 
Q fever fatigue syndrome [71]. It resembles other post-infectious fatigue syndromes, with 
the difference that there are stronger somatic attributions and other symptoms besides 
fatigue may preponderate [72]. Several different hypotheses arise on the etiology of this 
syndrome, in which a persistent immune response is assumed to play a role, for instance 
persisting antigenic stimulation, or epigenetic reprogramming of monocytes by Coxiella 
burnetii. Diagnosis is based on several criteria, of which the most important criteria are 
a symptomatic acute Q fever infection after which severe fatigue with or without other 
symptoms persist, a chronic Q fever infection is ruled out, and the symptoms cannot be 
attributed to other diseases [71]. Consistent with the successful eradication of the bacte-
rium, doxycycline does not improve the fatigue complaints, whereas cognitive behavioral 
therapy may result in partially resolved symptoms [73]. 
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THe inTerplay of THe HosT immune response and c. 
burneTii evasion
Usually, Coxiella burnetii enters the lung with aerosolized particles and will, as an intracel-
lular bacterium, specifically target cells of the myeloid lineage. In the lungs, these cells 
are the alveolar macrophages. Coxiella binds to the αvβ3 integrin receptor (CD51/CD61) 
and the complement receptor 3, in a C3b independent manner, and will subsequently be 
taken up by phagocytosis accompanied by membrane ruffling and pseudopodal extensions 
caused by mobilization of the actin cytoskeleton [74]. Several extracellular and intracellular 
pattern recognition receptors are involved in the recognition of C. burnetii, for instance 
Toll-like receptor (TLR) 1, TLR2, TLR4, TLR6 and NOD2 [75-77]. TLR4 remains to be an in-
teresting receptor, which is thought to be activated by Coxiella LPS. However, even though 
cytokine production is impaired in TLR4 knock-out models, it does not affect the C. burnetii 
clearance. Furthermore, the Coxiella LPS lipid A compound may actually antagonize TLR4, 
thereby serving as an immune stealth factor [76, 78]. Downstream mediators of these 
pattern recognition receptors are MAPKs such as P38, JNK and ERK [76]. 
The phagolysome in which Coxiella burnetii survives is called the Coxiella Containing 
Vacuole (CCV). As with regular phagosomes, different effector molecules are involved 
in the process of recruitment and maturation of lysosomal vesicles. These processes are 
regulated by, amongst others, Rab5, Rab7, EEA1, LAMPs and cathepsins and result in 
the acquisition of microbicidal properties. [79, 80]. Coxiella is able to persist inside pha-
golysosomes, despite the low pH and other microbicidal features. Furthermore, the acidic 
environment is necessary to transform from a spore-like form into the large cell variant, 
and with it the activation of its main virulence factor, the T4SS (secretion) system [81]. 
Coxiella effector molecules are pumped into the cytosol, where they can manipulate the 
host immune response and cell metabolism, such as reactive oxygen species production, 
autophagy and apoptosis. Reactive oxygen species and nitrogen species production are 
involved in the killing of C. burnetii, although C. burnetii has adopted strategies to prevent 
this by detoxification using superoxide dismutase, catalase and acid phosphatase [82, 83]. 
The autophagy pathway, which degrades cell organelles and also has a role in defense 
against intracellular bacteria, is exploited by C. burnetii. Experimental overexpression of 
autophagy genes proved to be beneficial for C. burnetii replication and the CCV is known 
to adopt the LC3 marker for autophagy [84]. Enhancement of C. burnetii survival through 
the autophagy pathway could be accomplished in different ways. Nutrient-rich autopha-
gosomes are recruited to the CCV and this recruitment delays the acidification, providing 
the necessary time to morphologically switch from a SCV to a LCV form, aided by the T4SS 
system [84-87]. Apoptosis of the host cell is also actively prevented by C. burnetii through 
recruitment of Beclin-1, ensuring its own survival in his intracellular niche [88]. 
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In response to C. burnetii, macrophages and monocytes produce proinflammatory cyto-
kines, such as TNF-α, interleukin (IL)-1β and IL-6. They also produce the anti-inflammatory 
cytokine IL-10 [60, 89, 90]. Dendritic cells will present Coxiella peptides on their MHCII 
molecules and migrate to the lymph nodes, where they can activate naïve T-cells. The pres-
ence of LPS from phase I pathogens partially impairs maturation of dendritic cells, reducing 
their interferon-producing capacity and HLA-DR expression. Despite this, after contact with 
C. burnetii, dendritic cells are able to activate naïve T-cells [91-93].
Eventually, B-cell activation leads to antibody production, mostly IgG subclass 1 and 3 [94]. 
The role of antibodies in the immune response to C. burnetii is much debated. In guinea 
pigs, passive transfer of anti-C. burnetii antibodies conferred protection from subsequent 
infection [95]. However, antibodies from chronic Q fever patients in-vivo do not seem to 
be able to eradicate the infection, while in-vitro, antibody-mediated opsonisation may 
even lead to increased replication in macrophages, although this could not be confirmed 
by another study [96, 97]. Whatever the role of anti-C. burnetii antibodies may be, it is 
generally recognized that cell-mediated immune responses are the principal component of 
an effective immune response to C. burnetii. 
Activated T-cells of individuals that have endured a Q fever infection produce the cytokine 
IFNγ [28]. It is evident that IFNγ is an indispensable cytokine for C. burnetii control as it has 
the ability to activate macrophages and promote their killing capacity [98-100]. Studies 
in mice have shown that CD4+ T-cells alone are indeed capable of controlling C. burnetii 
infection which may be attributed to their IFNγ-producing capacity, but in the absence 
of CD4+ T-cells, CD8+ T-cells are also able to inhibit bacterial replication most likely by 
perforin-mediated cytotoxicity of infected cells [101, 102]. A hallmark of a past (cured) 
Q fever infection is the presence of granulomas. Granulomas are organized structures of 
different cell types and macrophages are the central cell type that define the granuloma. 
Q fever granulomas are characterized by a paucibacillary center with a lipid vacuole sur-
rounded peripherally by a fibrinoid ring, giving it the appearance of a doughnut. They 
contain giant cells, epitheloid macrophages and neutrophils [103, 104]. The chemokines 
MCP1 and RANTES have been shown to be necessary for C. burnetii induced granuloma 
formation [105, 106]. For Coxiella burnetii induced granuloma formation in-vitro, both 
monocytes and T-cells are indispensable. Monocytes initiate the granulomatous response 
by interacting with C. burnetii, while complete granuloma formation requires early recruit-
ment of T-cells [107].
immune response in chronic Q fever patients
During the Q fever outbreak in the Netherlands, many individuals with risk factors – e.g. 
pre-existing heart valve disease or dilating aortic disease – were infected. Only a part of 
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these individuals (7-30%) developed chronic Q fever, while others successfully cleared the 
infection without intervention [41, 42]. Additional risk factors or protective mechanisms 
may thus be of importance for the development of persistent C. burnetii infection. The 
contribution of the immune response has been studied, but remains elusive. Key factors 
in the response to C. burnetii are the recognition, intracellular processing in myeloid cells, 
establishing an inflammatory reaction by recruitment of appropriate immune cells and the 
adaptive cellular immune response leading to the actual killing of C. burnetii. 
As to the recognition, several polymorphisms in genes of pattern recognition receptors 
that are involved in the recognition of C. burnetii have been identified that predispose 
to chronic Q fever or protect against the persistent infection (R80T in TLR1, 1007fsX1 in 
NOD2, and -930C>A in MyD88) [27]. Carrying the risk alleles of TLR1 R80T also influ-
ences cytokine response to C. burnetii [27, 108]. After recognition, C. burnetii inhabits the 
phagolysosome. Whether chronic Q fever patients have an altered intracellular processing 
of C. burnetii is unknown. It has been reported that chronic Q fever patients fail to recruit 
cathepsin D to the late phagolysosome [109], however, Q fever naïve individuals harbor 
cathepsin D devoid phagolysosomes as well. Another study describes the survival of C. 
burnetii despite complete maturation of the C. burnetii containing phagolysome [110]. 
As to the constitution of the cell types in chronic Q fever patients, several differences 
can be appointed. Chronic Q fever patients with endocarditis have less intermediate and 
non-classical monocytes circulating in venous blood, while classical monocytes, which are 
usually more capable of producing cytokines, are equally present in healthy controls. The 
circulating monocytes of chronic Q fever patients express the activation marker HLA-DR 
in a similar manner as controls [111]. The monocytes of chronic Q fever patients with 
endocarditis upregulate several genes, such as ALOX15, CLEC4F, CCL13 and CCL23, en-
coding for, respectively, lipoxygenase, a C-lectin type domain receptor and chemokines. 
These genes are selectively upregulated by chronic Q fever patients and not by acute Q 
fever patients [112]. Evidence of NK cell contribution to chronic Q fever is scarce. NK-cell 
deprived mice challenged with C. burnetii do not have a higher mortality, but they do 
show more severe histopathological lesions [98]. In chronic Q fever patients, a subset of NK 
cells, CD56dim, are decreased as compared to healthy controls [113]. CD56dim NK cells are 
predominantly present in blood and known for their strong cytolytic capacity as compared 
to their CD56bright counterparts who reside in lymphoid tissue and are known for their 
cytokine secretion [114]. The significance of this finding is unknown, especially as the role 
of NK-cells in chronic Q fever is not established.
Initially, chronic Q fever was thought be an inflammatory disease. This notion was derived 
from the high levels of TNF-α, IL-6 and IL-1β produced by peripheral blood mononuclear 
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cells of chronic Q fever patients upon stimulation with C. burnetii [115]. Later, it was rec-
ognized that this proinflammatory cytokine production was accompanied by even higher 
levels of anti-inflammatory cytokines, among which are IL-1Ra, IL-10 and TGF-β [116, 117]. 
Of these, IL-10 is the most studied and possibly the most interesting cytokine in relation 
to the evolution of chronic Q fever [111, 116, 118, 119]. Excessive anti-inflammatory re-
sponses may be central to the pathogenesis of chronic Q fever. There are some indications 
that high IL-10 production is not merely the result of high inflammatory markers, but also 
underlies the sustained immunosuppressive responses. One of the most important is that 
individuals with pre-existent heart disease already have higher circulating IL-10 during their 
acute Q fever infection compared to healthy individuals who are not at risk for a chronic 
infection. The individuals with vasculopathy who had high IL-10 levels indeed went on to 
develop chronic Q fever [118]. Moreover, immune cells of chronic Q fever patients produce 
more C. burnetii induced IL-10 compared to individuals cured of a Q fever infection. The 
importance of IL-10 in the evolution of chronic Q fever may be related to differences in 
strains or population, as the excessive production of IL-10 in chronic Q fever patients 
related to C. burnetii could not be corroborated in a Dutch study [60]. The mechanism 
by which IL-10 exerts its effects may be multiple. One study indicates IL-10 as a driver 
of incomplete phagolysosomal maturation by inhibiting cathepsin D in chronic Q fever 
patients. [109]
As similarities with Mycobacterium tuberculosis are evident and the crucial role of IFNγ was 
established, studies focused on possible deficiencies in the IFNγ pathway that could explain 
bacterial persistence in chronic Q fever patients. In contrast to the initial hypothesis, IFNγ 
is abundantly produced by chronic Q fever patients upon stimulation with C. burnetii and 
the entire IFNγ pathway seems to be intact. Nevertheless, two polymorphisms in IL12B are 
associated with the progression to chronic Q fever [28, 29, 60, 120]. This abundance of 
pro-inflammatory cytokine production can be attenuated by counter-mechanisms. Circu-
lating regulatory T-cells are more prevalent in chronic Q fever patients than in past Q fever 
infected individuals. Interestingly, IL-10 is a strong inducer of regulatory T-cell proliferation 
[121]. Circulating CD4 + T-cells of chronic Q fever patients have also been described to 
carry the molecule PD-1 on their membrane, a co-inhibitory marker on exhausted T-cells 
that, upon engagement with PD-1 ligand on target cells, ensures survival of the target cell 
and apoptosis of the PD-1 expressing T-cell [111]. Whether these two immune regulatory 
mechanisms sustain the persistent infection or represent appropriate counter mechanisms 
that prevent autoimmunity, remains elusive. An interesting notion is that circulating naïve 
CD8+ T- cells, whose role in chronic Q fever also has not been established yet, are less 
present in peripheral blood of chronic Q fever patients. This may be explained by an altered 
distribution, for instance to lymphoid tissues. In 1985, however, decreased capacity of 
lymphocyte proliferation of T-cells from chronic Q fever patients to Coxiella antigens was 
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noted. This was attributed to prostaglandin produced by monocytes from chronic Q fever 
patients, mediated by an unknown lymphocytic factor [122]. Diminished proliferative ca-
pacity of T-cells through prostaglandin may be due to the inhibitory effect of prostaglandin 
on the cytokine IL-2. Only recently, it is recognized that IL-2 production by chronic Q fever 
patients is strongly decreased compared to individuals that have successfully cleared the 
infection [60, 120]. 
Inappropriate cell recruitment to the site of infection may also hamper an efficient immune 
response. Granuloma formation is considered an effective response by confinement of the 
infection and is driven by chemokines. Chronic Q fever has been associated with defective 
granuloma formation [107]. Chronic Q fever patients however produce copious amounts 
of RANTES and MCP-1, two chemokines that are important for granuloma formation 
[106]. Controversially, histopathological investigation of C. burnetii infected aneurysm 
tissue displayed a granulomatous response in the vascular wall in four of seven chronic Q 
fever patients [123]. Indeed in-vitro, cells of chronic Q fever patients were not or only par-
tially able to form granulomata. Deficient granuloma formation of chronic Q fever patients 
occurred in the early stages and was related to defective monocyte migration [107].
Despite the vastly expanding knowledge on the immune response to C. burnetii of chronic 
Q fever patients, the exact mechanisms underlying bacterial persistence in a small group 
of apparently immunocompetent individuals remain to be elucidated. Several questions 
remain to be answered in relation to susceptibility to chronic Q fever, diagnosis and treat-
ment and accompanying problems. 
ouTline of THesis
This thesis aims to create a better understanding of immunological factors related to 
susceptibility, diagnosis, complications and treatment of chronic Q fever infection. Two 
aspects of the immune system will be addressed. The first part will concentrate on the 
defective immune responses to C. burnetii of chronic Q fever patients leading to bacterial 
persistence and the immunological markers associated with diagnosis and treatment. The 
second part will focus on an aberrant overreaction of the immune response with the failure 
of self-tolerance, i.e. autoimmune diseases and other immunological phenomena that may 
accompany Q fever infection. Ultimately, knowledge of immunological risk factors may 
lead to preventative strategies for those that are most at risk. The assessment of additional 
markers that indicate ongoing immune responses may result in improved diagnosis and 
access to therapy. Immunotherapy may support the available antibiotic therapy and surgi-
cal interventions, most prominently for those patients that are therapy-resistant. Finally, 
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understanding immunological epiphenomena of Q fever may prevent these phenomena 
from interfering with diagnosis, monitoring and treatment. 
parT 1  cHronic Q fever suscepTibiliTy, diagnosis, and 
TreaTmenT 
1. Viable Coxiella burnetii induces differential cytokine responses in chronic Q fever patients 
compared to heat-killed Coxiella burnetii
2. Involvement of matrix metalloproteinases in chronic Q fever
3. Genetic variations in innate immunity genes affect response to Coxiella burnetii and are 
associated with susceptibility to chronic Q fever
4. CXCL9, a promising biomarker in the diagnosis of chronic Q fever
5. Failure of interferon-gamma treatment in a patient with chronic Q fever
parT 2  immunological epipHenomena during 
cHronic Q fever
6. Autoimmunity and B-cell dyscrasia in acute and chronic Q fever: a review of the literature
7. Chronic Q fever associated with Systemic Sclerosis
8. Autoimmunity and cryoglobulinemia in patients with chronic Q fever: a retrospective 
cohort study
part 1
In chapter 2, I conducted experiments in a BioSafety Level 3 laboratory with viable and 
heat-killed C. burnetii to assess whether research with heat-killed bacteria can be trans-
lated to viable bacteria. We also explored whether chronic Q fever patients and healthy 
individuals react differently to viable and heat-killed C. burnetii. 
In chapter 3 we used an integrative approach to examine the role of matrix metal-
loproteinases in chronic Q fever. Matrix metalloproteinases or MMPs are enzymes that 
cleave extracellular matrix, they are activated during infection, but also associated with 
symptomatic aneurysms. 
In chapter 4, the pathogenesis of chronic Q fever is further explored with genetic analysis 
by determining which factors in the innate cellular immune response contribute to the 
progression of chronic Q fever.
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The diagnosis of chronic Q fever mostly relies on anti-C. burnetii antibodies that have 
several limitations. In chapter 5, we identified promising biomarkers in an unbiased ap-
proach and examined their differentiating capacity in ex-vivo stimulated whole blood and 
serum of chronic Q fever patients and seropositive controls. 
In many cases, adequate therapy of chronic Q fever remains a challenge. Adjunctive host-
directed therapy may provide a solution. In chapter 6, we supplemented one therapy 
resistant patient with IFNγ and closely followed the clinical response with immunological 
and imaging studies. 
part 2
In chapter 7, I provide a systematic review of the literature on previously reported autoim-
mune diseases and other immunological phenomena following Q fever infection. 
In chapter 8, we describe four cases of chronic Q fever with concurrent systemic sclerosis, 
a severe immune mediated disease characterized by fibrosis, vasculopathy and auto-
antibodies. 
These and other puzzling immunological phenomena were found in chronic Q fever patients 
presenting at the outpatient clinic. To map these phenomena and to create awareness of 
the immunological manifestations and their consequences for chronic Q fever diagnosis, 
monitoring and treatment, we conducted a retrospective study with chronic Q fever pa-
tients treated at the Radboud university medical center Nijmegen, described in chapter 9.
Chapter 10 includes a summary and discussion of this thesis.
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absTracT
Cytokine responses of chronic Q fever patients to the intracellular bacterium Coxiella 
burnetii have mostly been studied using ex-vivo stimulation of immune cells with heat-
killed C. burnetii due to the extensive measures needed to work with viable BioSafety 
Level 3 agents. Whether research with heat-killed C. burnetii can be translated to immune 
responses to viable C. burnetii is imperative for the interpretation of previous and future 
studies with heat-killed C. burnetii. Peripheral blood mononuclear cells (PBMCs) of chronic 
Q fever patients (n = 10) and healthy controls (n = 10) were stimulated with heat-killed 
or viable C. burnetii of two strains, Nine Mile and the Dutch outbreak strain 3262 for 
24 hours, 48 hours and 7 days, in the absence or presence of serum containing anti-C. 
burnetii antibodies. When stimulated with viable C. burnetii, PBMCs of chronic Q fever 
patients and controls produced less pro-inflammatory cytokines (IL-6, TNFα, IL-1β) after 
24 hours compared to stimulation with heat-killed C. burnetii. In the presence of Q fever 
seronegative serum, IL-10 production was higher after stimulation with viable as compared 
to heat-killed C. burnetii, however when incubating with anti-C. burnetii antibodies serum, 
the effect on IL-10 production was reduced. Adaptive, merely T-cell derived, cytokine (IFNγ, 
IL-17, IL-22) and CXCL9 production were not different between heat-killed and viable C. 
burnetii stimulatory conditions. Results of previous and future research with heat-killed C. 
burnetii should be interpreted with caution for innate cytokines, but heat-killed C. burnetii-
induced adaptive cytokine production is representative of stimulation with viable bacteria. 
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inTroducTion
Coxiella burnetii is the causative micro-organism of Q fever, a highly infectious zoonosis 
that is prevalent world-wide. Infection is contracted by inhalation of contaminated aerosols. 
After inhalation and infection, the obligate intracellular growing C. burnetii invades the 
alveolar macrophages. Replication and outgrowth of Coxiella takes place in a peculiar com-
partment called the Coxiella containing vacuole (CCV) within macrophages or monocytes 
[8]. Unlike other intracellular bacteria, C. burnetii does not try to escape phagolysosomes, 
but instead uses the acidic compartment to activate an important virulence factor, the type 
IV secretion system (T4SS), through which it modulates host cell metabolism and gene 
expression to enhance its CCV survival [87].
In humans, acute Q fever is most often associated with a relatively mild flu-like disease or, 
in some cases, pneumonia or hepatitis. Initial infection occurs asymptomatically in 60% of 
infections. In a minority of infected individuals, however, initial symptomatic or asymptom-
atic infection persists, often manifesting as an endocarditis or infection of an aneurysm or 
vascular prosthesis [8]. During such persistent infection, also referred to as chronic Q fever 
or persistent focalized Q fever infection [124], C. burnetii is not eradicated by the host 
immune response. Individuals with heart valve defects, aneurysms or vascular prostheses 
are susceptible to develop a persistent infection [38]. During the major Q fever epidemic 
in the Netherlands, approximately 30% of individuals with known aorto-iliac disease and 
serological evidence of Q fever infection developed chronic Q fever [42]. Therefore, an 
additional risk factor resulting in a defective systemic or local immune response, is likely to 
be required for the development of chronic Q fever. 
To evaluate the systemic immune response in chronic Q fever patients, various studies 
examined the cytokine and chemokine response to heat-killed C. burnetii. Nearly all these 
studies showed a robust innate cytokine response in chronic Q fever patients, with a 
strikingly more profound production of interferon-γ (IFNγ) than in Q fever seronegative 
controls, who lacked IFNγ response [29, 60, 91, 120]. Various studies also showed a higher 
production of anti-inflammatory interleukin-10 (IL-10) in chronic Q fever patients [109, 
111, 116, 118]. 
Due to its highly infectious nature, C. burnetii is classified as a Biosafety Level 3 (BSL3) 
agent [7]. Therefore, nearly all stimulation studies were performed with heat-killed C. bur-
netii or with the avirulent phase II organisms to prevent researchers from exposure and to 
circumvent complicated and expensive biosafety procedures. Whether results obtained in 
experiments with heat-killed bacteria can be translated to the immune response to viable 
C. burnetii, armed with tools to influence host cell metabolism, has not been evaluated.
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Therefore, in the present study, we compare the cytokine-inducing capacity of strains of 
heat-killed and viable C. burnetii in peripheral blood mononuclear cell (PBMC) cultures of 
chronic Q fever patients and healthy controls.
meTHods
subjects
Healthy controls (n = 10) were hospital personnel, all seronegative for Q fever tested by 
immunofluorescence assay (IFA). Chronic Q fever patients (n = 10) were recruited from 
the outpatient clinic of the Radboud university medical center Nijmegen. Patients were 
diagnosed according to the Dutch Consensus Guidelines on chronic Q fever diagnosis [50], 
this guideline categorizes diagnosis as either proven, probable or possible chronic infection 
and is based on serology, PCR, clinical symptoms, risk factors and diagnostic imaging. 
All patients fulfilled the criteria of proven chronic Q fever and were being treated with 
antibiotics, mostly doxycycline, and hydroxychloroquine, at the time of blood drawing. 
Patient characteristics are shown in supplementary table 1. Serum with anti-C. burnetii IgG 
phase I antibodies was drawn from a chronic Q fever patient with high IgG phase I titers 
(1: 4096) determined by IFA. Q fever naive serum was drawn from a healthy control that 
participated in the study.
bacteria
C. burnetii strains were cultured on Buffalo Green Monkey cells at Wageningen Bioveteri-
nary Research (former Central Veterinary Institute), the Netherlands, as described previ-
ously [125]. Two strains were used, the frequently used Nine Mile (RSA 493) strain, and the 
most prominent Dutch outbreak strain 3262, isolated in 2009 [126]. The Nine Mile strain 
is a laboratory strain isolated from a tick and generally used for research purposes [3]. The 
C. burnetii 3262 strain had been isolated from a goat during the Dutch epidemic and is 
pathogenic to humans.
Bacterial DNA, measured to quantify the amount of bacteria, was isolated using a DNA iso-
lation kit (DNeasy Blood & Tissue kit, Qiagen, the Netherlands). Quantification by qPCR was 
done as described by Roest et al. [126]. In brief, a single copy gene encoding a C. burnetii 
specific hypothetical protein (gene bank number AY502846) was targeted using the forward 
primer 5΄-ATAGCGCCAATCGAAATGGT-3΄, the reverse primer 5΄- CTTGAATACCCATCCC-
GAAGTC-3΄ and the NED-labeled probe 5΄-CCCAGTAGGGCAGAAGACGTTCCCC-3΄. To 
quantify the bacterial numbers, the commercially available C. burnetii standard positive 
control dilution series was used (Adiavet Cox, Adiagene, Marcy l’ Etoile, France). qPCR was 
performed on a 7500 Fast Real Time PCR system (Applied Biosystems, USA). After deter-
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mination of the amount of both Coxiella batches, they were brought to a concentration of 
4x107 bacteria/mL. The first half was heat-killed at 99⁰C for 30 min [34] while the second 
half remained viable. Both were aliquotted and frozen at -80⁰C until the experiment, which 
was performed within three months. Determination of C. burnetii gene copies at specific 
time points (4h, 24h, 48h, 7d) after stimulation experiments in frozen cell pellets was 
executed following the same DNA isolation and qPCR protocol as described above. 
peripheral blood mononuclear cell isolation and stimulation
PBMCs from all individuals were isolated according to a standardized protocol, described 
in detail by Oosting et al [127]. In short, cells were separated by density centrifugation 
with Ficoll Paque (GE Healthycare, Zeist, the Netherlands) and taken from the interphase 
layer and washed twice in cold Phosphate Buffered Saline. The cells were counted with 
Z1 Coulter Particle Counter (Beckman Coulter, Woerden, the Netherlands), brought to a 
concentration of 5x106 cells/mL in Roswell Park Memorial Institute medium 1640 (RPMI) 
(Life Technologies/Invitrogen, Breda, The Netherlands), supplemented with 2mM glutamax, 
and 1mM pyruvate without antibiotics. Cells were subsequently transported on ice to the 
BSL3 facility. In a round bottom 96-wells plate (Corning, New York, USA), 5x105 cells were 
incubated with 10% human serum, either Q fever naive serum or serum containing IgG 
phase I and II antibodies (original titers IFA 1:4096). Subsequently, the cells were stimulated 
with either 2x106 heat-killed or viable C. burnetii Nine Mile bacteria, and with heat-killed 
or viable 2x106 C. burnetii 3262 bacteria. The infection index i.e. ratio bacteria versus 
PBMCs was 4:1, the estimated number of bacteria per monocyte was 20:1, identical to 
that used in earlier studies on the measurements of cytokine production in chronic Q 
fever patients and healthy controls [60, 76]. Positive and negative controls were heat-killed 
Candida albicans conidia (105/mL) and culture medium, respectively. After 24h, 48h and 
7d, the supernatants were harvested after centrifugation and stored at -80⁰C. Cell death 
at 24h and 7d was assessed by measuring lactate dehydrogenase (LDH) in the supernatants 
using Cytotox96 non-radioactive cytotoxicity assay (Promega Corporation, Madison, WI, 
USA) and additionally at 7d by staining with Trypan Blue % and subsequent counting by 
microscopy. The remaining cell pellets were frozen at -80⁰C, to assess C. burnetii replica-
tion during the experiments. 
cytokine measurements
Cytokine concentration was measured at different time points in the PBMC culture super-
natants using enzyme linked immunosorbent assay (ELISA) according to the manufacturer’s 
instructions. After 24h, the concentration of Tumor Necrosis Factor α (TNF-α), interleukin-6 
(IL-6), interleukin-1β (IL-1β) and CXCL9 (R&D Systems, Minneapolis, USA) was measured. 
After 48h, the concentrations of interleukin-10 (IL-10) and IFNγ (Sanquin, Amsterdam, the 
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Netherlands) were determined. After 7d, the concentrations of IL-10, IFNγ and interleu-
kin-17 (IL-17) and interleukin-22 (IL-22) (R&D Systems) were measured.
statistical analysis
All data were analyzed using Graphpad Prism 5.0. Medians and interquartile ranges were 
calculated for cytokine production. Differences between cytokine production induced by 
heat-killed and viable bacteria were analyzed with a Wilcoxon signed-rank test. Differences 
in number of bacteria were analyzed by means of One-way ANOVA with Bonferonni post-
hoc-tests. A p-value below 0.05 was considered statistically significant. 
ethical consideration
This study was approved by the local institutional review board (CMO Arnhem-Nijmegen, 
NL35784.091.11). All subjects provided written informed consent.
resulTs
viable c. burnetii induces few cytokines in pbmcs of Q fever 
naive controls in the presence of Q fever naive serum
In a small study (n = 4) aimed to justify the final experimental set-up, the effect of heat-
killed and viable bacteria on cytokine production of PBMCs of Q fever naive controls in the 
presence of Q fever naive serum was examined. To this end, cells were stimulated with two 
C. burnetii strains, either viable or heat-killed Nine Mile or 3262 strain. It appeared that the 
production of TNF-α, IL-1β and IL-6, mostly secreted by monocytes, was lower after stimu-
lation with viable C. burnetii as compared to heat-killed C. burnetii (Supplementary Figure 
1). Generally, the Nine Mile and 3262 strains induced similar effects, although not for every 
cytokine. IL-10 production induced by the 3262 strain was similar for viable and heat-killed 
bacteria, but the live Nine Mile strain showed a higher cytokine response as compared to 
the heat-killed bacteria. Due to the small sample size, results are not statistically significant.
The cytokines IFNγ, IL-17 and IL-22, mostly secreted by T-cells and, therefore, belonging 
to the adaptive immune response, were determined in the supernatants after 48h and 7d. 
Stimulation with viable and heat-killed bacteria from either of the strains lead to similar 
cytokine production (Supplementary Figure 2). Cytokine concentration in the unstimulated 
cells remained below the detection limit. However, IL-17 production seemed to be higher 
after stimulation with viable compared to heat-killed bacteria. Due to the small sample 
size, results are not statistically significant. 
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The effect of anti-C. burnetii IgG phase I antibodies in the C. burnetii stimulation experi-
ments was determined with PBMCs four chronic Q fever patients and four healthy controls. 
The controls and patients responded similarly to the serum of a chronic Q fever patient 
with high anti-C. burnetii antibody titers (1: 4096) (Figure 1). 
Figure 1. Panels A-H. Tumor necrosis factor α (TNFα) and interleukin (IL)-1β production of peripheral 
blood mononuclear cells after 24 hours of stimulation with heat-killed C. burnetii NM (106/mL) (A, E), C. 
burnetii 3262 (106/mL) (B, F), Candida albicans conidia (105/mL) (C, G) and Escherichia coli LPS (10 ng/mL) 
(D, H). Cells (5x105) of chronic Q fever patients or healthy controls were incubated without serum, with 
Q fever naive serum or serum from a chronic Q fever patient with high IgG phase I titers. Abbreviations: 
HK: heat-killed, NM: Nine Mile strain, ns: non-significant. Q fever naive and Q fever serum conditions 
were compared with the Mann-Whitney test.
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viable c. burnetii induces less innate cytokine production in 
pbmcs of chronic Q fever patients and Q fever naive controls, in 
the presence of serum containing Q fever antibodies. 
PBMCs of 10 chronic Q fever patients and 10 healthy Q fever naive controls were stimu-
lated with viable or heat-killed C. burnetii. Cells of chronic Q fever patients were used in 
the experiments, because it is unknown whether these patients, who are assumed to have 
a defective immune response to C. burnetii, respond in a similar manner to viable bacteria 
as healthy individuals. To mimic the in-vivo situation, the cells were incubated with serum 
from a patient with chronic Q fever containing high titers of anti-C. burnetii IgG phase I. 
Two strains of C. burnetii were used, the laboratory strain Nine Mile and the predominant 
strain during the Q fever outbreak in the Netherlands (C. burnetii 3262) that infected 
approximately 40.000 individuals. 
The innate cytokines TNF-α, IL-1β and IL-6 were measured after 24 hours of stimulation 
(Figure 2). Cytokine production in unstimulated cells remained below the detection limit 
of the tests. 
In chronic Q fever patients, TNF-α production of viable C. burnetii 3262 stimulated cells 
was not different from the TNF-α production induced by heat-killed C. burnetii. However, 
viable C. burnetii Nine Mile induced less TNF-α production than heat-killed C. burnetii 
Nine Mile (p < 0.01). In controls, both C. burnetii strains showed the same effect, viable 
C. burnetii induced less TNF-α production than heat-killed (p < 0.01). Chronic Q fever 
patients showed high variability in cytokine production and the cytokine responses were 
not significantly different from healthy controls. 
The IL-1β production induced by viable C. burnetii 3262 in chronic Q fever patients was 
similar to heat-killed C. burnetii 3262, in contrast to the lower cytokine production induced 
by viable C. burnetii NM compared to heat-killed C. burnetii NM (p < 0.01) In controls, for 
both strains, the viable C. burnetii condition led to less cytokine production (p < 0.01). 
As for TNF-α, IL-1β production by PBMCs of patients was highly variable, there was no 
difference with IL-1β production by PBMCs of healthy controls. 
Chronic Q fever patients and controls readily produced the pro-inflammatory cytokine IL-6. 
For both C. burnetii strains, viable C. burnetii induced less IL-6 than heat-killed C. burnetii 
(C. burnetii 3262 p < 0.05, C. burnetii Nine Mile p < 0.01). For the C. burnetii 3262 strain, 
healthy controls showed similar IL-6 production in the viable and heat-killed conditions. 
With regard to the Nine Mile strain, viable C. burnetii induced less IL-6 than heat-killed C. 
burnetii (p < 0.01). IL-6 production was not different between chronic Q fever patients or 
controls in any of the stimulations.
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The anti-inflammatory cytokine IL-10 was measured after 48 hours. In chronic Q fever 
patients, viable C. burnetii 3262 induced less IL-10 than heat-killed C. burnetii (p < 0.01), 
although this was not the case for the Nine Mile strain. PBMCs of controls produced less 
IL-10 after viable C. burnetii 3262 and Nine Mile strain stimulation compared to heat-killed 
C. burnetii stimulation (p < 0.01 and p < 0.05 respectively). 
Bacterial replication, assessed with qPCR, did not take place within the first 48 hours of 
incubation (Figure 3). Cell lysis, measured by LDH release, did not differ between unstimu-
lated and stimulated conditions after 24 hours (Figure 3). 
Figure 2. Panel A- D. Innate cytokine production after heat-killed (HK) and viable (L) Coxiella burnetii 
stimulation in peripheral blood mononuclear cells of chronic Q fever patients (n=10) and healthy Q fever 
naive controls (n=10). The Dutch outbreak strain 3262 (Cb 3262) and the Nine Mile strain (Cb NM) were 
used to stimulate the cells with 2x106 bacteria per condition. Cells (5x105) were incubated in the pres-
ence of serum containing anti-C. burnetii antibodies for 24 hours after which interleukin (IL)-6, IL-1β 
and Tumor Necrosis Factor-α (TNF-α) were measured. IL-10 production was measured after 48 hours. 
Abbreviations: HK: heat-killed, L: viable, Cb 3262: C. burnetii 3262 strain, Cb NM: C. burnetii Nine Mile 
strain, interleukin (IL), Tumor Necrosis Factor-α (TNF-α) *: p < 0.05, ** p < 0.01, non-significant results 
are not indicated by a symbol, results were analyzed with the Wilcoxon signed-rank test. 
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Figure 3. Panel A-B. Lactate dehydrogenase (LDH) assay to asses necrotic cell death after 24 hours (A) or 
7 days ( B) of stimulation with heat-killed (HK) and live C. burnetii Nine Mile (NM) strain or 3262 strain. 
There was no difference in cell death compared to the medium control. Panel C-D C. burnetii genomic 
copies between start of experiment and 7 days. C. burnetii (Cb) Nine Mile copy numbers significantly 
decreased during cell culture, while C. burnetii 3262 did not significantly decrease. Abbreviations: HK: 
heat-killed, L: viable, Cb 3262: C. burnetii 3262 strain, Cb NM: C. burnetii Nine Mile strain, *: p<0.05, 
** p<0.01, ns: non-significant. Results are analyzed with the Wilcoxon signed rank test (panel A and B) 
and One-way ANOVA with Bonferonni’s multiple comparison test (panel C and D).
lower innate cytokine production by viable bacteria does not 
lead to reduced adaptive cytokine production 
After 7 days, IFNγ, IL-17 and IL-22 production was determined in the supernatants and 
IFNγ production was also measured after 48 hours (Figure 4). IL-10 production was also 
measured after 7 days, but was undetectable in all conditions. 
IFNγ is crucial in the defense against intracellular pathogens and known to be highly pro-
duced upon stimulation with heat-killed C. burnetii by chronic Q fever patients, in contrast 
to healthy controls [29, 60]. In contrast to the mostly innate cytokines, IFNγ production was 
not influenced by C. burnetii viability in chronic Q fever patients. Controls also showed no 
differences in cytokine production between viable and heat-killed C. burnetii conditions. 
At both time points and regardless of the viability of the bacteria, IFNγ production was 
higher in chronic Q fever patients after stimulation with C. burnetii 3262 (viable, median 
638 pg/mL, range 78 – 46733) compared to controls (77 pg/mL, 8-890 pg/mL, p < 0.01) 
or with C. burnetii Nine Mile (viable, patients: 728 pg/mL, 78 – 41295 pg/mL, controls: 59 
pg/mL 8-900 pg/mL). In chronic Q fever patients and controls, IL-17 and IL-22 production 
also did not differ between heat-killed and viable C. burnetii, which was apparent in both 
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strains. There was no difference between chronic Q fever patients and controls regarding 
IL-17 and IL-22 production. 
After 7 days, bacterial numbers did not exceed the number of bacteria used to initially 
stimulate the cells (Figure 3). There was no difference in cell death, assessed by LDH release 
and Trypan blue staining, between the unstimulated and stimulated conditions after 7 days 
of culture (Figure 3).
Figure 4. Panel A- D. Adaptive cytokine production after heat-killed (HK) and viable (L) Coxiella burnetii 
stimulation in peripheral blood mononuclear cells of chronic Q fever patients (n = 10) and healthy Q 
fever naive controls (n = 10). The Dutch outbreak strain 3262 (Cb 3262) and the Nine Mile strain (Cb 
NM) were used to stimulate the cells with 2x106 bacteria per condition. Cells (5x105) were incubated 
in the presence of serum containing anti-C. burnetii antibodies for 48 hours and 7 days after which 
interferon-γ (IFNγ) production measured. Interleukin (IL)-17 and IL-22 production was measured after 
7 days. Abbreviations: HK: heat-killed, L: viable, Cb 3262: C. burnetii 3262 strain, Cb NM: C. burnetii 
Nine Mile strain, interferon-γ (IFNγ), interleukin (IL). Non-significant results are not indicated by a symbol, 
results were analyzed with the Wilcoxon signed-rank test.
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chemokine cXcl9 is not differentially produced after 
incubation with viable or heat-killed coxiella
CXCL9, also known as monokine induced by interferon gamma (MIG), is a chemokine 
that is primarily induced by IFNγ. It predominantly attracts T-cells and thereby plays a role 
in orchestrating the T-helper 1 cell response [128]. We previously reported that CXCL9 is 
scarcely produced after heat-killed C. burnetii stimulation of PBMCs of healthy controls, 
but evidently produced by cells taken from chronic Q fever patients [129]. Apart from 
altered cytokine production, dysfunctional chemokine production may prevent adequate 
influx of T effector cells, affecting the adaptive immune response. Therefore we determined 
the CXCL9 concentration after 24 hours of incubation (Figure 5). There was no significant 
difference in CXCL9 concentration after live or heat-killed C. burnetii incubation.
Figure 5. CXCL 9 production after heat-killed (HK) and viable (L) Coxiella burnetii stimulation in periph-
eral blood mononuclear cells of chronic Q fever patients (n=10) and healthy Q fever naive controls (n = 
10). The Dutch outbreak strain 3262 (Cb 3262) and the Nine Mile strain (Cb NM) were used to stimulate 
the cells with 2x106 bacteria per condition. Abbreviations: HK: heat-killed, L: viable, Cb 3262: C. burnetii 
3262 strain, Cb NM: C. burnetii Nine Mile strain. Non-significant results are not indicated by a symbol, 
results were analyzed with the Wilcoxon signed-rank test
discussion
In the present study, we showed that viable C. burnetii induces less innate cytokines TNF-α, 
IL-1β, IL-6 and IL-10 than heat-killed bacteria, but equal amounts of T-cell derived (adap-
tive) cytokines IFNγ, IL-17, IL-22 and the IFNγ-dependent chemokine CXCL9. Hence, data 
obtained in studies evaluating innate cytokine production induced by heat-killed C. bur-
netii cannot be extrapolated to the real life situation where infection is induced by viable 
C. burnetii. Regarding the interpretation of previous research with heat-killed C. burnetii, 
the in-vivo immune activation due to viable bacteria has likely been overestimated. On the 
other hand, measurements of the adaptive cytokine production, such as with an IFNγ assay 
[28], reflect the response to viable bacteria appropriately. Consistent with previous studies 
performed by our research group [29, 60, 129], heat-killed C. burnetii induced high IFNγ 
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and CXCL9 production in chronic Q fever patients compared to controls, which could now 
also be confirmed for viable C. burnetii. 
Multiple theories may explain the attenuated cytokine production after incubation with 
viable bacteria compared to heat-killed bacteria. It is conceivable that heat-killing increases 
the release and exposure of bacterial Pathogen Associated Molecular Patterns (PAMPs) 
and thus affects signaling by PAMP receptors. The uptake, internalization and phagosomal 
pathway of viable and dead bacteria are less likely to influence cytokine production, be-
cause viable and dead bacteria are both taken up passively via actin-dependent phago-
cytosis and the maturation of the CCV occurs irrespective from C. burnetii replication or 
protein synthesis [130, 131]. However, once arrived in the CCV, viable bacteria are likely 
to influence the host-cell due to the type IV secretion system (T4SS), which can deliver 
bacterial effector proteins into the cytosol of the host. For example, C. burnetii is able to 
inhibit apoptosis, promote fusion of the CCV with autophagosomes and modulate host 
gene expression, among which are genes of the immune response. Reportedly, the genes 
IL-8, CCL2, CXCL1 and SPP1, that control cell trafficking and IL-12 production, are actively 
down-regulated by C. burnetii [132]. Thus, several probable mechanisms may explain the 
lower pro-inflammatory innate cytokine induction after stimulation with viable compared 
to non-viable C. burnetii.
In addition to the observed differences in cytokine induction by viable and heat-killed 
C. burnetii, we noticed a trend towards higher anti-inflammatory IL-10 production after 
stimulation with viable bacteria in the presence of Q fever naive serum. If this observation 
can be validated, it supports the assumption that the induction of IL-10 early in the course 
of the disease may be one of the immune evasion strategies of (viable) C. burnetii. Similar 
to our observation, Mycobacterium tuberculosis has been reported to enhance IL-10 pro-
duction and downregulate pro-inflammatory cytokines [133]. Differences between strains 
in the induction of IL-10 may also be one of the virulence factors of C. burnetii. In a mice 
model of Q fever, the Nine Mile strain appeared to be more virulent than the 3262 strain 
[134]. Notably, in the presence of C. burnetii IgG phase I antibodies, this shift towards 
higher IL-10 production was absent. In Q fever patients, phase I antibodies appear during 
the transition to chronic infection. The role of anti-C. burnetii IgG antibodies has remained 
controversial. It was shown that opsonisation of C. burnetii favors replication in human 
derived monocytes, while unopsonized bacteria survive poorly [97]. However, Fcγ receptor 
(FcγR)-mediated phagocytosis by dendritic cells induces cytokine production, whereas non-
antibody-containing serum with C. burnetii does not induce changes in dendritic cells [96]. 
In mice, FcγR- or complement-mediated phagocytosis does not play a role in-vivo [96]. If 
the observed trend of higher IL-10 production after stimulation with viable bacteria can be 
validated, our results may suggest that in the chronic phase of the disease, C. burnetii IgG 
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phase I antibodies prevent a possible deleterious overproduction of IL-10 and thus may be 
considered in part protective.
A note of caution is due here, because all patients used antimicriobial drugs, which are 
known to influence cytokine production through inhibited transcription [135] and may also 
affect bacterial elimination. It should also be noted that patients were recruited multiple 
months after they started antibiotic treatment. Furthermore, the viable bacteria inoculum 
inevitably contained a small percentage of dead bacteria, which could have affected the 
cytokine production. The percentage of dead bacteria in the viable stimulatory condition is 
unknown, however, C. burnetii is very resilient and can resist many chemical compounds, 
therefore, large percentages of dead C. burnetii were unlikely.
conclusion
Heat-killed C. burnetii is frequently used as an alternative for viable C. burnetii, due to the 
requirement of dedicated facilities. However, innate pro-inflammatory cytokine production 
induced by viable bacteria is lower than by heat-killed C. burnetii. Adaptive cytokine pro-
duction is comparable between induction by viable and heat-killed C. burnetii in humans. 
The results of this study can be used to interpret previous and future research with heat-
killed C. burnetii regarding C. burnetii specific cytokine production in healthy individuals 
and chronic Q fever patients.
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supplemenTary files
Supplementary table 1: Characteristics of chronic Q fever patient cohort
Focus of infection PCR positive Anti-C. burnetii IgG 
phase I at experiment
months after start 
treatment
1 vascular and valvular tissue 1:32768 7
2 vascular, valvular and lung blood & sputum 1:32768 46
3 valvular tissue 1:8192 2
4 vascular blood & tissue 1:8192 30
5 vascular tissue 1:4096 40
6 vascular tissue 1:1024 8
7 vascular tissue 1:1024 35
8 valvular blood 1:512 35
9 vascular tissue 1:512 68
10 vascular tissue 1:128 6
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Supplementary figure 1. Panel A-D. Innate cytokine production after heat-killed (HK) and viable (L) 
Coxiella burnetii stimulation in peripheral blood mononuclear cells of healthy Q fever naive controls (n 
= 4, described as c1 to c4). The Dutch C. burnetii outbreak strain 3262 (Cb 3262) and the C. burnetii 
Nine Mile strain (Cb NM) were used to stimulate the cells with 2x106 bacteria per condition. Cells (5x105) 
were incubated in the presence of Q fever naive human serum for 24h after which interleukin (IL)-6, 
IL-1β and Tumor Necrosis Factor-α (TNF-α) were measured. IL-10 production was measured after 48h. 
Abbreviations: HK: heat-killed, L: viable, Cb 3262: C. burnetii 3262 strain, Cb NM: C. burnetii Nine Mile 
strain, interleukin (IL), Tumor Necrosis Factor (TNF-α).
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Supplementary figure 2. Adaptive cytokine production after heat-killed (HK) and viable (L) C. burnetii 
stimulation in peripheral blood mononuclear cells of healthy Q fever naive controls (n = 4, described as 
c1 to c4). The Dutch C. burnetii outbreak strain 3262 (Cb 3262) and the C. burnetii Nine Mile strain (Cb 
NM) were used to stimulate the cells with 2x106 bacteria per condition. Cells (5x105) were incubated 
in the presence of Q fever naive human serum for 48 hours and 7 days after which interferon-γ (IFNγ) 
production measured. Interleukin (IL)-17 and IL-22 production was measured after 7 days. Abbrevia-
tions: HK: heat-killed, L: viable, Cb 3262: C. burnetii 3262 strain, Cb NM: C. burnetii Nine Mile strain, 
interferon- γ (IFNγ), interleukin (IL).
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absTracT
Objectives. Chronic Q fever is a persistent infection with the intracellular Gram-negative 
bacterium Coxiella burnetii, which can lead to complications of infected aneurysms. Matrix 
metalloproteinases (MMPs) cleave extracellular matrix and are involved in infections as well 
as aneurysms. We aimed to study the role of MMPs in the pathogenesis of chronic Q fever. 
Methods. We investigated gene expression of MMPs through microarray analysis and 
MMP production with enzyme-linked immunosorbent assay in C. burnetii-stimulated pe-
ripheral blood mononuclear cells (PBMCs) of chronic Q fever patients and healthy controls. 
Twenty single nucleotide polymorphisms (SNPs) of MMP and tissue inhibitor of MMP (TIMP) 
genes were genotyped in 139 chronic Q fever patients and 220 controls with similar car-
diovascular co-morbidity. Additionally, circulating MMPs levels in chronic Q fever patients 
were compared to cardiovascular controls with and without a history of past Q fever.
Results In healthy controls, the MMP pathway involving 4 genes (MMP1, MMP7, MMP10, 
MMP19) was significantly up-regulated in C. burnetii-stimulated but not in E. coli LPS-
stimulated PBMCs. C. burnetii induced MMP-1 and MMP-9 production in PBMCs of healthy 
individuals (both p < 0.001), individuals with past Q fever (p < 0.05, p < 0.01 respectively) 
and of chronic Q fever patients (both p < 0.001). SNPs in MMP7 (rs11568810) (p < 0.05), 
and MMP9 (rs17576) (p < 0.05) were more common in chronic Q fever patients. Circulat-
ing MMP-7 serum levels were higher in chronic Q fever patients (median 33.5 ng/mL, IQR 
22.3-45.7 ng/mL) than controls (20.6 ng/mL, 15.9-33.8 ng/mL). 
Conclusion C. burnetii-induced MMP production may contribute to the development of 
chronic Q fever.
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inTroducTion
Chronic Q fever is a life-threatening condition caused by Coxiella burnetii, an obligate 
intracellular Gram-negative bacterium that infects monocytes and macrophages. Upon 
exposition, individuals may remain asymptomatic or can develop acute Q fever, often 
manifested as flu-like illness or an airway infection. In some individuals, a chronic infection 
develops that may become apparent several years later. In these individuals, C. burnetii 
infects aberrant endovascular foci, such as vascular prostheses and aneurysms. Risk factors 
for chronic Q fever include valvulopathy, aortic aneurysm and aortic prosthesis [38, 39]. 
To effectively cure these patients, surgical intervention is frequently required in addition 
to long-term antibiotics. Mortality in both chronic Q fever endocarditis (9.3%) and endo-
vascular infection (18.0%) is high [53]. From 2007 to 2010, a large outbreak of Q fever 
infected many individuals in the Netherlands. Although the epidemic ended in 2010, new 
chronic Q fever patients are still diagnosed in 2016 [36, 136]. How C. burnetii persists and 
eventually causes chronic infection in these patients is still largely unknown.
Matrix metalloproteinases (MMPs) comprise a family of 23 soluble or membrane bound 
Ca2+-dependent proteolytic enzymes characterized by a zinc ion at the catalytic site. MMPs 
were first recognized for their ability to degrade extracellular matrix proteins, but are also 
involved in cell migration, proliferation and differentiation, angiogenesis, inflammation 
and cleavage of cytokines [137-139]. They are systemically produced as inactive enzymes 
(zymogens) that gain activity by various mechanisms and lose activity by tissue inhibitors 
of MMPs (TIMPs). MMPs have a dual role in the immune response to infection and tissue 
repair. Migration of immune competent cells requires MMP-mediated degradation of the 
extracellular matrix. On the other hand, excess of MMP activity can lead to tissue destruc-
tion and thus the spread of bacteria [140-142] or, as it has been reported for MMP-2 
and MMP-9, contributes to the development of vascular aneurysms and aortic dilatation 
[143-146].
MMPs have been implicated in the pathology of various infections [147-149], including 
Q fever [141], but their contribution to the pathogenesis of chronic Q fever is largely 
unknown. To get more insight in the role of MMPs in the progression to chronic Q fever, 
we examined C. burnetii-induced transcription of MMP genes, the production of MMPs by 
peripheral blood cells of healthy individuals, patients with current or past Q fever infection, 
and patients with chronic Q fever. Additionally, we genotyped polymorphisms in MMP 
genes and determined serum concentrations of various MMPs in chronic Q fever patients 
and controls.
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meTHods
subjects 
Healthy volunteers (n = 21) were hospital personnel or students without a known history 
of Q fever. Acute Q fever patients (n = 8) were recruited from patients that visited the 
outpatient clinic of the Radboud University medical center. Individuals with risk factors 
for chronic Q fever and positive Q fever serology but without evidence of chronic Q fever 
(n = 17), were selected from the cohort that was invited to participate in the Dutch Q 
fever vaccination campaign [28]. Chronic Q fever patients (n = 38, Supplementary table 
1), diagnosed according to the Dutch consensus guideline [50], were recruited from the 
participating hospitals. For analysis in serum samples, anonymized aliquots left over after 
diagnostic procedures were used from seronegative individuals with vascular disease (n = 
10) and from individuals with positive Q fever serology without progression to chronic Q 
fever, but with similar cardiovascular co-morbidity (n = 10).
For experiments with antibiotics, peripheral blood mononuclear cells (PBMCs) were derived 
from buffycoats of blood donors (Sanquin, Nijmegen, the Netherlands) with an unknown 
history of Q fever. 
The study was approved by the Medical Ethics Committee Arnhem-Nijmegen 
(NL35784.091.11). Written informed consent was obtained from all subjects, with excep-
tion of anonymized left over specimens from diagnostic procedures, for which written 
informed consent was waivered. 
pbmc isolation
PBMCs from whole blood and buffycoats were isolated by density centrifugation on 
Ficoll-Paque (Pharmacia Biotech) [150]. Cells were aspirated and washed twice in sterile 
phosphate buffered saline and resuspended in Roswell Park Memorial Institute (RPMI) 1640 
Dutch modification culture medium (Sigma-Aldrich, St Louis, MO, USA) supplemented 
with 1% L-glutamine, 1% pyruvate and 1% gentamicin. After isolation, PBMCs were used 
in gene expression analysis or in PBMC stimulation experiments.
gene expression analysis
PBMCs were incubated in a flat-bottom 24-wells plate (107 cells/mL) in a volume of 1 mL/
well in the presence of culture medium (negative control), or stimulated with heat-killed C. 
burnetii Nine Mile RSA 493 phase I (C. burnetii NM) 107/mL or Escherichia coli lipopolysac-
charide (E. coli LPS) 10 ng/mL. RNA was extracted after 8 hours of incubation using the 
RNeasy MiniKit (Qiagen). Quality and quantity of the samples were assessed with the 2100 
Bioanalyzer RNA 6000 Nano LabChip kit (Agilent Technologies) and Nanodrop, respectively. 
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Whole Genome 4x44K microarrays (Agilent Technologies, Massy, France) were used to 
analyse PBMC gene expression [151]. R and Bioconductor software suites were used to 
analyze the data. Raw data were preprocessed and a quality check was performed with 
Agi4x44PreProcess library and quantile normalization was applied. Differential gene expres-
sion was performed using Limma library [152]. Genes were considered to be differentially 
expressed when the median absolute fold change (as compared to unstimulated samples) 
was above 2.0 and the False Discovery Rate was below 5%. Selected genes were tested 
in a functional enrichment analysis with David Tools [153], using Gene Ontology (GO) and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Data were generated in 
accordance with the Minimum Information About a Microarray Experiment (MIAME) guide-
lines [154] and were deposited in the National Center for Biotechnology Information’s Gene 
Expression Omnibus, (www.ncbi.nlm.nih.gov/geo/), accessible with number GSE66476.
pbmc stimulation
For measurement of MMP production by PBMCs, 100 µL containing 5x105 PBMCs was 
incubated with 100 µL of culture medium, or 100 µL containing heat-killed C. burnetii NM 
2x106 bacteria or E. coli LPS 2 ng (end concentrations 107/mL and 10 ng/mL respectively). 
After 24h, supernatants were stored at -80⁰C. 
To assess the effect of antibiotics on C. burnetii-induced MMP production in PBMCs from 
buffy-coat donors, 100 µL containing 5x105 cells was preincubated for 1h at 37⁰C with 
culture medium, 5, 10 or 25 mg/L doxycycline (Sigma-Aldrich, St Louis, MO, USA) or 5 and 
10 µg/mL moxifloxacin (VWR, PA, USA). In some experiments doxycycline was combined 
with 1 mg/L hydroxychloroquine (Sigma-Aldrich, St Louis, MO, USA). Subsequently, C. 
burnetii NM 106/mL was added and cells were incubated for 24 hours at 37⁰C and 5% 
CO2. Supernatants were stored at -20⁰C.
in vitro whole blood stimulation
Venous blood was drawn into 5 mL lithium-free heparin tubes (Vacutainer, BD Biosciences). 
Blood was diluted 1:5 and stimulated according to previously described methods [28] with 
either culture medium or C. burnetii NM (107/mL). After a 48h incubation period, the blood 
was centrifuged and the supernatants were stored at -80⁰C. 
measurement of mmps
MMP-1 and MMP-9 concentrations in supernatants were measured with commercially 
available ELISA kits (DY901 and DY911 respectively, R&D Systems) in accordance with the 
manufacturers’ instructions. The concentration of five MMPs (MMP-1, -2, -7, -9, -10) was 
determined using Luminex magnetic beads assay (Merck Millipore, Billerica, MA, USA). 
Activity of MMP-9 was quantified with a commercially available kit (F9M00, R&D Systems).
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single nucleotide polymorphism analysis
Two cohorts of patients were used for genotype analysis, the first comprised 220 individuals 
with serologically proven Q fever infection in the past. These individuals had cardiovascular 
risk-factors for chronic Q fever without serological evidence of progression to a chronic 
infection. The second cohort consisted of 139 chronic Q fever patients, with either proven 
or probable disease according to the Dutch consensus guideline [50]. DNA from both 
patients and controls was isolated from venous blood or epithelial cells from a buccal swab 
(Isohelix) using standard methods [155]. SNPs were selected based on known functional 
effects on protein function or gene expression, published associations with human disease 
and haplotype data (Table 1). The SNPs were genotyped with Sequenom mass spectrometry 
genotyping platform as described earlier [27]. Five percent of the samples was duplicated 
within and across plates to perform quality control. 
Table 1 Genotyped SNPs in genes encoding for MMPs and tissue inhibitors of MMPs
Gene SNP ID Gene region Nucleotide 
changea
Amino acid change
MMP1 rs1144393 440 bp upstream T>C NA
MMP1 rs7125062 Intron 4 T>C NA
MMP2 rs1053605 Exon 5 C>T Thr174Thr
MMP2 rs243865 1 kb upstream C>T NA
MMP3 rs679620 Exon 9 G>A Lys45Glu
MMP3 rs522616 600 bp upstream T>C NA
MMP7 rs11568818 180 bp upstream A>G NA
MMP8 rs3765620 Exon 10 A>G Thr32ILe
MMP8 rs1940475 Exon 9 T>C Lys64Glu
MMP9 rs17576 Exon 6 A>G Gln279Arg
MMP10 rs486055 Exon 9 C>T Arg53Lys
MMP12 rs12808148 300 bp downstream T>C NA
MMP12 rs2276109 30 bp upstream A>G NA
MMP13 rs2252070 80 bp upstream A>G NA
MMP13 rs671188 3 kb upstream T>C NA
TIMP1 rs2070584 330 bp downstream T>G NA
TIMP1 rs4898 Exon 5 T>C Phe124Phe
TIMP2 rs7212662 Intron 2 T>G NA
TIMP2 rs2277698 Exon 3 G>A Ser101Ser
TIMP3 rs738992 Intron 1 T>C NA
Abbreviations: SNP, single nucleotide polymorphism; ID, identification number; NA, not applicable. a The first 
nucleotide is the most common nucleotide. 
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statistical analyses
Statistical analyses were performed using GraphPad Prism v5.03. Differences in response 
to stimuli between 2 patient or control groups were analysed with the Mann-Whitney test. 
Differences between patient or control groups were analysed with the Wilcoxon signed 
rank test and differences within patient or control groups with the Kruskal-Wallis test, 
denoted as the H statistic (H). Dunn’s multiple comparisons test (Dunn’s) was used for 
post-hoc analysis. The presence of Hardy-Weinberg Equilibrium (HWE) was calculated for 
all SNPs. A gene dosage model was adopted to determine significance between the two 
genotype frequencies of both cohorts. With IBM SPSS18 software an univariate logistic 
regression was performed using dominant and recessive model analysis, reporting odds 
ratios (ORs) and their 95% confidence intervals (95% CI). The genetic variants were chosen 
based on candidate genes that were identified using a gene expression analysis. Therefore, 
correction for multiple testing was not applied. 
resulTs
Transcriptome analysis shows c. burnetii-induced up-regulation 
of mmp genes
In a whole transcriptome microarray analysis, transcriptional responses of PBMCs to heat-
killed C. burnetii and E. coli LPS were determined in healthy controls (n = 4) and in chronic 
Q fever patients (n = 6). In PBMCs of healthy volunteers, we identified a cluster of 32 genes 
(45 probes) that were significantly up-regulated after C. burnetii stimulation, but not after 
E. coli LPS stimulation (Supplementary table 2). In this set of genes there was a significant 
enrichment of collagen catabolic processes (FDR < 0.01) with 4 genes involved (MMP1, 
MMP7, MMP10 and MMP19). In PBMCs of chronic Q fever patients, these genes were also 
significantly up-regulated after stimulation with C. burnetii, although MMP7 and MMP10 
were also significantly up-regulated in response to E. coli LPS. Three additional MMPs 
genes encoding MMP-8, MMP-9 and MMP-14 were also up-regulated at least twofold in 
stimulated PBMCs from healthy controls and chronic Q fever patients (both by C. burnetii 
and E. coli LPS) (Supplementary table 3).
c. burnetii stimulation of whole blood and pbmcs results 
in production of mmp-1 and mmp-9 in healthy controls and 
chronic Q fever patients
To determine which MMPs are produced by PBMCs stimulated with C. burnetii, we 
assessed by Luminex assay the release in the supernatant of MMP-1, MMP-2, MMP-7, 
MMP-9 and MMP-10 using cells from 8 healthy controls, 8 past Q fever individuals with 
vascular co-morbidity, and 8 chronic Q fever patients (Supplementary figure 1). Only MMP-
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1 and MMP-9 production was significantly increased. Based on these results, we further 
focused on the production of MMP-1 and MMP-9 measured by ELISA in both supernatant 
of PBMCs and whole blood cultures. The response to C. burnetii was clearly increased 
in healthy controls (MMP-1: H:19.45, p < 0.001, Dunn’s p < 0.001, MMP-9: H:20.00, p 
< 0.001, Dunn’s p < 0.001) and chronic Q fever patients (MMP-1: H: 14.07, p < 0.001, 
Dunn’s: p < 0.001, MMP-9: H:15.69, p < 0.001, Dunn’s p<0.001) and more pronounced as 
compared to the LPS response (MMP-1 and MMP-9: healthy controls and chronic Q fever 
patients Dunn’s: p > 0.05), Figure 1). C. burnetii-induced MMP-1 and MMP-9 production 
did not differ between PBMCs from chronic Q fever patients and healthy controls or past 
Q fever infected individuals. (Wilcoxon signed rank test, p > 0.05). 
Figure 1. MMP-1 and MMP-9 production after E. coli LPS and C. burnetii stimulation in PBMCs. Healthy 
controls n = 10, individuals with past Q fever n = 10, chronic Q fever patients n = 10. Panel A. MMP-1 
concentration in PBMCs incubated with either culture medium, E. coli LPS 10 ng/mL or C. burnetii Nine 
Mile 107/mL. Panel B. MMP-9 concentration in PBMCs stimulated with either culture medium, E. coli LPS 
or C. burnetii. RPMI: Roswell Park Memorial Institute (culture medium), E. coli LPS: Escherichia coli Lipo-
polysaccharide, Cb Nm 1x107: Coxiella burnetii Nine Mile concentration 1x107/mL. Medians with 1.5 
IQR are shown. Analysis was done using the Wilcoxon signed rank test for difference in stimuli between 
groups, the Kruskal-Wallis test with Dunn’s Multiple Comparison test was used to determine differences 
within groups. *=p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant
Similar to what was found in PBMCs, C. burnetii-stimulated whole blood cultures of healthy 
controls (n = 12), acute Q fever patients (n = 8), past Q fever infected individuals (n = 8) 
and chronic Q fever patients (n = 10) showed an increase in MMP-1 and MMP-9 compared 
to unstimulated cultures (H: 79.27, p < 0.001, Dunn’s: healthy controls p > 0.05, acute Q 
fever p < 0.01, past Q fever p < 0.01, chronic Q fever p < 0.05 and MMP-9: H: 43.22, p 
< 0.001, Dunn’s healthy controls p < 0.01, acute Q fever patients p > 0.05, past Q fever 
patients p < 0.01, chronic Q fever patients p < 0.01) (data not shown). 
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snps in mmp genes are more common in chronic Q fever 
patients 
We assessed whether SNPs in MMP genes were more common in chronic Q fever patients 
than in controls, indicating a risk for the development of chronic Q fever. For the genetic 
association analysis, two cohorts were used. The first cohort comprised of 139 proven 
or probable chronic Q fever patients. They were compared to a cohort of 220 control 
subjects with a positive serology for C. burnetii without progression to chronic Q fever, but 
with similar cardiovascular co-morbidity. Polymorphisms were successfully genotyped in 
genes encoding for the soluble MMPs, MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, 
MMP-10, MMP-12, MMP-13 and TIMP-1, TIMP-2, TIMP-3. For each polymorphism >93% 
of subjects were genotyped. All SNPs were in Hardy-Weinberg equilibrium in the control 
group, except for TIMP2 (rs2277698) which was therefore excluded. Genotyping revealed 
an association between chronic Q fever and MMP7 (rs11568818, A>G) and MMP9 
(rs17576, A>G). In MMP7, the investigated SNP (rs11568818), is located in the promoter 
region and the G allele was more prevalent in chronic Q fever patients (p < 0.05, OR 1.63, 
CI% 1.01-2.66). In MMP9 rs17576 the G allele was more prevalent in chronic Q fever 
patients compared to the control subjects (p < 0.05), OR 1.67, CI% 1.08-2.58). The other 
genotyped MMP and TIMP polymorphisms were not differentially distributed.
We determined the consequences of the rs17576 SNP with respect to the production 
of MMP-9 in C. burnetii stimulated PBMCs from chronic Q fever patients (n = 11) and 
found that patients carrying the risk allele G (n = 9) did not differ in MMP-9 production 
from patients with the wild-type AA (n = 2, p > 0.05). MMP9 rs17576 leads to an amino 
acid change in the substrate binding region of MMP-9 [156, 157], therefore we checked 
whether the activity of MMP-9 was affected by the SNP and studied the C. burnetii-induced 
MMP-9 activity in 10 healthy individuals, with known genotypes for MMP9 rs17576 (5 
wild-type individuals, 4 with the risk genotype AG and 1 with genotype GG). Following C. 
burnetii stimulation, MMP-9 activity could be detected (compared to unstimulated PBMCs, 
p < 0.001) but activity did not differ between the wild-type (median 12.5 ng/mL; IQR 
8.7-17.10 ng/mL) and genotypes with the risk allele (median 16.2 ng/mL, IQR 11.1-18.9 
ng/mL) (p > 0.05). 
mmp plasma and serum concentrations in patients and healthy 
individuals 
We performed pilot experiments to determine which MMPs can be measured in serum 
and plasma from patients with chronic Q fever, identified during or after the last Dutch 
outbreak. Serum samples were available in this cohort, but plasma samples had not been 
collected on a large scale. Only the MMPs that showed no large variation between serum 
and plasma were eligible for further assessment in the left-over serum samples of patients 
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[158, 159]. The latter was the case for MMP-2, MMP-7 and MMP-10 (Supplementary 
figure 2). MMP-1 and MMP-9 showed differences between serum and plasma from differ-
ent collection tubes and were therefore considered not suitable for comparisons. 
Circulating concentrations of MMP-2, MMP-7 and MMP-10 were assessed in serum of 
controls with vascular diseases without a history of Q fever, controls with vascular disease 
and a past Q fever infection and chronic Q fever patients (Figure 2). MMP-2 concentrations 
were increased in individuals with past Q fever infection compared to healthy controls (p = 
0.03) and chronic Q fever patients (p = 0.05). Compared to healthy controls, serum levels 
of MMP-7 were higher in chronic Q fever patients (median 20.6 ng/mL, IQR 15.9-33.8 ng/
mL; median 33.5 ng/mL, IQR 22.3-45.7 ng/mL respectively, p = 0.03, Mann-Whitney test). 
MMP-10 serum concentrations were not different between the groups. 
Figure 2. Serum concentrations of MMP-2, MMP-7 and MMP-10 in control individuals with similar 
vascular disease (n = 10), past Q fever infected individuals with vascular disease (n = 10) and chronic Q 
fever patients (n = 27) serum obtained within 1.5 years after diagnosis. Medians with IQR are indicated. 
*= p < 0.05; ns=p > 0.05
doxycycline but not other antibiotics, inhibit mmp-1 production
All chronic Q fever patients enrolled in the study were treated with doxycycline or a 
combination of doxycycline and hydroxychloroquine during blood sampling. Tetracyclines, 
including doxycycline, are known to inhibit MMP transcription and activity [160]. To as-
sess the effect of doxycycline on C. burnetii-induced MMP production, PBMCs from blood 
donors were stimulated with C. burnetii in the presence of doxycycline. During chronic Q 
fever treatment, serum concentrations of doxycycline are 5 to 10 mg/L, therefore these 
concentrations as well as 25 mg/L were used in the experiments. After 24h, treated cells 
with 25 mg/L of doxycycline produced less MMP-1 (Mann-Whitney test, p<0.05), whereas 
MMP-9 concentration only slightly decreased (n = 9; p < 0.05, see Figure 3). Hydroxychlo-
roquine treatment of PBMCs did not result in a reduction of MMP (p > 0.05), neither did 
it have an additive effect on MMP production under doxycycline treatment (p > 0.05). 
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Due to side effects or low response to doxycycline, some patients switched to other drug 
regimens such as moxifloxacin, a fluoroquinolone. Moxifloxacin did not change the C. 
burnetii-stimulated MMP-1 or MMP-9 production (data not shown).
Figure 3. MMP-1 (panel A) and MMP-9 concentrations (panel B) in PBMCs (n = 9) of healthy blood 
donors, preincubated with doxycycline and stimulated with C. burnetii NM in 107/mL. Medians with 
IQR are provided. Asterisks indicate significant p-values (p < 0.05) compared to culture medium (RPMI). 
*= p < 0.05
discussion
In the current study, we investigated through several immunological and genetic approaches 
the role of MMPs in the pathophysiology of chronic Q fever. We show that the expression 
of certain MMP genes (MMP1, MMP7, MMP8, MMP9, MMP10, MMP14 and MMP19) 
is up-regulated upon stimulation with heat-killed C. burnetii. This leads in turn to the 
release of at least MMP-1 and MMP-9. For gene expression as well as protein production, 
the C. burnetii-induced MMP response is more pronounced than the LPS response. MMP 
transcripts are up-regulated in both healthy controls and chronic Q fever patients and do 
not differ between them. In accordance with these results we did not detect a difference 
between patients and controls in MMP protein production. In addition, we demonstrate 
that MMP-7 serum concentrations are higher in chronic Q fever patients than controls with 
similar cardiovascular co-morbidity. Although MMPs have been studied in other infectious 
diseases, only one paper addressed the involvement of MMPs in Q fever and reported 
elevated MMP-2 and MMP-9 in sera of acute Q fever patients [141].
We show that subtle variations in MMP7 and MMP9 are more common in chronic Q 
fever patients than in the control group with past Q fever and similar cardiovascular co-
morbidity. MMP7 and MMP9 polymorphisms have been associated with susceptibility to 
various malignancies [161-163] and cardiovascular diseases [164]. In infectious diseases, 
these associations have been less extensively investigated and the genotyped SNPs were 
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not yet found to be associated with susceptibility to infection. In Helicobacter pylori in-
fection, a SNP in the promoter region of MMP7 (rs11568818) leads to increased risk of 
precancerous lesions [165]. Genetic variations in MMP9 have a protective role in malarial 
disease [166] and carrying SNP rs17576 reduces the risk of disease specific sequelae after 
ocular Chlamydia trachomatis infection [167]. Polymorphisms in these MMP genes are 
associated with an increased risk of development of chronic Q fever. The genetic variant 
in MMP9 (rs17576) is noteworthy, because it results in a change from a positively charged 
amino-acid to an uncharged amino-acid, located in the domain required for substrate 
binding [156, 157]. In a small group of 10 healthy volunteers with known genotypes for 
this MMP-9 SNP, however, we did not find a significant difference in activity. 
The involvement of MMPs in chronic Q fever is not surprising since both are associated 
with aneurysms and infective endocarditis. Chronic Q fever develops in patients with 
cardiovascular risk factors which include aneurysms and valvulopathy [38, 39]. MMP9 
expression is up-regulated in tissue of abdominal aortic aneurysms (AAA) [168, 169] and 
is associated with the initiation and expansion of aortic aneurysms [169, 170]. Circulating 
MMP-9 concentrations have been found to be higher in individuals with AAA [145]. The 
pathology of infective endocarditis is also thought to involve MMPs [171] and circulating 
MMP-9 concentrations in infective endocarditis are associated with the risk of embolic 
events [172]. Additionally, doxycycline has been suggested to lower MMP-9 gene expres-
sion and protein production in aortic aneurysm tissue in humans [173]. 
We demonstrate that doxycycline, belonging to the tetracyclines, can inhibit C. burnetii-
induced MMP-1 and MMP-9 production in PBMCs. Maitra et al. showed that chemically 
modified tetracyclines are able to inhibit MMP production independently from their an-
timicrobial effect [174]. Doxycycline acts by down-regulating gene transcription and its 
effects on activity are due to the chelation of zinc and calcium ions that are necessary for 
enzymatic activity [160]. We showed only a partial inhibition of MMP-9 production by 
doxycycline. The inhibitory effect on MMP activity may, however, have an additive effect to 
the decreased production. The inhibitory effect on MMP production and activity may thus 
prevent or halt tissue destruction of the vascular wall in chronic Q fever patients. 
The strength of the current study is that for the genetic risk evaluation we had access to 
the largest cohort ever of patients with chronic Q fever and a control group of individuals 
with past Q fever infection and cardiovascular co-morbidity. Drawbacks of the study are 
that, we did not have insight into the serological Q fever status of all healthy controls 
and we had only access to sera and not to appropriately anti-coagulated plasma for the 
measurement of circulating MMP-concentrations. Preanalytical conditions such as blood 
specimen collection are critical for reliable determination of MMPs. Dependent on the 
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type, anticoagulants may elicit further release of certain MMPs by blood cells [158, 175, 
176]. Therefore, only MMP-2, MMP-7 and MMP-10 could be measured and the protein 
concentrations of MMP-1 and MMP-9, possibly more relevant for the disease, could not be 
determined. The other MMPs that were identified in the gene expression analysis (MMP8, 
MMP14, MMP19) were not analysed due to absence of commercially available assays. 
Lastly, the use of doxycycline by all patients might also have reduced the production and 
serum concentration of MMPs. 
In conclusion, C. burnetii is able to induce MMP gene expression in and protein production 
by peripheral blood immune cells. Sera of chronic Q fever patients contain higher concen-
trations of MMP-7 compared to healthy controls and genetic variants in MMPs (MMP7 and 
MMP9) are associated with chronic Q fever. Taken together, our findings suggest that C. 
burnetii-induced production of MMPs may play a role in chronic Q fever. 
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supplemenTary files
Supplementary table 1.
Pt 
nr
Gender Age at 
diagnosis
IgG 
phase I at 
diagnosis
Diagnosis Focus Months 
after 
diagnosis 
(pbmcs)
Months 
after 
diagnosis 
(serum
1 M 30 1:65536 proven Vascular prosthesis 23 17
2 F 77 > 1:32768 proven Valvular 0
3 M 66 1:2048 proven Vascular prosthesis 18
4 M 86 1:16384 proven Vascular prosthesis 0
5 M 66 1:131072 proven Vascular prosthesis 20 2
6 M 46 1:65536 proven Vascular prosthesis 24
7 M 68 1:4096 proven Vascular prosthesis 5
8 M 80 1:2048 proven Vascular prosthesis 9
9 M 82 1:2048 proven Aortic aneurysm 13
10 M 51 1:4096 probable Valvular 2 2
11 M 69 1:8192 proven Valvular 3
12 M 71 1:4096 probable Vascular prosthesis 6 6
13 M 56 1:32768 proven Vascular prosthesis 19
14 M 64 1:8192 proven Vascular prosthesis 2 3 
49 (plasma)
15 M 69 1:1024 proven Vascular prosthesis 0
16 F 65 1:8192 proven Valvular 6
17 M 53 1:8192 probable Immunocomprised 2 4
18 M 63 1:4096 proven Vascular prosthesis 2
19 M 75 1:4096 probable Vascular and 
valvular
3
20 M 74 1:8192 proven Valvular 7
21 M 57 1:1024 proven Vascular 2
22 F 51 1:2048 proven Valvular 1 0
23 M 70 1:32768 proven Valvular 2 1
24 F 77 1:2048 proven Valvular 38
25 M 67 1:4096 probable Aortic aneurysm 1
26 M 78 1:16384 probable Aortic aneurysm 0 0
27 M 78 1:65536 proven Valvular 1
28 M 85 1:4096 probable Not determined 1
29 M 80 1:16384 proven Vascular prosthesis 30
30 M 61 1:8192 proven Aortic aneurysm 2
31 M 69 1:32768 proven Valvular 1
32 M 76 1:32768 proven Vascular prosthesis 20
33 M 81 1:1024 proven vascular prosthesis 18
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Supplementary table 1. (continued)
Pt 
nr
Gender Age at 
diagnosis
IgG 
phase I at 
diagnosis
Diagnosis Focus Months 
after 
diagnosis 
(pbmcs)
Months 
after 
diagnosis 
(serum
34 M 77 1:32768 proven Aortic aneurysm 14
35 M 72 1:32768 proven Aortic aneurysm 0
36 M 22 1:16384 proven Valvular 20
37 M 64 1:2048 proven Aortic aneurysm 5
38 M 74 1:4096 proven Aortic aneurysm 0
Supplementary table 1.Characteristics of participating chronic Q fever patients. Last columns depict the time 
after diagnosis in months at which the blood drawing for experiments occurred.
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Supplementary Table 2. 
Genes Number of probes
AK4 1
C10orf10 1
C3 1
CD63 1
CEBPE 1
DLK2 1
FAM177A1 1
FCRL4 1
FGF2 1
FGFR4 1
GK 1
IL24 1
IL36RN 1
IRAK3 1
KCNC3 1
MACC1 1
MMP1 1
MMP10 1
MMP19 2
MMP7 1
NAB1 1
NFKBIZ 1
PFKFB3 1
PHLDA2 1
PLAGL2 1
PTGR1 1
SDC2 1
SLC3A2 2
SLC7A11 3
ST3GAL1 1
TMEM105 1
TNIP2 1
Supplementary Table 2. More than two fold significantly up-regulated genes of PBMCs of healthy controls (n = 
4) after C. burnetii stimulation that are not significantly up-regulated after LPS stimulation. 
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Supplementary Table 3.
C. burnetii E.coli LPS
Healthy control Chronic Q fever Healthy control Chronic Q fever
MMP-8 2.2 2.2 1.7 2.2
MMP-9 7.3 2.5 2.0 2.2
MMP-14 25.6 37.5 25.6 24.5
Supplementary Table 3. Fold change in RNA expression of MMP-genes from PBMCs in healthy controls (n = 4) 
and chronic Q fever patients (n = 6). Mean change from unstimulated condition is indicated. 
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Supplementary figure 1. MMP production in stimulated PBMCs of healthy controls (n = 8), past Q 
fever individuals (n = 8) and chronic Q fever patients (n = 8). Panel A-E show MMP-1, MMP-2, MMP-7, 
MMP-9 and MMP-10 production respectively. Medians with 1.5 interquartile range are shown. Abbre-
viations: RPMI, Roswell Park Memorial Institute (culture medium), E. coli LPS: Escherichia coli Lipopoly-
saccharide 10ng/mL, C.b. nm: C. burnetii Nine Mile 107 bacteria/mL. Kruskal-Wallis test was performed 
and results are shown for the Dunn’s multiple comparison test (post-hoc analysis). ns: not significant p 
> 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001
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Supplementary figure 2. MMP concentrations of lepirudin -, heparin-, EDTA- anticoagulated plasma 
and serum of healthy controls (n = 3) and chronic Q fever patients (n = 7). Means with standard error 
of mean (SEM) are indicated. 
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Objectives Chronic Q fever is a persistent infection, mostly of aortic aneurysms, vascular 
prostheses or damaged heart valves caused by the intracellular bacterium Coxiella burnetii. 
Only a fraction of C. burnetii-infected individuals at risk develops chronic Q fever. In these 
individuals, a defective innate immune response may contribute to the development of 
chronic Q fever. We assessed whether genetic variations in genes involved in the killing 
machinery for C. burnetii by macrophages, contribute to the progression to chronic Q fever.
Methods The prevalence of 66 single nucleotide polymorphisms (SNPs) in 31 genes pivotal 
in phagolysosomal maturation, bacterial killing and autophagy, was determined in 173 
chronic Q fever patients and 184 controls with risk-factors for chronic Q fever and serologi-
cal evidence of a C. burnetii infection. Associations were detected with univariate logistic 
regression models. To assess the effect of these SNPs on innate responses to C. burnetii, 
C. burnetii-induced cytokine production and basal ROS production of healthy volunteers 
was determined.
Results RAB7A (rs13081864) and P2RX7 loss-of-function SNP (rs3751143) were more 
common in chronic Q fever patients than in controls. RAB5A (rs8682), P2RX7 gain-of-func-
tion SNP (rs1718119), MAP1LC3A (rs1040747) and ATG5 (rs2245214) were more com-
mon in controls. In healthy volunteers, RAB7A (rs13081864) and MAP1LC3A (rs1040747) 
influenced the C. burnetii-induced cytokine production. RAB7A (rs13081864) modulated 
basal ROS production. 
Conclusions RAB7A (rs13081864) and P2RX7 (rs3751143) are associated with the de-
velopment of chronic Q fever, whereas RAB5A (rs8682), P2RX7 (rs1718119), MAP1LC3A 
(rs1040747) and ATG5 (rs2245214) may have protective effects. 
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inTroducTion
Chronic Q fever is a persistent infection with the obligate intracellular Coxiella burnetii that 
occurs mainly in individuals with valvular heart disease, aneurysms or vascular prostheses. 
Interestingly, although the risk-factors for chronic Q fever are well established [38], only a 
minority (7-30%) of the infected individuals at risk develops chronic Q fever [41, 42], sug-
gesting that other factors resulting in an attenuated immune response contribute as well. 
Replication of C. burnetii takes place in a so-called Coxiella Containing Vacuole (CCV) 
in macrophages, despite the bacteriolytic properties of the phagolysosome. Reportedly, 
macrophages of chronic Q fever patients are not able to kill C. burnetii effectively [109]. 
Furthermore, in contrast to cured acute Q fever patients, chronic Q fever patients rarely 
develop granulomas, which are a hallmark of an effective immune response to C. burnetii 
infection [107]. Currently, it is thought that either an incomplete phagolysosomal matura-
tion is the culprit for C. burnetii survival in chronic Q fever patients[109], or that C. burnetii 
resists degradation by a fully matured lysosome [110].
The phagolysosomal pathway and fusion of the phagolysosome with autophagosomes, 
followed by the production of bactericidal molecules, are essential for the cellular response 
of macrophages to intracellular bacteria in general and C. burnetii specifically. Within sev-
eral minutes of infection, proteins are recruited to the CCV that facilitate the maturation 
and fusion of the phagolysosome, such as Rab5, Rab7, LAMP1 and autophagy proteins. 
Subsequently, lysosomal enzymes, among which is cathepsin-D, accumulate in the CCV 
and further support acidification. Several other, yet unidentified mechanisms help to eradi-
cate C. burnetii, aided by reactive oxygen species (ROS) and nitric oxide [177]. 
We hypothesized that genetic variations in the phagolysosomal pathway, microbial killing 
pathways, and the autophagy pathway contribute to the development of chronic Q fever. 
To test this hypothesis, we used an unique cohort of 173 chronic Q fever patients and 184 
controls with risk-factors for chronic Q fever and a cured C. burnetii infection, originating 
from the world’s largest Q fever outbreak. In both groups, we analyzed the prevalence of 
single nucleotide polymorphisms (SNPs) in selected genes involved in the phagolysosomal 
pathway, microbial killing pathways and autophagy pathway, that are recognized in the 
defense against intracellular bacteria and involved in the response to C. burnetii. To study 
the effect of the identified SNPs on the innate immune response to C. burnetii, we investi-
gated C. burnetii-induced cytokine or basal ROS production by peripheral immune cells in 
a large cohort of healthy individuals. 
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ethics statement
The study was approved by the local institutional review board (CMO Arnhem-Nijmegen, 
NL35784.091.11). All participants provided written informed consent. 
participants
The study group comprised 173 chronic Q fever patients that visited the outpatient clinic 
of eight participating hospitals; 139 were included in earlier reports [27, 29, 30].Chronic Q 
fever diagnosis was based on positive C. burnetii PCR in blood or tissue, or anti-C. burnetii 
IgG phase I titers of ≥ 1:1024 determined by Immunofluorescence assay with a definite 
endocarditis [178] or a proven large vessel disease or prosthetic infection. Patients with IgG 
phase I ≥ 1:1024 and large vessel disease or valvulopathy without signs of infection or with 
an immunocompromised state, were classified as ‘probable’ [50]. Patients with IgG phase 
I ≥ 1:1024 without further signs of infection were not enrolled. 
The group of at-risk controls consisted of 184 individuals living in the Q fever epidemic 
region during the Dutch outbreak, randomly selected from the control cohort as described 
previously [27]. The individuals were recruited in the Q fever pre-vaccination screening 
campaign of people with risk-factors in 2011 [25] and in a screening of at-risk individuals 
in the Q fever outbreak area in 2009 [42]. All individuals had valvular or vascular disease 
and a previous Q fever infection (≥1:32 anti-C. burnetii IgG phase II). The controls had no 
progression to chronic Q fever, as indicated by lack of symptoms and low anti-C. burnetii 
IgG phase I titers. 
Cytokine production data in healthy controls (n = 534) were derived from the Human Func-
tional Genomics Project described by Li et al. [179]. ROS-production data were obtained 
from 241 healthy controls described by Oosting et al. [127].
dna isolation
DNA was isolated from either venous blood (135 patients, 150 controls) or from buc-
cal swabs (39 patients, 34 controls) using Gentra Pure Gene blood kit (Qiagen, Hilden, 
Germany) or buccal DNA isolation kit (Isohelix, Kent, UK).
genotyping
Genes were selected based on their involvement in the defense against C. burnetii (Supple-
mentary table 1). Two to four SNPs were selected for each gene based on their allelic 
frequency (preferably Minor Allele Frequency > 5%), position, linkage disequilibrium and 
functional effect or disease association. In total, 66 SNPs in 32 genes were genotyped with 
a Sequenom mass spectrometry genotyping platform. Quality control was performed by 
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duplicating 5% within and across plates and incorporating negative and positive control 
samples. The genotypes were verified by sequencing various samples. 
c. burnetii stimulation of peripheral blood mononuclear cells 
and cytokine measurement
Peripheral blood mononuclear cells (PBMCs) from healthy volunteers were isolated with 
density gradient centrifugation using Ficoll-Hypaque (GE Healthcare, Uppsala, Sweden) 
as described earlier [127]. PBMCs (5x105) were incubated for 24 hours in a 96-wells plate 
with 2x105 heat-killed C. burnetii Nine Mile (RSA493, kindly provided by dr Hendrik-Jan 
Roest from Wageningen University Veterinary Research). Cytokine concentrations (Tumor 
Necrosis Factor (TNF), interleukin 6 (IL-6) and IL-1β) were measured by enzyme-linked 
immunosorbent assay (R&D Systems, USA). ROS production was measured with luminal-
enhanced luminescence for 1 hour using the Biotek Synergy reader. 
statistical analysis
Chi-square analysis for deviation from the Hardy-Weinberg equilibrium (HWE) was per-
formed for all SNPs in the controls, using a web-based HWE calculator [180]. The major 
allele was considered wild type. Associations between chronic Q fever and the SNPs were 
investigated by comparing relative allele frequencies. For X-chromosomal genes, relative 
allele frequencies of women only were calculated. Odds ratios (ORs), 95% confidence in-
tervals (CIs) and P-values are reported. SNPs were evaluated in the dominant model univari-
ate logistic regression analysis in which homozygous wild type is compared to genotypes 
containing the allelic variant using IBM SPSS software. In the recessive model univariate 
logistic regression analysis, the genotype homozygous for the allelic variant is compared to 
genotypes containing the major allele. A P-value of <0.05 was considered significant and 
no correction for multiple testing was performed. Effects of the SNPs on C. burnetii-specific 
cytokine production and basal ROS production were tested with linear logistic regression, 
cytokine production was controlled for the covariates age, gender and BMI [179]. 
resulTs
In total, 173 chronic Q fever patients and 184 C. burnetii-infected controls with valvular or 
vascular risk-factors were included in the analysis (Table 1). Patients had more vascular risk-
factors and an immunocompromised state was more prevalent, whereas the controls had 
more valvular risk-factors. Sixty-six SNPs were chosen from genes from the phagolysosomal 
pathway, microbial killing mechanisms, and the autophagy pathway (Supplementary Table 
1). 
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Table 1 Baseline characteristics in patients with chronic Q fever and controls
Characteristic Chronic Q fever 
patients (n=173)
Controls 
(n=184)
P-valuea
Age median (IQR), year 70 (63-76) 68 (59-74) 0.045
Male sex, no (%) 142 (82) 141 (77) 0.240
Classification Q feverb
  Proven (%) 122 (71) - -
  Probable (%) 49 (28) - -
Diagnostic criteria
  IgG anti-C. burnetii phase Ic 1: 5414 1:14
   IgG anti-C. burnetii phase IIc 1: 6183 1:123
Risk factorsd
   Vascular aneurysm/ prosthesis 118 (68) 99 (54) 0.007
   Valvular defect/ prosthesis 50 (29) 106 (57) <0.001
   Any prosthesis 79 (46) 75 (41) 0.393
   Immunocompromised statee 22 (13) 11 (6) 0.030 
a P-values based on Mann Whitney test for non-parametric data or Fisher’s Exact test for categorical data. 
b Two patients with unknown status proven or probable Q fever status 
c Geometric mean of IgG phases
d 10 patients and 21 controls had both vascular and valvular disease. 
e 10 of 22 chronic Q fever patients also had vascular or valvular disease, 12 of 22 were immunocompromised 
without vascular of valvular disease. Immunocompromised state included for cases: autoimmune disease with 
immunosuppressant use (n = 16), cancer (n = 3), renal transplant (n = 1), renal insufficiency (n = 1), predniso-
lon use (n = 1). For controls: autoimmune disease with immunosuppressant use (n = 4), cancer (n = 2), renal 
transplant (n = 2), prednisolon use (n = 3).
polymorphisms in the phagolysosomal rab genes are 
associated with chronic Q fever
We determined the relative frequency of 18 SNPs in nine genes of the phagolysosomal 
pathway in the Q fever cohorts (Supplementary Table 2). SNP rs8839 within the CTSD gene 
and SNP rs764597 in PIGU were not in HWE. RAB5A rs8682 was found to be less prevalent 
in chronic Q fever patients compared to controls in a recessive model analysis (P < 0.001, 
OR 0, CI not determined). RAB7A rs13081864 was differently distributed between patients 
and controls with regard to allele frequency (P = 0.04) and in a dominant model analysis 
(Table 2). 
Two SNPs in TNF were genotyped as well. Genetic variation rs1800610 was significantly 
differently distributed between patients and controls in a chi-square analysis without a 
model (P = 0.03).
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Table 2. Distribution of genotypes in innate immunity genes of chronic Q fever patients and 
controls 
Polymorphism Genotype distribution Logistic regression Model#
Wildtype
No. (%)
Heterozygous
No. (%)
Homozygous 
No. (%)
P-value Odds Ratio 
(95% CI)
RAB5A rs8682 CC CG GG 0.00 0 (0-)
controls 133 (75) 43 (24) 2 (1)
patients 131 (79) 35 (21) 0 (0)
RAB7A rs13081864 CC CT TT 0.04* 1.6 (1.0-2.5)
controls 127 (71) 46 (26) 6 (3)
patients 100 (61) 56 (34) 9 (5)
P2RX7 rs1718119 CC CT TT 0.02 0.6 (0.4-0.9)
controls 58 (33) 94 (53) 24 (14)
patients 71 (46) 65 (42) 20 (13)
P2RX7 rs3751143 TT GT TT 0.03 4.1 (1.1-14.2)
controls 127 (71) 49 (27) 3 (2)
patients 114 (69) 41 (25) 11 (7)
ATG5 rs2245214 CC CG GG 0.04 0.5 (0.2-0.96)
controls 65 (37) 85 (49) 25 (14)
patients 75 (45) 80 (48) 12 (7)
MAP1LC3A s1040747 CC CG GG 0.01 0.6 (0.4-0.9)
controls 75 (43) 73 (41) 28 (16)
patients 89 (57) 53 (34) 14 (9)
Table 2. Distribution of significantly different genotypes in genes of the phagolysosomal pathway, micro-
bial killing mechanisms and autophagy in chronic Q fever patients and at-risk controls. Non-significant 
genetic variants are shown in the supplementary tables.# Univariate logistic regression, recessive model 
unless indicated otherwise. *Dominant regression model. CI = confidence interval.
polymorphisms in p2rX7 genes predispose to and protect 
against chronic Q fever
We determined the relative frequency of 20 SNPs in ten genes involved in microbial killing, 
including ROS production, in the Q fever cohorts (Supplementary Table 3). All SNPs were in 
HWE for the controls. Two of the three SNPs in P2RX7 were differently distributed between 
chronic Q fever patients and controls. P2RX7 SNP rs3751143 is known to result in a loss-of-
function of the P2RX7 receptor [181]. This SNP was significantly different in the recessive 
model analysis (P = 0.03, OR 4.2, CI: 1.1-14.2).The second SNP in P2RX7, rs1718119, is 
known to lead to a gain-of-function of the P2RX7 receptor [182]. This rs1718819 SNP was 
significantly different in a recessive model analysis (P = 0.02, OR: 0.6, CI: 0.4-0.9) and the 
allelic variant was more frequently found in controls (Table 2). 
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genetic variants in autophagy genes aTg5 and map1lc3a are 
associated with chronic Q fever
We determined the relative frequency of 17 SNPs in twelve autophagy genes in the Q 
fever cohorts (Supplementary Table 4). The frequency of the allelic variant was absent or 
very low for four SNPs, in ATG16L2, EREG, ATG9B and ATG2A, and they were therefore 
not further analyzed. ATG5 harbors the SNP rs2245214, which was significantly different 
in allele frequency (P = 0.045) and in a recessive model (P = 0.04, OR: 0.5, CI: 0.23-0.96). 
Additionally, SNP (rs1040747) in MAP1LC3A was also less common in patients regarding 
allele frequency (P = 0.003) and in a recessive model analysis (P =0.009, OR 0.6; CI: 0.4-
0.9, Table 4). 
functional effects of polymorphisms on c. burnetii-induced 
cytokine and ros production by pbmcs
Analysis of functional effects of the identified SNPs on C. burnetii-stimulated PBMCs from 
healthy controls (n = 534) revealed that RAB7A rs13081864 reduced basal ROS production 
(P =0.018, n=241) and C. burnetii-induced IL-6 production (P = 0.016). SNPs in P2RX7 
(rs3751143 and 1718819) did not influence IL-1β, TNF or IL-6 production, nor did RAB5A 
rs8682 and ATG5 rs2245214. MAP1LC3A rs1040747 increased IL-6 (P = 0.016), but not 
IL-1β and TNF production after C. burnetii stimulation (Supplementary Figure 1). 
discussion
This study identifies genetic variants that may be associated with progression to chronic 
Q fever. While pre-existent vascular or valvular disease are major risk-factors for chronic Q 
fever, a defective immune response is also required for the progression to chronic Q fever, 
as shown by the fact that not all infected individuals at risk develop chronic Q fever [42]. 
We identified three SNPS in 3 genes (RAB7A, P2RX7 and TNF) that are more prevalent in 
chronic Q fever patients, and four SNPs in 4 genes (RAB5A, P2RX7, MAP1LC3A and ATG5) 
that are more common in controls with resolved Q fever. In healthy individuals, RAB7A and 
MAP1LC3A SNPs influenced cytokine responses to C. burnetii and basal ROS production, 
mechanisms which could be pivotal in the early survival of C. burnetii.
Inside cells of the mononuclear phagocyte lineage, C. burnetii passes through the pha-
golysosomal pathway, in which Rabs, small Ras-related GTPases that are involved in the 
process of recruitment and maturation of lysosomal vesicles, play an essential role [79, 
183]. The Rab5 protein is associated with early endosomes, whereas Rab7 is associated 
with late endosomes and the transformation to lysosomes. Certain pathogens, including 
Mycobacterium tuberculosis, hijack Rab-mediated vesicle trafficking to evade the micro-
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bicidal effects of mature phagolysosomes [85]. The phagolysomal maturation arrest for 
M. tuberculosis is due to a block in the conversion of Rab5 to Rab7. Correspondingly, 
Helicobacter pylori containing vacuoles have the ability to retain Rab7 and thereby limit 
the degradative capacity [184]. Some Rab7 mutants interfere with cathepsin-D-mediated 
lysosome maturation and inhibit degradation of low-density lipoproteins [183]. Both 
processes are thought to be implicated in the pathology of Q fever [109]. Rab5 and Rab7 
sequentially colocalize to C. burnetii-inhabited vacuoles and participate in the biogenesis 
of the CCV. Inhibition of Rab5 and Rab7 impairs the expansion of the CCV and inhibition 
of Rab5 also impairs entry, whereas overexpression of Rab5 promotes C. burnetii entry 
into the cell [185]. Hence, genetic variations that influence Rab function or expression may 
also affect the efficiency of the phagolysosomal processes and thus pathogen killing. The 
polymorphisms of RAB5A and RAB7A are located at the 3’UTR and the first intron, near 
the promoter region of the genes. According to publically available gene expression data 
[186], they influence expression levels in peripheral blood, RAB5A rs8682 (P= 6.1* 10-11) 
and RAB7A rs13081864 (P = 2,3*10-4). The finding that RAB7A rs13081864 is more com-
mon in chronic Q fever patients could indicate that RAB7A is important in the progression 
to chronic Q fever. This observation is strengthened by the reduced C. burnetii-induced 
cytokine production for RAB7A SNP rs13081864.
The role of purinergic cation-channel gated receptor 7 (P2RX7) in chronic Q fever patho-
genesis is independently supported by two SNPs with different functional effects: the 
rs3751143 loss-of-function SNP is associated with an increased risk for chronic Q fever, 
while the gain-of-function rs1718119 has a protective role. P2RX7 is predominantly ex-
pressed on macrophages. It has various functions in cell communication and in innate 
immunity, it senses ATP accumulation at the site of tissue inflammation, after which it 
mediates NLRP3 inflammasome activation, stimulates ROS and apoptosis [187]. Homozy-
gosity for the Glu496Ala polymorphism (rs3751143) leads to a complete loss-of-function 
of the receptor and impaired ATP-induced lymphocyte cytotoxicity [181]. From genetic 
association studies, polymorphisms in the P2RX7 gene have emerged as major risk-factors 
for susceptibility to tuberculosis [188]. Furthermore, M. tuberculosis is killed in response 
to ATP-induced P2RX7 activation, but this is impaired in individuals carrying the P2RX7 
rs3751143 (Glu496Ala) loss-of-function mutation, possibly through downstream effects 
affecting phospholipase D and phagosome-lysosome fusion [189]. In addition to M. tuber-
culosis, intracellular Toxoplasma gondii [190, 191] and Chlamydia trachomatis [192] have 
enhanced survival in-vitro in the presence of Glu496Ala loss-of-function P2RX7. Compat-
ible with the previous observations, the gain-of-function SNP rs1718119 (Ala348Thr), is 
associated with a protective effect in ocular toxoplasmosis [190]. 
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These earlier findings in different intracellular pathogens, support our findings for chronic 
Q fever. A previous transcriptome analysis performed by our group [29] (GSE66476; www.
ncbi.nlm.nih.gov/geo/) showed that the P2RX7 gene is highly (10x) up-regulated after 
heat-killed C. burnetii stimulation of PBMCs from chronic Q fever patients compared to 
healthy controls. Arguably, P2RX7 receptor function may influence the development of 
chronic Q fever, probably by modulating killing of C. burnetii in macrophages.
The TNF polymorphism rs1800610 could not be verified in a dominant or recessive model 
analysis, therefore the role of this TNF polymorphism for Q fever needs to be further 
validated.
Autophagy is a catabolic pathway, allowing degradation of cell organelles in autopha-
gosomes. Although non-canonical autophagy is also a defense mechanism, it can be 
exploited by some pathogens to suit their own survival. Autophagy-related genes (ATG) 
are involved in the formation of double membrane vesicles, that will eventually fuse with 
a lysosome. The CCV is decorated with microtubule associated protein light chain (LC3), 
a hallmark of autophagy, but this process is actively orchestrated by C. burnetii itself. 
Overexpression of autophagic proteins actually favors C. burnetii replication, probably by 
providing the CCV with essential nutrients [84]. Furthermore, by exploiting the autophagic 
pathway, recruitment of cathepsin-D and therefore lysosomal maturation will be momen-
tarily delayed, giving C. burnetii time to morphologically change [193]. For the first time, 
we could pin-point two autophagy genes, ATG5 and MAP1LC3A, to be associated with the 
development of chronic Q fever. Interestingly, both SNPs are more prevalent in the controls, 
implying that interference with the autophagy pathway protects the host. This is supported 
by the higher C. burnetii induced cytokine production for the individuals homozygous for 
MAP1LC3A rs1040747. 
 This study represents the largest, but still relatively small, genetic analysis of chronic Q 
fever patients. The control cohort matches the patient group in terms of exposition to C. 
burnetii and gender. It should be noted however that the control cohort had more valvular 
risk-factors, which -in the Netherlands- were less likely to result in chronic Q fever than 
vascular risk-factors [41]. No adjustment for multiple comparisons was performed, we 
therefore tried to minimize false positive results by selecting genes expected or known to 
be involved in innate immune response to C. burnetii, and by functional validation with 
C. burnetii-induced cytokine production. To validate the results of the current study, these 
genetic variations should be confirmed in an independent cohort. 
To conclude, this study identifies SNPs in genes RAB5A and RAB7A of the phagolysosome 
pathway; P2RX7, a receptor involved in killing of intracellular pathogens; and two genes 
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of the autophagy pathway, MAP1LC3A and ATG5, to be associated with chronic Q fever. 
For RAB7A and MAP1LC3A, the SNPs influenced C. burnetii-induced cytokine production. 
Thus, common genetic variations in innate immune pathways involved in intracellular 
processing of pathogens are not equally distributed among chronic Q fever patients and 
past Q fever controls, indicating that they might be associated with progression to chronic 
Q fever. 
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supplemenTary files
Supplementary table 1. Genotyped single nucleotide polymorphisms in genes of the phagolysosomal 
pathway, microbial killing pathways and autophagy pathway
Gene SNP ID Chromosome: 
position*
Gene region Nucleotide 
change
Amino 
Acid 
Change
MAF C. burnetii 
association
RAB5A rs62241280 3: 19947170 5’UTR A > G na 22% (1-3)
rs8682 3: 19984917 3’UTR C > G na 16%
RAB5B rs11171710 12: 55974294 exon 2 G > A na 47% (1-3)
rs705702 12: 55996852 3’downstream T > C na 32%
RAB7A rs13081864 3: 128771430 intron 1 C > T na 19% (1-3)
rs7372263 3: 128780352 intron 1 A > C na 44%
LAMP1 rs9549380 13: 113295436 5’upstream G > A na 16% (1-5)
rs12871648 13: 113316347 intron 4 A > C na 25%
rs9577229 13: 113319517 exon 4 C > T Ala204Val 8%
LAMP2 rs5909722 X: 120434622 intron 8 G > A na 32% (1-3)
rs6603623 X: 120417857 3’ downstream T > G na 29%
EEA1 rs10735304 12: 92772762 3’UTR G > A na 30% (1-3)
rs4760506 12: 92939274 intron 1 C > T na 45%
CTSD rs17571 11: 1761364 exon 2 C > T Ala58Val 7% (1-5)
rs7122341 11: 1760560 intron 2 T > C na 20%
rs8839 11: 1752906 3’UTR C > G na 18%
STX17 rs10760706 9: 99961410 intron 6 T > C na 34% (6, 7)
rs9556 9: 99969955 3’UTR G > A na 32%
VPS35 rs794279 16: 46679780 intron 5 T > C na 17% (6, 7)
rs2304492 16: 46663186 intron 13 T > G na 40%
PIGU rs764597 20: 34573421 intron 13 C > T na 38% (6, 7)
TNF rs1800610 6: 31576050 intron 1 G > T na 10% (8, 9)
rs1800629 6: 31575254 5’upstream G > A na 13%
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Microbial killing pathways
Gene SNP ID Chromosome: 
position*
Gene 
region
Nucleotide 
change
Amino 
Acid 
Change
MAF C. burnetii 
association
CYBA rs9932581 16: 88651945 promoter C > T na 40% (10-13)
rs4673 16: 88646828 exon 4 T > A Tyr72His 34%
rs3794623 16: 88644480 3’UTR G > T na 48%
rs1049255 16: 88643329 3’UTR A > G na 49%
CYBB rs6610650 X: 37777261 5’upstream A > G na 10% (10-13)
rs5917471 X: 37793265 intron 4 T > C na 31%
NCF2 rs10911363 1: 183580622 intron 2 G > T na 37% (10-13)
rs17849502 1: 183563445 exon 14 G > T His389Gln 6%
NCF4 rs4821544 22: 36862461 intron 1 T > C na 35% (10-13)
rs729749 22: 36867804 intron 4 C > T na 22%
RAC2 rs1476002 22: 37234748 intron 5 C > T na 12% (10-13)
rs6572 22: 37225405 3’UTR C > G na 44%
NOX1 rs7049377 X: 100880499 5’upstream G > A na 18% (10-13)
rs4827881 X: 100874684 promoter C > A na 16%
rs1343216 X: 100767972 3’downstream T > G na 36%
NOX4 rs1836882 11: 89498993 promoter/intron 2 T > C na 19% (10-13)
rs11018628 11: 89473343 intron 14 T > C na 17%
NOS2 rs6505469 17: 27784860 intron 7 A > T na 47% (10-13)
IDO1 rs10089084 8: 39912430 5’upstream G > C na 34% (14)
rs10108662 8: 39922470 intron 4 C > A na 23%
rs3739319 8: 39927802 intron 10 G > A na 39%
P2RX7 rs2393799 12: 121132209 promoter C > T na 26% (15, 16)
rs1718119 12: 121177300 exon 11 C > T Ala348Thr 38%
rs3751143 12: 121184501 exon 12 T > G Glu496Ala 21%
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Gene SNP ID Chromosome: 
position*
Gene region Nucleotide 
change
Amino 
Acid 
Change
MAF C. burnetii 
association
ATG16L2 rs11235604 11: 72822491 exon 6 C > T Arg220Trp 33% (17-21)
ATG10 rs3734114 5: 82058570 exon 5 T > C Ser62Pro 21% (17-21)
rs1864183 5: 82253397 exon 9 A > G Tyr212Met 48%
ATG16L1 rs2241880 2: 233274722 exon 9 T > C Tyr300Ala 39% (17-21)
ATG5 rs2245214 6: 106214866 intron 7 C > G na 46% (17-21)
EREG rs78803121 4: 74382788 exon 4 G > T Cys141Phe 4% (17-21)
rs34477425 4: 74384731 exon 5 A > G Arg145Gly 1%
ATG2A rs77228473 11: 64898810 exon 32 C > G Glu1499Asp nd (17-21)
ATG2B rs9323945 14: 96315575 exon 19 C > T Asn1124Ser 9% (17-21)
rs3759601 14: 96311131 exon 28 C > G Gln1383Glu 25%
rs74719094 14: 96302043 exon 34 T > G Arg1701Ser 2%
LAMP3 rs482912 3: 183135882 exon 8 G > A Ile318Val 50% (17-21)
IRGM rs4958847 5: 150860025 intron 1 G > A na 37% (17-21)
rs72553867 5: 150848404 exon 2 C > A Thr94Lys 6%
ATG9B rs61733329 7: 151017080 exon 9 C > T Gly749Ser 2% (17-21)
WIPI1 
(ATG18)
rs883541 17: 68452981 exon 2 A > G Thr31Ile 26% (17-21)
MAP1LC3A rs1040747 20: 34558028 intron/ 5’ UTR C > G na 39% (17-21)
Supplementary table 1. MAF: minor allele frequency, UTR: untranslated region, na: not applicable, nd: not 
determined, *position based on genome assembly version GRCh38.p7 
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Supplementary Table 2. Distribution of genotypes in genes of the phagolysosomal pathway in chronic 
Q fever patients and controls 
Polymorphism Genotype distribution Recessive model#
Wildtype
No. (%)
Heterozygous
No. (%)
Homozygous 
No. (%)
P-value Odds Ratio 
(95% CI)
RAB5A rs66241280 AA AG GG 0.39 1.5 (0.6-3.2)
controls 103 (58) 67 (37) 9 (5)
patients 100 (61) 53 (32) 12 (7)
RAB5A rs8682 CC CG GG 0.00 0 (0-)
controls 133 (75) 43 (24) 2 (1)
patients 131 (79) 35 (21) 0 (0)
RAB5B rs11171710 GG GA AA 0.32 1.3 (0.8-2.1)
controls 52 (29) 88 (50) 37 (21)
patients 51 (31) 72 (44) 42 (25)
RAB5B rs705702 TT TC CC 0.27 1.4 (0.8-2.7)
controls 83 (46) 76 (42) 20 (11)
patients 72 (44) 67 (41) 25 (15)
RAB7A rs13081864 CC CT TT 0.04* 1.6 (1.0-2.5)
controls 127 (71) 46 (26) 6 (3)
patients 100 (61) 56 (34) 9 (5)
RAB7A rs7372263 AA CA CC 0.89 1.0 (0.6-1.9)
controls 70 (39) 82 (46) 26 (15)
patients 56 (34) 84 (51) 25 (15)
LAMP1 rs9549380 GG GA AA 0.80 0.90 (0.4-2.1)
controls 109 (61) 58 (32) 12 (7)
patients 98 (59) 58 (35) 10 (6)
LAMP1 rs12871648 AA AC CC 0.89 1.0 (0.5-1.7)
controls 77 (43) 74 (41) 28 (16)
patients 65 (39) 76 (46) 25 (15)
LAMP1 rs9577229 CC CT TT 0.56 1.1 (-,-)
controls 176 (98) 3 (2) 0 (0)
patients 169 (98) 1 (1) 0 (0)
LAMP2a rs6603623 Allele T Allele G 0.68a
controls 140 (65) 77 (35)
patients 112 (62) 68 (38)
EEA1 rs10735304 GG GA AA 0.38 1.2 (0.8-1.9)
controls 69 (40) 81 (47) 23 (14)
patients 71 (45) 58 (36) 30 (19)
EEA1 rs4760506 CC CT TT 0.08 0.6 (0.3-1.1)
controls 57 (32) 84 (47) 38 (21)
patients 55 (33) 88 (53) 23 (14)
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Supplementary Table 2. Distribution of genotypes in genes of the phagolysosomal pathway in chronic 
Q fever patients and controls  (continued)
Polymorphism Genotype distribution Recessive model#
Wildtype
No. (%)
Heterozygous
No. (%)
Homozygous 
No. (%)
P-value Odds Ratio 
(95% CI)
CTSD rs17571 CC CT TT 0.38 0.7 (0.4-1.4)
controls 152 (86) 25 (14) 0 (0)
patients 139 (89) 16 (10) 1 (1)
CTSD rs7122341 TT TC CC 0.09 0.3 (0.1-1.3)
controls 105 (59) 66 (37) 8 (4)
patients 110 (67) 53 (32) 2 (1)
STX17 rs10760706 TT TC CC 0.88 0.8 (0.5-2.0)
controls 84 (47) 78 (44) 17 (9)
patients 82 (49) 69 (42) 15 (9)
STX17 rs9556 GG GA AA 1.00 1.0 (0.5-2.1)
controls 83 (47) 77 (44) 17 (10)
patients 82 (49) 68 (41) 16 (10)
VPS35 rs794279 TT CT CC 0.59 1.6 (0.3-9.9)
controls 126 (71) 50 (28) 2 (1)
patients 109 (66) 52 (32) 3 (2)
VPS35 rs2304492 CC CT TT 0.81 1.1 (0.7-1.7)
controls 68 (40) 71 (41) 27 (16)
patients 57 (37) 79 (51) 23 (15)
TNF rs1800610 CC CT TT 1.00 1.8*109  (0,-)
controls 146 (84) 28 (16) 0 (0)
patients 138 (85) 19 (12) 5 (3)
TNF rs1800629 CC CT TT 0.88 1.0 (0.6-1.5)
controls 116 (67) 48 (28) 8 (5)
patients 101 (65) 46 (29) 3 (2)
Supplementary Table 2. Distribution of genotypes in genes of the phagolysosomal pathway in chronic Q fever 
patients and at-risk controls. # Univariate logistic regression, recessive model unless indicated otherwise, *Domi-
nant regression model, aX-chromosomal polymorphism allele frequencies of men and women in total, P-value 
of Fisher’s Exact test. CI = confidence interval
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Supplementary Table 3. Distribution of genotypes of genes involved in microbial killing of chronic Q 
fever patients and controls. 
Polymorphism Genotype distribution Recessive model#
Wildtype
No. (%)
Heterozygous
No. (%)
Homozygous 
No. (%)
P-value Odds Ratio 
(95% CI)
CYBA rs9932581 CC CT TT 0.30 0.6 (0.7-1.8)
controls 60 (34) 96 (54) 21 (12)
Patients 61 (39) 69 (44) 25 (16)
CYBA rs4673 CC CT TT 0.64 0.9 (0.6-1.4)
controls 79 (45) 79 (45) 21 (12)
patients 61 (39) 74 (47) 18 (12)
CYBA rs3794623 GG GT TT 0.59 0.9 (0.5-1.4)
controls 44 (25) 86 (48) 48 (27)
patients 45 (27) 79 (48) 40 (24)
CYBA rs1049255 GG GA AA 0.18 0.7 (0.4-1.2)
controls 39 (22) 89 (50) 50 (28)
patients 49 (30) 80 (48) 36 (22)
CYBBa rs5917471 Allele C Allele T 0.18a
controls 127 (58) 91 (42)
patients 117 (65) 63 (35)
CYBBa rs6610650 Allele G Allele A 0.16a
controls 179 (83) 36 (17)
patients 158 (88) 21 (12)
NCF2 rs10911363 GG GT TT 0.80 1.1 (0.7-1.6)
controls 94 (55) 65 (38) 13 (8)
patients 82 (53) 65 (42) 7 (5)
NCF2 rs17849502 GG GT TT 0.99 1.8*109  (0,-)
controls 168 (94) 11 (6) 0 (0)
patients 153 (93) 10 (6) 2 (1)
NCF4 rs4821544 TT CT CC 0.41 0.7 (0.3-1.6)
controls 97 (51) 67 (37) 15 (8)
patients 85 (52) 70 (42) 10 (6)
NCF4 rs729749 CC CT TT 0.89 1.1 (0.4-3.2)
controls 106 (59) 66 (37) 7 (4)
patients 101 (61) 58 (35) 7 (4)
RAC2 rs1476002 CC CT TT 0.31 3.2 (0.3-31.3)
controls 132 (76) 41 (24) 1 (1)
patients 131 (80) 30 (18) 3 (2)
RAC2 rs6572 CC CG GG 0.32 1.3 (0.8-2.3)
controls 56 (31) 92 (52) 30 (17)
patients 53 (32) 78 (47) 35 (21)
NOX1a rs7049377 Allele G Allele A 0.67a
controls 164 (75) 56 (25)
patients 142 (72) 54 (28)
NOX1a rs1343216 Allele T Allele G 0.11a
controls 123 (57) 94 (43)
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Supplementary Table 3. Distribution of genotypes of genes involved in microbial killing of chronic Q 
fever patients and controls.  (continued)
Polymorphism Genotype distribution Recessive model#
Wildtype
No. (%)
Heterozygous
No. (%)
Homozygous 
No. (%)
P-value Odds Ratio 
(95% CI)
patients 87 (48) 93 (52)
NOX1a rs4827881 Allele C Allele A 1.00a
controls 167 (77) 50 (23)
patients 138 (77) 42 (23)
NOX4 rs1836882 TT TC CC 0.96 1.1 (0.1-17.3)
controls 138 (78) 38 (21) 1 (1)
patients 129 (78) 35 (21) 1 (1)
NOX4 rs11018623 TT TC CC 0.93 1.0 (0.5-1.9)
controls 155 (88) 20 (11) 1 (1)
patients 137 (88) 18 (12) 0 (0)
NOS2 rs6505469 AA AT TT 0.80 0.9 (0.6-1.5)
controls 57 (32) 79 (44) 43 (24)
patients 45 (27) 83 (50) 38 (23)
IDO1 rs10089084 GG CG CC 0.74 1.1 (0.6-2.0)
controls 66 (37) 85 (48) 26 (15)
patients 62 (40) 69 (44) 25 (16)
IDO1 rs10108662 CC CA AA 0.43 0.8 (0.4-1.4)
controls 61 (35) 80 (46) 28 (16)
patients 67 (41) 80 (49) 21 (13)
IDO1 rs3739319 GG GA AA 0.57 0.9 (0.6-1.4)
controls 62 (35) 90 (51) 24 (14)
patients 54 (35) 79 (51) 24 (15)
P2RX7 rs2393799 CC CT TT 0.28 1.7 (0.7-4.5)
controls 108 (59) 69 (38) 7 (4)
patients 101 (58) 61 (35) 11 (6)
P2RX7 rs1718119 CC CT TT 0.02 0.6 (0.4-0.9)
controls 58 (33) 94 (53) 24 (14)
patients 71 (46) 65 (42) 20 (13)
P2RX7 rs3751143 TT GT TT 0.03 4.1 (1.1-14.2)
controls 127 (71) 49 (27) 3 (2)
patients 114 (69) 41 (25) 11 (7)
Supplementary Table 3. Distribution of genotypes of genes involved in microbial killing of chronic Q fever pa-
tients and at-risk controls. # Univariate logistic regression, aX-chromosomal polymorphism allele frequencies of 
men and women in total, P-value of Fisher’s Exact test. CI= confidence interval.
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Supplementary Table 4. Distribution of genotypes in genes of the autophagy pathway in chronic Q 
fever patients and controls 
Polymorphism Genotype distribution Recessive model# 
Wildtype
No. (%)
Heterozygous 
No. (%)
Homozygous 
No. (%)
P-value Odds Ratio 
(95% CI)
ATG10 rs3734114 TT CT CC 0.53 1.4 (0.5-3.8)
controls 127 (69) 49 (27) 7 (4)
patients 103 (60) 60 (35) 9 (5)
ATG10 rs1864183 GG GA AA 0.48 1.2 (0.7-2.2)
controls 65 (37) 86 (49) 26 (15)
patients 52 (30) 90 (52) 30 (17)
ATG16L1 rs2241880 CC CT TT 0.74 0.9 (0.6-1.5)
controls 54 (29) 88 (48) 42 (23)
patients 36 (21) 100 (58) 37 (21)
ATG5 rs2245214 CC CG GG 0.04 0.5 (0.2-0.96)
controls 65 (37) 85 (49) 25 (14)
patients 75 (45) 80 (48) 12 (7)
EREG rs78803121 GG GT TT 1.00 0.0 (0.0,-)
controls 164 (89) 19 (10) 1 (1)
patients 155 (90) 18 (10) 0 (0)
ATG2B rs9323945 CC CT TT 0.56 1.06 (-.-)
controls 178 (99) 2 (1) 0 (0)
patients 165 (96) 7 (4) 0 (0)
ATG2B rs3759601 CC CG GG 0.66 1.1 (0.7-1.8)
controls 48 (26) 97 (53) 39 (21)
patients 50 (29) 83 (48) 40 (23)
LAMP3 rs4829212 CC CT TT 0.56 1.06 (-,-)
controls 176 (98) 3 (2) 0 (0)
patients 169 (99) 1 (1) 0 (0)
IRGM rs4958847 GG GA AA 0.94 1.1 (0.2-5.4)
controls 136 (74) 45 (24) 3 (2)
patients 125 (72) 45 (26) 3 (2)
IRGM rs72553867 CC CA AA 1.00 0.0 (0.0,-)
controls 162 (88) 21 (11) 1 (1)
patients 152 (88) 21 (12) 0 (0)
ATG9B rs61733329 CC TC TT 0.56 1.1 (-,-)
controls 183 (99) 1 (1) 0 (0)
patients 172 (99) 0 (0) 1 (1)
WIPI1/ATG18 rs883541 AA AG GG 0.20 0.5 (0.1-1.5)
controls 108 (59) 67 (36) 9 (5)
patients 108 (62) 61 (35) 4 (2)
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Supplementary Table 4. Distribution of genotypes in genes of the autophagy pathway in chronic Q 
fever patients and controls  (continued)
Polymorphism Genotype distribution Recessive model# 
Wildtype
No. (%)
Heterozygous 
No. (%)
Homozygous 
No. (%)
P-value Odds Ratio 
(95% CI)
MAP1LC3A rs1040747 CC CG GG 0.01 0.6 (0.4-0.9)
controls 75 (43) 73 (41) 28 (16)
patients 89 (57) 53 (34) 14 (9)
Supplementary Table 4. Distribution of genotypes in genes of the autophagy pathway in chronic Q fever pa-
tients and at-risk controls. # Univariate logistic regression. CI= confidence interval.
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Panel A-C. C. burnetii induced cytokine production stratified by genotype for the identified polymor-
phisms rs13081864 in RAB7A and rs1040747 in MAP1LC3A. Mean and SEM are displayed. Each dot 
represents one of the 534 healthy individuals for cytokine production or one of 241 healthy individuals 
for ROS production. Cytokine genotype associations were analyzed with linear regression controlled for 
age, gender and BMI for the analysis, uncontrolled data is shown. Basal ROS production was also tested 
with linear regression without controlling covariates. Analytes displayed were significant with a P-value 
of < 0.05 (*). Highest detection limit of test: IL-6: 20,000 pg/ml. Abbreviations: interleukin (IL), Area 
Under Curve (AUC), Reactive Oxygen Species (ROS). 
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absTracT
Background In the aftermath of the largest Q fever outbreak in the world, diagnosing the 
potentially lethal complication chronic Q fever remains challenging. PCR, Coxiella burnetii 
IgG phase I antibodies, CRP and 18F-FDG-PET/CT scan are used for diagnosis and moni-
toring in clinical practice. We aimed to identify and test biomarkers in order to improve 
discriminative power of the diagnostic tests and monitoring of chronic Q fever. 
Methods We performed a transcriptome analysis on C. burnetii stimulated PBMCs of 
4 healthy controls and 6 chronic Q fever patients and identified genes that were most 
differentially expressed. The gene products were determined using Luminex technology 
in whole blood samples stimulated with heat-killed C. burnetii and serum samples from 
chronic Q fever patients and control subjects. 
Results Gene expression of the chemokines CXCL9, CXCL10, CXCL11 and CCL8 was 
strongly up-regulated in C. burnetii stimulated PBMCs of chronic Q fever patients, in con-
trast to healthy controls. In whole blood cultures of chronic Q fever patients, production of 
all four chemokines was increased upon C. burnetii stimulation, but also healthy controls 
and past Q fever individuals showed increased production of CXCL9, CXCL10 and CCL8. 
However, CXCL9 and CXCL11 production was significantly higher for chronic Q fever 
patients compared to past Q fever individuals. In addition, CXCL9 serum concentrations in 
chronic Q fever patients were higher than in past Q fever individuals. 
Conclusion CXCL9 protein, measured in serum or as C. burnetii stimulated production, is 
a promising biomarker for the diagnosis of chronic Q fever. 
Keywords
Chronic Q fever, Coxiella burnetii, Chemokines, Biomarker, CXCL9
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background
Q fever is a zoonosis caused by the intracellular bacterium Coxiella burnetii. Clinical pre-
sentation ranges from asymptomatic acute infection to pneumonia or hepatitis. One to 
five percent of infected individuals develop chronic Q fever, characterized by a persistent 
infection of heart-valves, vascular aneurysms or prostheses. Chronic Q fever patients may 
present years after their initial infection with C. burnetii. If left untreated, this condition 
has a high mortality rate [63, 194]. To prevent irreparable damage, early diagnosis of 
chronic Q fever is essential [69]. Today, diagnosis of chronic Q fever depends on Polymerase 
Chain Reaction (PCR), measurement of anti-C. burnetii phase I IgG titers and imaging 
techniques [50, 54, 195]. Both laboratory techniques have drawbacks: PCR on blood has 
a low sensitivity and the cut-off values of anti-C. burnetii phase I to distinguish past from 
chronic infection are still debated and are either not sensitive or specific enough [33]. 
Even more challenging is the monitoring of chronic Q fever during treatment. Currently, 
monitoring relies on anti-C. burnetii phase I IgG titers, with a fourfold decrease or a drop 
below 1:800 as criteria to stop treatment [63]. In daily practice, titers hardly decrease and 
antibiotic therapy is continued for many years [196]. In addition, many clinicians measure 
C-reactive protein levels to monitor disease activity. Imaging by FDG-PET/CT scan is a 
promising tool in antimicrobial treatment decision making and its value in chronic Q fever 
is under investigation [54, 195]. The limitations of the current tests highlight the need for 
additional biomarkers in diagnosis and monitoring.
To assess new candidate biomarkers for the diagnosis of chronic Q fever and monitoring 
treatment, we performed a transcriptome analysis on C. burnetii-stimulated peripheral 
mononuclear cells of chronic Q fever patients. We validated the results in whole blood 
cultures and serum of patients with Q fever and control subjects. 
meTHods
subjects
Four groups were included: healthy controls, patients with acute Q fever, patients with 
a history of cured acute Q fever (past Q fever), and patients with chronic Q fever (Figure 
1). Healthy controls (n = 28) were hospital personnel and students without a history of Q 
fever. Healthy controls with available serum samples (n = 9) were Q fever seronegative. 
Specimens of anonymous acute Q fever patients (n = 9), all PCR-positive for C. burnetii 
at the time of blood-drawing, were collected from left-over samples of patients identi-
fied between 2008 and 2009 in the Canisius Wilhelmina (CWZ) Hospital. Left-over serum 
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specimens of past Q fever patients (n = 20), were also derived from the CWZ-hospital. 
Another 10 individuals with past Q fever, who provided heparin-anticoagulated blood, 
were recruited in the Q fever prevaccination screening program, described in detail by 
Schoffelen et al. [27]. All samples were Coxiella burnetii phase II IgG positive and had low 
phase I IgG titers, indicative for the absence of chronic Q fever. Chronic Q fever patients 
(n = 65) visited the outpatient clinic of the Radboud university medical center (n = 29) or 
the other participating hospitals: Catharina Hospital Eindhoven (n = 12), Elisabeth Hospital 
Tilburg (n = 9), CWZ-Hospital (n = 6), Elkerliek Hospital Helmond (n = 5) and Bernhoven 
Hospital Uden (n = 4). The chronic Q fever group comprised 47 proven and 18 probable 
chronic Q fever patients diagnosed according to the Dutch consensus guideline on chronic 
Q fever [50]. Thirty-seven patients presented with a vascular focus in an aneurysm or aortic 
prosthesis, 19 had valvular defects, 6 had both a vascular and valvular localization, and 3 
patients were immunocomprised. All patients were on antibiotic treatment. 
EDTA-anticoagulated blood for isolation of peripheral blood mononuclear cells (PBMCs) 
was collected from chronic Q fever patients and healthy controls. Heparin-anticoagulated 
blood for stimulation experiments was drawn from healthy controls, past Q fever and 
chronic Q fever patients. 
 
 
 
 
 
 
 
 
  
Figure 1. Total number of individuals in each group is depicted in the circles. The number of specimens 
per experiment of each group is described in the squares.*, ** : for chronic Q fever patients, 6 patients 
that were included in the transcriptome analysis and 22 patients of whom ex-vivo whole blood stimula-
tions were performed, also provided serum specimens
peripheral blood mononuclear cells isolation and transcriptome 
analysis
PBMCs were isolated from blood centrifuged with Ficoll-Paque (GE Healthcare, Uppsala, 
Sweden) according to standardized procedures [127]. Cells were taken from the interphase 
layer, washed twice in Phosphate Buffered Saline, and counted in a Coulter Counter Z 
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(Beckman Coulter, Fullerton, CA, USA). PBMCs were then incubated in flat-bottom 
24-wells plates in 1mL (107cells/mL) and stimulated with heat-killed C. burnetii Nine Mile 
(NM) RSA493 phase I (kindly provided by dr HJ Roest, CVI, Lelystad) in 107/mL at 37⁰C for 
8 hours. RNA was extracted with the RNeasy Mini kit (Qiagen, Hilden, Germany). With the 
2100 Bioanalyzer (Agilent Technologies, Massy, France) and the RNA 6000 Nano LabChip 
kit, the quality of the RNA was ensured. RNA quantity was determined with the Nanodrop 
(Thermo Scientific). Gene expression was analysed using Whole Human Genome 4x44K 
microarrays (Agilent Technologies, Massy, France) and One-color Microarray based Gene 
Expression Analysis kit, as previously described [151]. Gene expression data was analysed 
with R and Bioconductor software suite. Data was normalized with quantile normalization 
after being preprocessed and quality checked (Agi4x44PreProcess library). With the Limma 
library, differential gene expression was assessed. Data was compliant with the Minimun 
Information About a Microarray Experiment (MIAME) guidelines, accessible with number 
GSE66476 at the National Center for Biotechnology Information’s Gene Expression Omni-
bus, (www.ncbi.nlm.nih.gov/geo/). 
whole blood stimulation experiments 
Blood was drawn into 5mL heparinized tubes. Subsequently 500 µL blood was incubated 
with either heat-killed C. burnetii NM in an end concentration of 107/ mL or with culture 
medium (negative control) [28]. After 24 hours of incubation at 37⁰C and 5% CO2, the 
supernatants were harvested and stored at -80⁰C. 
measurement of proteins and anti-c. burnetii serology
Interferon-γ (IFN-γ) production in stimulated whole blood supernatants was measured with 
commercially available enzyme-linked immunosorbent assay (ELISA) (Sanquin, Amsterdam, 
Netherlands) according to the manufacturer’s instructions. The CXCR3-chemokines and 
CCL8 were determined in stimulated whole blood supernatants and serum using Luminex 
technology (Bio-Rad, CA, USA). CRP from serum was measured with immunoturbidim-
etry (Architect, Siemens; and Cobas 6000, Roche) and anti-C. burnetii antibodies were 
determined in serum by indirect immunofluorescence measuring IgM and IgG against C. 
burnetii NM phase I and II a commercially available immunofluorescence assay (IFA, Focus 
Diagnostics Inc., Cypress, CA, USA). 
statistical analysis
Data was analysed using GraphPad Prism and SPSS software programs and presented with 
medians and interquartile range (IQR) or minimum to maximum range (range) as cytokine 
and chemokine data is considered non-parametric. Differences between groups were as-
sessed with the Kruskal Wallis test and completed with Dunn multiple comparison tests, 
a p-value of <0.05 was considered significant. Spearman’s rho was used for determining 
104 Chapter 5
correlation. To assess the accuracy the proposed biomarkers, a receiver operator charac-
teristic (ROC) curve was constructed and the area under the curve (AUC) was calculated . 
Whether there was a correlation of the biomarkers with time after start of treatment was 
determined per patient by a non-linear best fit regression model. 
resulTs
gene expression profiles reveal up-regulation of ifn-γ inducible 
genes in chronic Q fever 
Transcriptional profiles of PBMCs of 4 healthy controls were compared to the PBMCs of 6 
chronic Q fever patients that were in-vitro stimulated with heat-killed C. burnetii. To look 
for candidate biomarkers, genes were selected that were most differentially expressed in 
both groups. Four genes encoding for chemokines ended at the top of the list: CXCL9 
also named Monokine Induced by IFN-γ (MIG), CXCL10 (IFN-γ Inducible Protein-10 (IP-10)) 
, CXCL11 (IFN-γ T-cell Attractant Chemokine (I-TAC)), and CCL8 (Monocyte Chemotactic 
Protein (MCP-2)) (Table 1). CXCL9, CXCL10 and CXCL11 are ligands for CXCR3 and are 
therefore named CXCR3-chemokines. 
Tabel 1 RNA expression in C. burnetii stimulated PBMCs
C. burnetii stimulated PBMCs
Healthy
controls
Chronic Q fever 
patients
Ratio 
patient / healthy control
CXCL11 / I-TAC 0.10 15.5 155
CXCL9 / MIG 0.45 62.5 139
CCL8 / MCP-2 0.50 46.3 93
CXCL10 / IP-10 0.20 16.5 83
Table 1. RNA expression in C. burnetii stimulated PBMCs of healthy controls (n = 4) and chronic Q fever patients 
(n = 6). Median fold change from unstimulated condition is indicated. Abbreviations: PBMCs, peripheral blood 
mononuclear cells; I-TAC, IFN-γ T-cell Attractant Chemokine; MIG, Monokine Induced by IFN- γ; MCP, Monocyte 
Chemotactic Protein; IP-10, IFN- γ Inducible Protein-
whole blood cultures show that c. burnetii induces production 
of cXcr3-chemokines
To validate the results from the gene expression analysis and to assess the suitability of 
measurement of the gene-products, the production of these proteins in C. burnetii stimu-
lated whole blood was determined (Figure 2). These experiments were performed with 
blood from 15 healthy volunteers, 20 past Q fever and 36 chronic Q fever patients, who 
were diagnosed (median) 20 months before blood sampling. 
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Figure 2. A-D Chemokine production in whole blood cultures of healthy controls (n = 15), past Q fever 
infected patients (n = 20) and chronic Q fever patients (n=36) after 24h stimulation with C. burnetii 
107/mL compared to culture medium RPMI. Medians with IQR are indicated. Kruskal Wallis with Dunn’s 
multiple comparisons test was performed. *: p < 0.05, **: p < 0.01, ***: p < 0.001, ns: not significant. 
Abbreviations: RPMI, Roswell Park Memorial Institute Medium; Cb NM, C. burnetii Nine Mile, IQR, In-
terquartile range.
Healthy controls showed significant C. burnetii-induced production of CXCL9, CXCL10 and 
CCL8, but no production of CXCL11. The same pattern was seen in past Q fever individu-
als. Chronic Q fever patients showed increased production of all four chemokines (CXCL9, 
CXCL10, CXCL11 and CCL8). CXCL9 production was significantly higher in chronic Q 
fever patients (median 15.1 ng/mL, IQR 8.5-26.5) than in healthy controls (median 3.6 ng/
mL, IQR 1.7–8.2, p < 0.05) and past Q fever patients (median 3.8 ng/mL, IQR 2.8-5.3, p 
< 0.05). CXCL11 production in chronic Q fever patients (median 146 pg/mL, IQR 83-230) 
was higher than in past Q fever patients (median 66 pg/mL, IQR 43-183, p < 0.05).
A Receiver-operator-curve (ROC) analysis was performed for CXCL9 and CXCL11 to dis-
tinguish between chronic Q fever patients and past Q fever patients. The test accuracy, 
denoted by the area under the curve (AUC), was 85% (CI: 75-95%) for CXCL9 and 78% 
(CI: 66-90%) for CXCL11.
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Further analysis of the CXCL11 production in chronic Q fever patients showed that produc-
tion in samples taken within 3 months after diagnosis (n = 5) was significantly higher than 
in samples taken later in the course of the disease (n = 20, p < 0.05), but not for the other 
chemokines.
Because the identified chemokines are all induced by IFN-γ, their correlation with C. 
burnetii-specific IFN-γ production in the whole blood culture supernatants was assessed. 
Generally, correlation was moderate (Supplementary Figure 1). The correlation coefficient 
(Spearman) was 0.54 for CXCL9 (p < 0.001), 0.70 for CXCL10 (p<0.001), 0.50 for CXCL11 
(p<0.001) and 0.53 for CCL8 (p<0.001). 
circulating cXcl9 serum levels are high in chronic Q fever 
patients 
We measured circulating chemokines in serum of 9 healthy controls, 10 past Q fever 
individuals, 9 acute Q fever and 51 chronic Q fever patients. Chronic Q fever patients were 
treated for a median of 13 months (range 0-46). 
Chronic Q fever patients exhibited significantly higher serum concentrations of CXCL9 
(median 899 pg/mL, range 92-12734), CXCL10 (median 311 pg/mL, range 16-1497) and 
CXCL11 (median 21 pg/mL, 4-106) compared to healthy controls (CXCL9 230 pg/mL, 164-
557, p < 0.001, CXCL10 151 pg/mL, 73-264, p < 0.05, CXCL11 10 pg/mL, 5-15, p < 0.01, 
Figure 3). Chronic Q fever patients showed higher CXCL9 serum concentrations than past 
Q fever individuals (median 537 pg/mL, 82-927). Chronic Q fever patients did not have 
higher levels of CXCL10 or CXCL11 than past Q fever individuals (median 204 pg/mL,10-
464 and median 18 pg/mL, 6-72). Concentrations of CCL8 were low in all groups and did 
not differ between groups. As compared to chronic Q fever patients, acute Q fever patients 
had higher CXCL10 serum concentrations (median 1204 pg/mL, 180-1439, p < 0.01). The 
other chemokines did not differ between chronic Q fever and acute Q fever patients.
ROC analysis of the CXCL9 serum concentrations of chronic Q fever compared to past 
Q fever individuals resulted in a test accuracy of 79% (denoted by the AUC, CI 67-92%, 
Figure 3E). The sensitivity was 73% and specificity 80%, when a cut-off (580 pg/mL) was 
chosen that yielded both a high sensitivity and specificity. 
Clinical parameters of the patients at diagnosis, such as PCR positivity in blood or tis-
sue, and anti C. burnetii phase I IgG titers were compared to the performance of CXCL9 
serum concentration at the 580 pg/mL cut-off value (Table 2 and a detailed description in 
Supplementary Table 1). Further analysis of the CXCR3-chemokine serum concentrations 
revealed that samples taken within one month after diagnosis of chronic Q fever (n = 9) 
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were significantly higher for CXCL9 (p < 0.05) and CXCL10 (p < 0.05) than samples taken 
more than 1 month after diagnosis (n = 41). 
Figure 3. Circulating levels of chemokines, medians with interquartile range are indicated. Panel A-D display 
CXCL9, CXLC10, CXCL11 and CCL8 serum levels respectively, in healthy controls (n =9), past Q fever individuals 
(n = 10), acute Q fever (n = 9), and chronic Q fever (n = 51). Kruskal Wallis with Dunn’s multiple comparisons 
test was performed. Panel E represents the Receiver Operating Characteristic (ROC curve) of CXCL9 concentra-
tion in serum in chronic Q fever patients or past Q fever individuals. *: p < 0.05, **: p < 0.01, ***: p < 0.001, 
ns: not significant. 
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Table 2 Comparison of diagnostic characteristics and CXCL9 serum concentration 
Diagnostic parameters Proven chronic Q fever
(n=38), (%)
Probable chronic Q fever
(n=13), (%)
IgG phase I > 1:1024 at diagnosis 32/32 (100%) 11/13 (85%)* 
PCR blood/tissue positive 26/31 (81%) - 
CRP >10mg/L at diagnosis 5/14 (36%) 1/2 (50%)
Serum CXCL9 >580 pg/mL 31/38 (82%) 6/13 (46%)
Table 2. * Two patients had IgG phase I levels of 1: 512 and were diagnosed based on FDG-positive lesions on 
the ventral side of the heart with a mechanical aortic valve and a FDG-avid lesion in the ascending aorta, near 
the pre-existing aneurysm of the thoracic aorta.
circulating serum concentrations of cXcr3-chemokines during 
follow-up show no correlation with treatment duration
As circulating CXCR3-ligands were high in chronic Q fever patients, we investigated 
whether they would decrease during the course of treatment and could be used as marker 
for monitoring the effect of treatment. To this end, we analysed serum samples taken at 
regular intervals of 28 chronic Q fever patients during their visits to the outpatient clinic. 
In total, 137 serum samples were available (median 5 samples per patient (range 2-7), 
between 0 to 62 months after start of treatment). In a nonlinear best fit regression model, 
the slopes of the regression lines per patient were calculated and the median slope was 
generated for CXCL9 (-5.0, range -1959 to 23), CXCL10 (-0.8, range -125550 to 22), 
CXCL11 (-0.2, -14 to 1.6) and CCL8 (-0, -19 to 35) indicating that there was no relation 
between chemokine levels and treatment duration per patient (Figure 4). Similar results 
were obtained when time after last positive PCR in blood was taken into account. 
Figure 3. Non-linear regression lines of CXCL9 serum concentrations per chronic Q fever patient in 
months from diagnosis, a best fit model was adapted. 
CXCL9, a promising biomarker in the diagnosis of chronic Q fever 109
5
cXcr3-chemokines are weakly correlated to igg phase i and 
c-reactive protein 
In 135 serum samples from 40 chronic Q fever patients the corresponding anti-C. burnetii 
IgG phase I titers were known. There was a weak correlation between IgG phase I titers 
and CXCL9 (Spearman r = 0.24, p < 0.01) but no correlation with the other chemokines.
The acute phase protein C-reactive protein is elevated in various inflammatory conditions 
including Q fever and is determined during treatment to monitor disease activity. Seventy-
six CRP values were available from 27 patients. Fifty-eight samples were below the detec-
tion limit of the test (5 mg/L), whereas only 5 CRP values were above 50 mg/L. We assessed 
the correlation of the CRP values to the concurrent chemokine serum concentrations and 
found a weak correlation with CXCL9 (r = 0.25, p < 0.05) and CXCL11 (r = 0.47, p < 
0.001), but not with the other chemokines. 
discussion
In the present study, we searched for new biomarkers for diagnosis and monitoring of 
chronic Q fever. With a transcriptome analysis, we found 4 highly up-regulated chemokine 
genes, induced by IFN- γ, in response to heat-killed C. burnetii. Subsequent whole blood 
stimulation experiments and the measurement of serum concentrations showed that C. 
burnetii-stimulated CXCL9 and CXCL11 production was higher in chronic Q fever patients 
compared to past Q fever individuals, and that serum concentrations of CXCL9 were 
higher in chronic Q fever patients compared to past Q fever individuals. This suggests that 
particularly CXCL9 could aid in the diagnosis of chronic Q fever.
CXCL chemokines are small chemotactic proteins, characterized by the presence of four 
cysteines with a variable amino acid ‘X’ dividing them [128]. As suggested by their alterna-
tive names, the four mentioned chemokines share the same inducer IFN-γ. In addition, 
CXCL10, CXCL11 and CCL8 can also be induced by type I interferons and by TNF-α, 
whereas this is not the case for CXCL9. These chemokines can be expressed by a variety of 
cells such as PBMCs, macrophages, endothelial cells and fibroblasts [128]. CXCL9, CXCL10 
and CXCL11 are a ligand of the same CXCR3-receptor located on NK-cells, effector T-cells, 
dendritic cells and many non-immune cell types. Even though these 3 chemokines have 
similar properties, their affinity for CXCR3 varies and their expression depends on time and 
stimulus, suggesting critical differences in production and function [197, 198]. CXCL9 and 
CXLC10 are degraded by matrix metalloproteinase-8 (MMP-8) and MMP-9 respectively 
[199], therefore, differences in concentration of active MMP-8 or MMP-9 may 
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influence the levels and functionality of CXCL9 and CXCL10. With respect to the immune 
response against intracellular bacteria such as C. burnetii, it is of interest that CXCR3-
chemokines have also been examined as candidate markers for the differentiation between 
active and latent tuberculosis [200], as a possible alternative for IFN-γ release assay (IGRA) 
in latent tuberculosis [201] and for follow-up of tuberculosis treatment [202].
As we published recently, C. burnetii antigen-specific CXCL10 production was high during 
the acute stage of C. burnetii-infected BALB/c mice [203]. In line with this, we report high 
CXCL10 serum concentrations in human acute Q fever patients during the early stage of 
their disease. Although it is tempting to speculate that CXCL10 may be an early marker 
for acute Q fever, CXCL10 is likely an inflammation marker rather than being specific for 
acute Q fever [204, 205]. 
Previously, we published that cytokine production (TNF-α, IL-1β, IL-1Ra, IL-4, IL-5, IL-6, 
IL-10, IL-12p70, IL-23, IL-18) in C. burnetii-stimulated diluted blood did not distinguish 
seropositive controls from chronic Q fever patients, whereas the ratio of IFN-γ/IL-2 produc-
tion appeared to accurately identify chronic Q fever patients with 79% sensitivity and 96% 
specificity [60]. Despite its usefulness, this assay is rather laborious, because it demands 
stimulation and incubation of whole blood cultures. Reviewing the results from the current 
study we can argue that simple measurement of CXCL9 serum concentration may also be 
of help in distinguishing chronic Q fever from past infection, although its specificity and 
sensitivity is somewhat lower than the IFN-γ/IL-2 production assay. 
It is reasonable to believe that the circulating CXCR3 ligands are not exclusively raised 
in chronic Q fever. Circulating CXCL9 and CXCL10 concentrations are also elevated in 
patients with heart failure, but to a lesser extent than what we observed in chronic Q fever 
patients [206, 207]. More importantly, we have not addressed the specificity of CXCL9 in 
relation to other pathogens that elicit a T-helper 1 cell response, such as mycobacterium 
tuberculosis and others. It is likely that these infections will at least temporarily induce 
elevated serum concentrations of the CXCR3 ligands. These caveats need to be considered 
when measuring CXCL9 serum concentrations in patients suspected of a chronic infection. 
C. burnetii stimulated CXCL9 production may be more specific than serum concentration, 
although this was not tested in the current study. It has to be noted that conclusions on 
CXCR3 biomarkers should not be based on the transcriptome analysis alone, but need to 
be considered in light of the validation experiments. Additionally, the small sample size of 
the transcriptome analysis deems cautious interpretation. 
Another limitation is the variable time after diagnosis of chronic Q fever at which the first 
sample was taken, 9 serum samples were taken within one month after diagnosis. This 
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may have led to an underestimation of the discriminative power in the early phase of the 
disease. Adding to this effect is the unknown Q fever status of part of the healthy controls 
who provided samples for whole blood stimulation. In the Netherlands, within the center 
of the endemic area, the prevalence of C. burnetii antibodies is about 5% [21]. 
We also focused on the capacity of IFN-γ induced CXCR3-chemokines to monitor disease 
activity in chronic Q fever. Overall, we found that serum samples taken shortly after diag-
nosis displayed higher CXCL9 and CXCL10 concentrations compared to samples drawn 
after long-term antibiotic treatment. Assuming that antibiotics are effective in lowering 
disease activity, this may indicate that CXCL9 and CXCL10 levels are related to disease 
activity. However, we found no correlation between chemokine levels and duration of 
antibiotic treatment. Of note, all chronic Q fever patients included in the present study 
were still under treatment and according to the traditional markers of disease activity, were 
considered to have active disease. The absence of cured patients in our cohort limited our 
ability to detect any direct correlation between chemokine levels and disease activity. 
Traditional markers for diagnosing and monitoring chronic Q fever are anti-phase I IgG 
titers, reflecting a specific B-cell derived humoral immune response and CRP, a product 
of an aspecific IL-6 mediated inflammatory response, used to detect complications and 
concomitant infections. Arguably, these markers might not accurately reflect disease activ-
ity, since the protective immune response against C. burnetii is predominantly an IFN-γ 
mediated T-helper 1 response. Anti-phase I IgG antibodies play a relatively small role in the 
adequate immune response to C. burnetii [98, 101]. 
Reportedly, CRP is high in the acute stage of acute Q fever [32, 208]. However, as we have 
shown, CRP is undetectable in most samples of chronic Q fever patients and therefore 
not a suitable marker for disease remission in chronic Q fever. Thus, the weak correlation 
of CRP and CXCL9 found in our study is expected. Given the small role of the humoral 
immune response in intracellular infections, it may not be surprising that serum CXCL9 is 
only weakly correlated with anti-phase I IgG titers.
conclusion
In conclusion, CXCL9, as a marker of cell-mediated immunity, is a promising candidate to 
improve the diagnostic accuracy of chronic Q fever.
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supplemenTary files
Supplementary Table 1 Diagnostic parameters of the chronic Q fever patient cohort
Patient Chronic Q fever 
diagnosis
PCR blood/
tissue
IgG phase I at 
diagnosis 
CRP at diagnosis 
(mg/L)
CXCL9 
(pg/ml)
1 proven positive 1:32768 5 12734
2 proven positive 1:2048 unknown/nd 10170
3 proven positive 1:4096 unknown/nd 4978
4 proven positive 1:131072 22 4295
5 proven positive unknown unknown/nd 3250
6 proven unknown 1:32768 unknown/nd 3052
7 proven positive 1:8192 unknown/nd 2464
8 proven unknown 1:2048 unknown/nd 2248
9 proven positive 1:32768 15 2206
10 proven positive 1:8192 unknown/nd 2088
11 proven positive 1:32768 5 1808
12 proven negative 1:65536 58 1496
13 proven unknown 1:1024 unknown/nd 1215
14 proven negative 1:65536 unknown/nd 1080
15 proven positive 1:4096 unknown/nd 1056
16 proven positive 1:4096 unknown/nd 1038
17 proven negative 1:1024 34 990
18 proven positive unknown unknown/nd 930
19 proven positive 1:1024 unknown/nd 926
20 proven positive 1:8192 6 900
21 proven negative unknown 93 886
22 proven unknown 1:2048 unknown/nd 837
23 proven unknown unknown unknown/nd 824
24 proven positive 1:8192 unknown/nd 782
25 proven positive 1:4096 unknown/nd 775
26 proven positive 1:4096 unknown/nd 724
27 proven positive unknown unknown/nd 698
28 proven positive 1:32768 5 672
29 proven positive 1:65536 5 612
30 proven positive 1:4096 unknown/nd 589
31 proven positive 1:8192 unknown/nd 583
32 proven positive unknown 5 542
33 proven unknown 1:32768 unknown/nd 484
34 proven positive 1:131072 5 394
35 proven positive 1:8192 5 307
36 proven positive 1:2048 unknown/nd 213
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Supplementary Table 1 Diagnostic parameters of the chronic Q fever patient cohort (continued)
Patient Chronic Q fever 
diagnosis
PCR blood/
tissue
IgG phase I at 
diagnosis 
CRP at diagnosis 
(mg/L)
CXCL9 
(pg/ml)
37 proven negative 1:8096 unknown/nd 207
38 proven negative 1:1024 5 92
39 probable unknown 1:1024 unknown/nd 2778
40 probable negative 1:4096 unknown/nd 1741
41 probable unknown 1:16384 30 1009
42 probable negative 1:2048 unknown/nd 934
43 probable negative 1:512 unknown/nd 929
44 probable negative 1:512 unknown/nd 899
45 probable unknown 1:16384 unknown/nd 553
46 probable negative 1:4096 unknown/nd 550
47 probable negative 1:32768 unknown/nd 443
48 probable negative 1:4096 5 409
49 probable negative 1:8192 unknown/nd 297
50 probable unknown 1:8192 unknown/nd 295
51 probable unknown 1:4096 unknown/nd 191
 Supplementary table 1. Diagnostic characteristics of chronic Q fever patient cohort. Abbreviations: unknown/
nd: unknown or not determined. 
Supplementary figure 1. Panel A-D scatter plots of C. burnetii stimulated chemokines production and 
corresponding C. burnetii stimulated interferon-γ production in an ex-vivo whole blood assay.
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absTracT
We report a 75-year-old man with chronic Q fever with an infected aortic prosthesis and a 
PCR positive C. burnetii psoas abscess. Because of clinical failure after intensive antibiotic 
treatment and surgery, a trial with IFN-γ injections was initiated. After 6 months, we were 
unable to show any beneficial effect on anti C. burnetii phase I and II IgG-titers, C. burnetii 
specific IFN-γ and IL-2 production, and 18F-fluorodeoxyglucose positron emission tomog-
raphy combined with CT scan (18F-FDG-PET/CT scan) imaging. We propose to consider 
IFN-γ supplementation only in other Q fever patients in case of in-vitro impaired C. burnetii 
specific IFN-γ production.
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inTroducTion
Chronic Q fever is a persistent infection of aneurysms, aortic prostheses or heart valves 
caused by the intracellular bacterium Coxiella burnetii. Chronic Q fever develops in 1-5% 
of patients after the initial infection [2]. Therapy of chronic Q fever, including long-term 
antibiotic regimens, surgery and radiologic drainage of abscesses, is often troublesome. In 
several patients the infection persists and mortality is up to 25% even with appropriate 
treatment [69, 70]. Therefore, additional therapies are highly needed.
The aid of adaptive immunity is crucial for effective eradication of Coxiella burnetii. IFN-γ, 
secreted by T-cells, enhances the killing capacity of macrophages and promotes maturation 
and alkalinisation of C. burnetii containing phagosomes, thereby contributing to effective 
clearance [209]. IFN-γ deficient mice are highly susceptible to C. burnetii infection [98]. 
In vitro, IFN-γ reduces bacterial viability of C. burnetii infected monocytes and induces 
apoptosis [99, 100]. This raised the question whether recombinant IFN-γ can be used as 
adjuvant therapy in chronic Q fever infection.
Here we report the clinical course of a 75-year-old patient with chronic Q fever, who had 
been unsuccessfully treated with multiple antibiotic regimens and surgery, and received 
IFN-γ therapy for 6 months.
meTHods
ifn-γ/il-2 production
Heparinized whole blood was stimulated with 107/mL heat-inactivated C. burnetii Nine 
Mile phase I (NM, RSA 493, kindly provided by H.I. Roest (Veterinary Institute, Lelystad, the 
Netherlands), 10 µg/mL phytohaemagluttinin (Sigma, St Louis, MO), or culture medium as 
described previously [60]. IFN-γ and interleukin 2 (IL-2) production were determined using 
commercially available enzyme-linked immunosorbent assays (ELISA, R&D, Minneapolis, 
USA).
peripheral mononuclear cell isolation and stimulation
Peripheral mononuclear cells (PBMCs) were isolated according to standardized protocols 
[150]. Cells (5x106/mL) were stimulated with heat-inactivated C. burnetii NM (107/mL) for 
24 hours. Cytokine production (interleukin (IL-6), tumor necrosis factor α (TNF-α), and 
interleukin 10 (IL-10)) was measured using commercially available ELISA kits.
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reactive oxygen species production
PBMCs (106/mL) were incubated for 1 hour and washed to acquire adherent monocytes. 
The cells were incubated with culture medium, opsonized heat-inactivated C. burnetii (107/
mL) or opsonized zymosan 10mg/mL (Sigma, st Louis, MO). Luminol (Sigma, st Louis, MO) 
was added to all wells and chemiluminescence was measured with the Biotek Synergy 
reader (Biotek, Winooski, USA).
ethics
The patient provided written informed consent. Research was conducted according to the 
principles of the Declaration of Helsinki.
case report
A 75-year-old man was diagnosed with chronic Q fever [50] in June 2011. In 2005, he 
had an abdominal aortic aneurysm (AAA) for which he was treated with an endovascular 
aneurysm repair (EVAR) procedure in 2009. In 2011, he started to complain of fatigue, 
without fever, night sweats or weight loss. Q fever serology was indicative for chronic Q 
fever: IgG phase I 1:4,096, IgG phase II 1:4,096 with negative results for IgM phase I and 
II (immunofluorescence assay [IFA] Focus Diagnostics Inc., Cypress, CA, USA). Serum PCR 
(in-house real-time PCR targeting IS1111a) for C. burnetii was negative. 18F-fluorodeoxy-
glucose positron emission tomography combined with CT (18F-FDG-PET/CT scan) showed 
an 18F-FDG-positive aortic prosthesis with abscess formation of the left psoas muscle in 
July 2011. Radiographic guided puncture of the fluid collection was PCR positive for C. 
burnetii. Transthoracic echocardiography and 18F-FDG-PET/CT did not show any signs of 
endocarditis. Subsequently, a combination of doxycycline 200 mg daily and hydroxychlo-
roquine 200mg t.i.d. was initiated in June 2011. Because of involvement of the aortic 
endoprosthesis and increase of the phase I IgG titer to 1:16,384, the EVAR was replaced 
by an autologous vene and the psoas abscess was drained surgically in January 2012. In 
the following year Q fever IgG phase I titers declined from 1:16,384 to 1:4,096. While in 
early 2012 the serum concentrations of doxycycline were in the therapeutic range (6.2 and 
7.5 mg/L), in the summer of 2012 the concentrations were 3.5 and 2.8 mg/L. Therefore, 
the doxycycline dosage was increased to 100 mg t.i.d. Six months later, dark pigmented 
skin was noticed on his upper legs and the patient complained of severe hypersensitiv-
ity to sunlight. These phenomena were considered side effects of doxycycline [210] and 
the regimen was switched to moxifloxacin 400 mg daily in April 2013. Moxifloxacin was 
stopped after 8 months because of calcaneal tendinitis. Subsequently, cotrimoxazol was 
started, but was stopped nearly immediately because of allergy. Therefore, clarithromycin 
was prescribed. In July 2014, 3 years after diagnosis, 18F-FDG-PET/CT showed persistent 
high uptake in the wall of the aortic aneurysm and an unchanged abscess of the ile-
opsoas muscle. Meanwhile, serologic titers were still high: IgG phase I 1:2,048; serum PCR 
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remained negative. Clarithromycin was continued, but 18F-FDG-PET/CT in January 2015 
showed no improvement.
Considering the insufficient scintigraphic and serological improvement after 3.5 years of 
intensive antibiotic therapy and surgery, we decided to initiate IFN-γ (Immukine, Boeh-
ringer Ingelheim, Germany) (100µg s.c.) thrice a week. The patient tolerated the IFN-γ well. 
Because of the experimental set-up, the patient was monitored by FDG-PET/CT scanning 
and repetitive measurements of the humoral and cellular immune response i.e. Q fever 
serology, C. burnetii-stimulated in-vitro cytokine production and C. burnetii-induced ROS 
production in monocytes. 
The serological titers after 4 months (IgG phase I 1:2,048) had not changed compared to 
the start of IFN-γ treatment. After 6 months, however, IgG phase I had increased twofold.
C. burnetii specific IFN-γ production in whole blood was high just before the start of IFN-γ 
therapy, and declined in the 4 months thereafter. The IFN-γ/IL-2 ratio decreased after 1 
month of treatment and stabilized the following months (Figure 1). TNF-α, IL-6 and IL-10 
production by C. burnetii-stimulated PBMCs was unaffected over the course of treatment.
Figure 1. Course of C. burnetii specific production of IFN-γ and IL-2 and the IFN-γ/IL-2 ratio, in whole 
blood cultures over time, starting just before initiation of IFN-γ therapy up to 4 months of therapy.
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ROS production was determined before treatment, after 1 week and after 1, 2 and 3 
months. The in-vivo administrated IFN-γ did not influence ROS production of in-vitro C. 
burnetii stimulated monocytes.
The 18F-FDG-PET/CT-scan, after 6 months of IFN-γ therapy, did not show any improvement 
(Figure 2) with a persistent multifocal pattern of increased 18F-FDG uptake in the native 
aortic wall, around the endoprosthesis and in the previously drained abscess region.
Figure 2. 18F-FDG-PET/CT scan after 6 months of IFN-γ therapy. Panel a. Sagittal and transverse images 
before start of therapy. Panel b. Sagittal and transverse images after approximately 6 months of therapy. 
The scans show persistent 18F-FDG uptake and no improvement after 6 months of therapy.
Based on the increased phase I C. burnetii specific IgG titers, the cellular C. burnetii specific 
immune responses that were in part unchanged, and the absence of improvement of the 
18F-FDG-PET/CT-scan, it was decided to stop IFN-γ injections and to add doxycycline, despite 
the possibility of deterioration of the hyperpigmentated skin lesions and photosensitivity.
discussion
We describe the first adult patient with therapy resistant chronic Q fever, treated with IFN-γ 
supplementation for 6 months. Although the patient endured the treatment well, clinical 
and laboratory tests reflecting his C. burnetii specific immune responses did not improve.
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C. burnetii specific phase I IgG titers are the generally accepted indicator for the response 
to treatment. However, titers often remain elevated for a considerable period of time and 
evidence for serology as a reliable prognostic factor for the persistence or cure of chronic Q 
fever is limited [63]. Therefore, we adopted an additional immunological biomarker, i.e. the 
IFN-γ/IL-2 production in C. burnetii stimulated whole blood [60]. IFN-γ/IL-2 ratio decrease 
in successfully treated chronic Q fever patients [120]; the ratio in our patient decreased as 
well, but had also been low 1 year before start of IFN- γ therapy, when antibiotic therapy 
was unsuccessful. In this situation, interpretation of the ratio is complex due to the IFN-γ 
administration. Because IFN-γ i- vitro has a stimulating effect on ROS production [99], we 
also measured the effect of the in-vivo administrated IFN-γ on in-vitro C. burnetii-induced 
ROS production by monocytes, but no effect was observed.
18F-FDG-PET/CT after 6 months of IFN-γ therapy remained unchanged. Increased 18F-FDG 
accumulation indicates increased inflammatory activity, whether this is due to active in-
fection or IFN-γ related inflammation cannot be determined. Nevertheless, a decrease in 
18F-FDG accumulation in infectious disease settings is associated with response to therapy 
[211] and was absent in this study, suggesting failure of treatment.
In literature, two young children suffering from Q fever related recurrent multifocal os-
teomyelitis and intractable fever without response to antibiotics, are described to have 
benefited from IFN-γ therapy [212, 213]. Chronic Q fever has rarely been described in 
children [214]. Our patient produced high levels of IFN-γ upon stimulation in vitro before 
IFN-γ supplementation was started, suggesting that production of IFN-γ was not defective. 
Arguably, if IFN-γ production in the two reported children was low, this would indicate a 
shortage of IFN-γ and administration might compensate the deficit. The differences in age, 
localization of infection, antibiotic therapy and immune status may all explain why IFN-γ 
therapy was not successful in our patient. The dosage used was consistent with success-
ful dosages for chronic granulomatous disease [215] and severe fungal infections [67]. 
Although we observed no effect in our patient, we propose to consider IFN-γ supplementa-
tion in other Q fever patients with in-vitro impaired C. burnetii specific IFN-γ production.
In conclusion, we describe an adult patient with chronic Q fever with an infected aneurysm, 
who was treated for 6 months with IFN-γ injections. Due to lack of improvement monitored 
with antibody titers, cellular immunity assays and FDG-PET/CT, the IFN-γ supplementation 
strategy was abandoned.
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summary
Q fever infection can lead to chronic Q fever, a potentially lethal disease occurring in 
1-5% of patients infected with Coxiella burnetii, characterised by the persistence of this 
intracellular bacterium. It usually presents as endocarditis, infected vascular aneurysms, 
or infected vascular prostheses. This systematic review of the literature discusses the vari-
ous autoimmune syndromes and B-cell dyscrasias in acute and chronic Q fever patients, 
that may interfere with or impede recognition and diagnosis of Q fever. Reportedly, high 
concentrations of anti-cardiolipin antibodies may be found in acute Q fever patients, while 
specifically cardiac muscle antibodies have been reported during chronic Q fever. Systemic 
lupus erythematosus and antiphospholipid syndrome are the most frequently reported 
autoimmune syndromes, followed by neuromuscular disorders and vasculitis. B-cell dyscra-
sia, mostly cryoglobulinaemia, is predominantly described in chronic Q fever patients with 
endocarditis. We conclude that immunological (epi)phenomena are not rare during Q fever 
and may obscure the infectious etiology of the disease.
Keywords
Chronic Q fever, acute Q fever, Coxiella burnetii, immunological manifestations, autoim-
munity, cryoglobulinaemia. 
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inTroducTion
Q fever is a zoonosis caused by the intracellular bacterium Coxiella burnetii [216]. Upon 
inhalation of the bacterium, approximately 40% of patients develop symptomatic disease, 
referred to as acute Q fever, while 60% remain asymptomatic. Acute Q fever usually 
presents as a flu-like illness with fever, headache, and occasionally pneumonia or hepatitis 
[216]. Of those who get infected with C. burnetii, including those who undergo an asymp-
tomatic infection, around 1-5% will develop chronic Q fever, a disease with high mortality 
that is characterised by the persistence of C. burnetii. Chronic Q fever usually manifests as 
endocarditis or infection of pre-existing aneurysms or vascular prostheses [53].
Recently, we were confronted with a patient with a chronic Q fever infection who simul-
taneously presented with various autoimmune syndromes, a Monoclonal Gammopathy of 
Unknown Significance (MGUS) and cryoglobulinaemia. During follow-up, anti-C. burnetii 
IgG phase I antibodies declined dramatically even though the patients’ clinical condition 
worsened. Further research however showed high anti-C. burnetii IgG phase I antibod-
ies in the cryoprecipitate. This surprising finding, that could have erroneously led to the 
assumption that the infection was treated successfully, and the observation that various 
chronic Q-fever patients in our hospital had one or more positive immunological laboratory 
tests, motivated us to perform a literature study. We aim to inform clinicians of the clinical 
relevance of these concomitant immunological phenomena through a review of literature 
on such epiphenomena in relation to both chronic and acute Q fever. 
meTHods
search strategy and study selection.
Articles were identified through a systematic search in the scientific database Medline on the 
subjects autoimmunity and Q fever. Studies dating back to 1960 were traced up to October 
2016.The following terms were used: “Q fever” and (“autoimmun*” or “autoantibodies” 
or “cryoglobulinaemia” or “vasculitis” or “SLE” or MESH [Monoclonal Gammopathy of 
Unknown Significance] or “gammaopathy”). The reference lists of the included studies 
were checked for studies that were not found with the search strategy. Studies in English 
and French were included in the search. Only human studies were considered for inclusion. 
Records were screened for full text availability and assessed for eligibility. Only full-text 
articles were included. Eligibility criteria included the presence of an acute of chronic Q 
fever infection and the presence of autoimmune phenomena. Reports that did not or only 
remotely addressed Q fever issues, such as Q fever vaccine effects, were excluded. Reports 
describing inflammatory conditions of non-autoimmune etiology were excluded, except 
134 Chapter 7
for B-cell dyscrasias. Study eligibility was assessed by one author (AFMJ) and in case of 
uncertainty, a second author (MvD) was consulted. Detailed search strategy is described in 
Supplementary Table 1.
data extraction and items
A data extraction form was designed to collect data from the reports. For the articles in 
qualitative review, the following items were recorded i.e. research question, detailed meth-
ods (number of participants, inclusion and exclusion criteria, Q fever diagnosis criteria, 
determinants, primary outcome measure, statistical analysis) and results (outcome, follow-
up time). For case series and case reports in the case analysis (or quantitative analysis), 
extracted data for every patient comprised Q fever status, gender, age at diagnosis and 
symptoms of autoimmune phenomena. Anti-C. burnetii titers, PCR positivity and all immu-
nological parameters were extracted from the manuscript. The final diagnosis with regard 
to autoimmune phenomena was described and the course of the autoimmune phenomena 
and follow-up time was included. Q fever diagnosis was revised by the authors and the 
criteria of the Dutch consensus guideline [50] were applied if there was a discrepancy 
between the definition of acute or chronic Q fever in the report and the Dutch consensus 
guidelines.
Quality assessment 
Quality of case control and cross-sectional studies was assessed with the Newcastle-
Ottawa Scale for assessing non-randomized studies [217]. The quality of case series was 
assessed with the checklist ‘quality appraisal of case series studies using a modified Delphi 
technique’[218]. Case reports were not quality assessed as they generally have a low level 
of evidence. 
review
The presence of immunological manifestations in various chronic Q fever patients treated 
at our hospital prompted us to conduct an analysis of case reports and a review of cross 
sectional studies of immunological and autoimmune phenomena in acute and chronic Q 
fever patients. In the qualitative analysis, 1610 acute Q fever patients and 372 chronic Q 
fever patients (mostly endocarditis) were included in total. In the case analysis, we identi-
fied 37 studies reporting on 33 acute Q fever patients and 8 chronic Q fever patients with 
immunological phenomena (Figure 1). The quality of the included papers was generally 
low to moderate according to the NOS scores (see Table 1), due to the fact that most 
articles did not include a control group. 
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Figure 1. Search fl ow diagram, indicating the search fl ow with 32 reports included in the quantitative 
analysis (case analysis) and 6 studies that were suitable for the qualitative analysis.
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Autoimmunity
Autoimmunity, defined as an immune response of T- and B-cells directed against self-anti-
gens, is recognized as a disease state, i.e. autoimmune syndrome, if the immune response 
results in tissue injury. To prevent autoimmunity, several mechanisms are adopted either 
centrally, e.g. in the thymus or bone marrow, or peripherally, where self-reactive lympho-
cytes await deletion (death) or anergy, an unresponsive state. Failure of these mechanisms 
gives self-reactive lymphocytes the opportunity to survive and become activated. Certain 
conditions are necessary to develop autoimmunity. It is assumed that the HLA type and 
other genetic traits predispose to autoimmunity following an environmental trigger, such 
as an infection [225]. Various mechanisms of infection-related autoimmunity induction 
have been proposed, of which molecular mimicry is the most accepted [226, 227]. For 
example, membrane proteins of Chlamydia species show similarity to myosin present 
in the myocardium and it has been shown that Chlamydia-derived peptides can induce 
autoimmune myocarditis in mice [228]. Another, non-excluding, theory is that of epitope 
spreading, characterized by the start of a response to a primary specific self-epitope, 
which, via immune activation and cell damage, leads to diversification of recognition of 
self-epitopes. This mechanism of autoimmunity was first described using a mouse model of 
experimental autoimmune encephalitis, which starts with the self-reactive response to one 
myelin basic protein epitope, but progresses to multiple other myelin basic protein epitopes 
as the disease advances [229]. A third theory, called bystander activation, is related to 
this concept and based on excessive local production of inflammatory mediators and the 
presence of bacterial superantigens, that by the polyclonal activation of T-cells also activate 
self-reactive T-cells [227, 230]. In view of these mechanisms, patients with chronic infec-
tions may be particularly prone to develop autoimmunity.
Prevalence of autoantibodies in Q fever
As for the qualitative analysis, the prevalence of autoantibodies during acute Q fever is 
generally high (Table 1), with anti-cardiolipin antibodies (aCL) being reported in 47-81% 
of cases [219, 221, 223]. In patients with pre-existing valvular heart disease, high titres 
of anti-cardiolipin IgG were associated with progression to chronic Q fever endocarditis 
[219, 220], but not to chronic Q fever with a vascular focus. Anti-smooth muscle antibod-
ies (ASMA) form a second important group of antibodies in patients with acute Q fever, 
with prevalences ranging from 23-29% [222, 224]. Other autoantibodies found in acute 
Q fever patients are cardiac muscle antibodies (CMA) (12%), anti-neutrophil cytoplasmic 
antibodies (ANCA) (13%), anti-nuclear antibodies (ANA) (13%) and anti-dsDNA antibodies 
(4%). Antigen positivity to nuclear components of HeLa cells was 57% in this group [222]. 
In our case analysis (Table 2), 17 acute Q fever patients presented with autoantibodies 
without an autoimmune syndrome. Most commonly described were aCL and ASM anti-
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bodies, followed by ANA and ANCA. Some rare autoantibodies, such as an anti-protein 
S antibody [231], anti-glomerular basement membrane (anti-GBM) antibodies [232] and 
anti-prothrombinase [224, 233] have also been reported. These patients did not exhibit 
signs of a clinical syndrome, except for one with anti-prothrombinase antibodies, who 
showed signs of anti-phospholipid syndrome. 
In chronic Q fever patients autoantibodies are also prevalent, with up to 67% of patients 
testing positive for at least one [222]. In contrast to the high aCL prevalence reported for 
acute Q fever patients, aCL in chronic Q fever, persistent Q fever endocarditis in particular, 
seems to be uncommon (5%)[219]. The median concentration of aCL in a cohort of 227 
chronic Q fever patients was 5 IgG Phospholipid Units (GPLU), which is below the cut-off 
value of 22 GPLU [220]. Moreover, in chronic Q fever, the autoantibody profile seems to 
have switched from aCL to other autoantibodies, among which are CMA (38% positive) 
and ASMA (27%). Other autoantibodies are ANCA (12%), ANA (15%), anti-dsDNA (9%) 
and Parietal Cell Antibodies (PCA) (9%) [222]. The high prevalence of CMA in chronic Q 
fever patients, as opposed to acute Q fever patients, is an interesting finding in the setting 
of chronic Q fever endocarditis. Most of the patients with persistent infection had endo-
carditis, but some of the individuals without cardiac involvement also had CMA antibodies. 
Additional chronic Q fever patients with asymptomatic autoantibodies were not retrieved 
from the case analysis, undoubtedly due to a publication bias. 
Clinical syndromes
In the qualitative analysis, a recent observational cohort study from Million et al. [221], has 
convincingly shown the relationship between acute Q fever and thrombosis emphasizing 
the role of anti-phospholipid antibodies in a cohort of 664 acute Q fever patients. Of the 
patients with acute Q fever and thrombosis, comprising 2% of the acute Q fever cohort, 
92% was positive for aCL IgG and 83% for lupus anti-coagulant. Anti-cardiolipin IgG 
was found to be dose dependently associated with thrombosis. The authors stress that 
anti-phospolipid antibodies should be measured in acute Q fever patients, due to their 
association with thrombosis, acquired valvular heart disease and progression to chronic Q 
fever. Anti-cardiolipin IgG may also give rise to a Libman-Sacks endocarditis, a verrucous 
valvular thickening which is thought to be caused by damaging immune complexes in a 
hypercoagulable state, the proposed mechanism for acute Q fever endocarditis. Acute Q 
fever endocarditis is prevalent in 1.2% of patients with acute Q fever and considered a 
distinct clinical entity [234].
Our case analysis, summarized in Table 2, shows that clinical autoimmune syndromes in 
acute Q fever patients can be categorized into four groups. The first category is systemic 
lupus erythematosus (SLE) and antiphospholipid syndrome (APS) and comprises seven 
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acute Q fever patients [235-238], of which some did not completely fulfill the criteria 
for SLE and APS, mostly due to missing laboratory results. The second category involves 
autoimmune neuritis/myelitis and consists of four acute Q fever patients [239-242]. The 
third group is vasculitis, involving one small, one medium, and one large vessel vasculitis 
case [243-245]. One patient with autoimmune hemolytic anaemia [246] forms the fourth 
‘mixed’ category. Eight patients were found with chronic Q fever that had autoimmune 
phenomena or cryoglobulinaemia. Two patients had a vasculitis, one patient who was 
immunocompromised and one patient with a possible vascular focus of the infection [245]. 
One patient that had a persistent C. burnetii hepatitis presented with an autoimmune 
hepatitis/primary biliary cirrhosis overlap syndrome [247]. The concurrence of these phe-
nomena does not necessarily imply causality, but it is an association. The clinical relevance 
of these immunological epiphenomena is not based on the perceived autoimmune disease, 
but on its implications on diagnostic and therapeutic decision making during an already 
complex diagnostic process of for instance fever of unknown origin. 
Monoclonal Gammopathy of Undetermined Significance
MGUS, part of the spectrum of B-cell dyscrasia, refers to the presence of a monoclonal 
protein produced by a plasma cell clone. It is a premalignant asymptomatic condition, with 
a prevalence of approximately 5% in persons above 70 years of age. Most patients are 
incidentally identified through medical evaluation. Deducted from the case analysis, one 
case of MGUS IgG kappa has been described In acute Q fever, which waned off after suc-
cessful treatment of the infection [245]. There are no reports of MGUS in chronic Q fever, 
although one case showed a polyclonal gammopathy with mixed cryoglobulinaemia [248].
Cryoglobulinaemia
Cryoglobulinaemia is a systemic inflammatory disease associated with vasculitis and also 
belongs to the B-cell dyscrasias. Cryoglobulins are immunoglobulins that precipitate at 
temperatures below 37⁰C and are able to form complexes that primarily contain immuno-
globulins, but may also comprise complement and antigens [249]. Unlike autoimmunity, 
cryoglobulinaemia is not necessarily characterized by self-reactive lymphocytes, but results 
from monoclonal, oligoclonal, or polyclonal production of aberrant immunoglobulins 
[249]. Precipitation at temperatures below body temperature is thought to be due to 
altered glycosylation of the protein [250], aggravated by certain physiological states such 
as pH or temperature fluctuation. Organ damage results from classical-pathway comple-
ment activation and other immune-mediated mechanisms after deposition of complexes 
in the vessel wall, resulting in vasculitis. Purpura, arthritis, and kidney disease are the most 
common manifestations, but cryoglobulinaemia may also remain asymptomatic. Often, 
cryoglobulinaemia is a manifestation of an underlying disease, such as chronic infection, 
connective tissue diseases and lymphoproliferative disorders. Each cause has its distinctive 
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type of cryoglobulinaemia, described in the Brouet classification [251], based on the clonal-
ity of immunoglobulins. Cryoglobulinaemia of an infectious origin is mostly comprised of 
polyclonal immunoglobulins with a monoclonal component and rheumatoid factor activity, 
i.e. mixed or type II. Polyclonal immunoglobulins without a monoclonal component are 
often secondary to infectious diseases or autoimmune disorders, i.e. mixed or type III, 
whereas cryoglobulinaemia secondary to a hematological malignancy is monoclonal, i.e. 
type I.
The prevalence of cryoglobulinaemia was not described in any of the articles for the quali-
tative analysis. In the case analysis, one case of cryoglobulinaemia has been described with 
acute Q fever. In chronic Q fever however, five cases of cryoglobulinaemia [248, 252-255] 
have been reported, most of them of the mixed cryoglobulinaemia type and all cases 
involved persistent C. burnetii endocarditis. In more than half of the cases, purpuric skin 
eruptions prompted the investigation of cryoglobulinaemia, even before the chronic Q 
fever diagnosis was made. It is unclear when these patients were infected with C. burnetii; 
however, a substantial delay in diagnosis is possible for chronic Q fever. Cryoglobulinaemia 
with accompanying symptoms may therefore be the first presentation of a chronic Q 
fever infection. Disappearance of cryoglobulins during antibiotic therapy was seen in two 
patients, adequate treatment of the infection may therefore have a positive effect. It is 
important to note that anti-C. burnetii IgG phase I antibodies may precipitate in the cryo-
precipitate. Clinicians should bear in mind that a decrease in Q fever antibody titres with 
concomitant cryoglobulinaemia warrants investigation of the cryoprecipitate, as has been 
previously recognised in hepatitis C [256]. Arguably, any unexpected substantial decrease 
in C. burnetii antibody titre, in a patient that otherwise does not respond well to therapy, 
should be followed by an assessment of cryoglobulins.
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discussion 
Inherent to the underreporting of Q fever, cross-sectional studies on (chronic) Q fever 
are mostly small, with the exception of the studies of the French Reference center. Most 
studies do not include an appropriate control group, which substantially decreases the 
quality of the studies. With regard to the case analysis, our review is particularly prone to 
reporting and to publication bias due to the fact that we selected only reports published 
in English and French. More studies on cohorts of acute and chronic Q fever patients are 
needed to provide better insight into the real prevalence of immunological phenomena 
and their consequences in clinical practice.
conclusions
This review of known literature shows that Q fever may be accompanied by a variety of 
immunological manifestations, e.g. autoimmunity, and B-cell dyscrasias such as cryoglobu-
linaemia, that have the potential to delay its diagnosis, but also complicate serological 
follow-up and treatment. Clinicians should therefore keep Q fever in mind when encoun-
tering such manifestations, especially in (previously) endemic areas, and even more so in 
case of risk factors for chronic Q fever. Furthermore, interpretation of Q fever serology 
should be done with care in case of cryoglobulinaemia and negative or low titres should 
lead to serological investigation of the cryoprecipitate. These immunological manifesta-
tions in Q fever warrant further investigation, especially since they have the potential to 
obscure diagnostic and therapeutic decision making.
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supplemenTary files
Supplementary Table 1. Detailed methods of systematic review of the literature
Methods Explanation
Eligibility criteria Case reports and case series regarding Q fever and autoimmune syndromes 
and autoantibodies were considered. Studies in English and French were 
included in the search, as many Q fever cases originate from France. Studies 
dating back to 1960 were traced as earlier studies could not be found. Full 
text was required for entry into the database.
Information 
source
Pubmed
Search terms - Q fever AND
- Autoimmun*OR
- Autoantibodies OR
- Cryoglobulinaemia OR
- Arteritis OR
- Vasculitis OR
- SLE OR
- MESH [Monoclonal Gammopathy of Unknown Significance] OR
- Gammopathy OR
No limits
Study Selection First selection procedure: all articles not fulfilling the eligibility criteria were 
excluded
Second selection procedure based on title and abstract: non-autoimmune or 
non-cryoglobulinaemia were excluded.
Third selection procedure based on full-text: studies that described 
interventions or fundamental research were excluded
Data Items Data was extracted using a predefined form after determination of relevant 
items. Items noted were Q fever status, age, gender, symptoms, laboratory 
parameters, immunological parameters, IgG phases and treatment
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Objectives: to increase awareness of concomitant chronic Q fever infection and systemic 
sclerosis (SSc) and to give insight into the course of SSc during persistent Q fever infection.
Methods: Patients in this case series were identified after the Dutch Q fever outbreak in 
2007-2010. SSc was diagnosed by a scleroderma expert and patients fulfilled the 2013 
Classification Criteria for Systemic Sclerosis. Chronic Q fever was diagnosed by a combina-
tion of PCR, serology and a proven infection on imaging studies. 
Results: Four cases presented with chronic Q fever, persistent Coxiella burnetii infection, 
shortly preceded or followed by the diagnosis of limited cutaneous SSc. The three male 
patients of 60 years or older developed a relatively mild SSc, which did not require im-
munosuppressive therapy during adequate treatment of the chronic Q fever infection. The 
58-year-old female patient used immunosuppressives for her ne nwly diagnosed SSc at the 
time she likely developed a chronic Q fever infection. 
Conclusions: Chronic Q fever can be associated with or even predispose to SSc. In this 
case series, chronic Q fever preceding SSc was associated with a mild course of SSc without 
the necessity of immunosuppressive drugs, while chronic Q fever development due to 
immunocompromised state was associated with a more deteriorating course of SSc.
Keywords: chronic Q fever, Coxiella burnetii, systemic sclerosis, persistent focalized Q 
fever infection 
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inTroducTion
Chronic Q fever is a persistent infection with the intracellular bacterium Coxiella burnetii, 
which affects individuals with pre-existing heart valve abnormalities, aneurysms, aortic 
prostheses, a compromised immune system or pregnancy [8]. After the major Q fever 
outbreak in the Netherlands (2007-2011), chronic Q fever patients presented with diverse 
clinical symptoms and complications. The infection is severe, life-threatening and can be 
associated with immunological phenomena and autoimmune diseases [224, 245].
Systemic sclerosis (SSc) is a complex immune disorder with an unknown pathogenesis. It 
has three distinctive hallmarks: inflammation, vasculopathy and extensive fibrosis. Clini-
cally, these hallmarks are expressed as progressive fibrosis of skin and internal organs, 
digital ulcera, pulmonary arterial hypertension, interstitial lung disease, and renal disease. 
Infectious agents have long been implicated in the pathology of SSc and different views ex-
ist on how they contribute to the development of SSc [268]. One of those is the discovery 
of the interferon signature in patients with SSc, which implies that innate immunity is 
imperative in the disease process [269]. While chronic viral infections have been postulated 
to be involved in the development of SSc, this link is not firmly established for bacterial 
infections [270]. Until now, SSc has not been associated with Q fever.
We report four cases of chronic Q fever coinciding with SSc, although presentation and 
diagnostic course varied greatly. By reporting these four cases, we aim to raise awareness 
for the concomitant occurrence of chronic Q fever and systemic sclerosis.
ethical statement
All patients or their legal representatives provided written informed consent for publica-
tion. This study was performed according to the guidelines of the Helsinki Declaration. 
funding
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patient 1
This 62-year-old man was diagnosed with chronic Q fever in November 2009 after several 
months of malaise with bouts of fever. He had recently been diagnosed with an aortic 
aneurysm, which was treated with an endovascular aneurysm repair (EVAR). His anti-C. 
burnetii phase I IgG antibodies were 1:4096, indicative of a chronic Q fever infection 
according to the Dutch consensus guidelines on chronic Q fever [50]. Pus removed around 
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the EVAR during another operative procedure was PCR positive for C. burnetii. He was 
started on doxycycline 200mg and hydroxychloroquine 600mg. In the same month, the 
patient was referred to a dermatologist because of red purpuric lesions on his toes. A 
skin biopsy unveiled superficial and deep perivascular chronic dermatitis with signs of a 
vasculopathy, a lymphocytic infiltrate and a thickened vascular wall. A rheumatologist 
diagnosed him with limited cutaneous systemic sclerosis (LcSSc), which was based on 
positive antinuclear antibodies (ANA), positive anticentromere antibodies (ACA), skin scle-
rosis, Raynaud’s phenomenon, facial teleangiectasia and nailfold capillaroscopic changes 
consistent with an active scleroderma pattern. The modified Rodnan skin score (mRSS), 
which is used to monitor the extensiveness of skin involvement, was nine at his first visit. 
There were no signs of organ involvement. Therapy was not started due to the relatively 
mild complaints. During follow-up visits, the patient presented with digital ulcera and 
sclerodactyly. In November 2011, anti-C. burnetii phase I antibody titers had sufficiently 
decreased to 1:128 and treatment for chronic Q fever was stopped. The LcSSc remained 
uneventful.
patient 2
This 68-year-old man was referred to the outpatient clinic of the Rheumatology department 
on suspicion of systemic sclerosis by his general physician in January 2012. His medical 
history revealed arterial and venous insufficiency with venous thrombosis and pulmonary 
emboli in 2011. Since 4 years, he experienced Raynaud’s phenomenon and recently started 
to feel the skin of his fingers thicken. The mRss was 0 at that time. Nailfold capillaroscopy, 
however, demonstrated an early scleroderma pattern with dilated loops, irregular structure 
and micro-hemorrhages. His laboratory parameters revealed positive ANA and anticen-
tromere antibodies. He was diagnosed with early LcSSc and nifedipine 2 dd 40mg was 
prescribed for his Raynaud’s phenomenon. Gradually, sclerodactyly developed and his mRss 
increased to 2 in 2014. There were no signs of pitting scars, digital ulcera or internal organ 
involvement. Meanwhile in 2013, an aortic aneurysm was discovered and follow-up visits 
were performed yearly. An FDG PET/CT-scan performed in September 2016 showed an 
aneurysm with surrounding infected soft tissue. Upon this finding, anti-C. burnetii phase I 
IgG antibodies were determined and a highly increased titer of 1:8192 was detected, PCR 
for C. burnetii on blood was negative. Chronic Q fever was diagnosed [50] and he was 
started with doxycycline and hydroxychloroquine therapy. In July 2017, his mRSS was 3, 
based on skin thickening of the fingers and lower arm. Due to a sudden expansion of his 
aneurysm, an EVAR was performed. He is currently still being treated and monitored for his 
chronic Q fever infection and LcSSc respectively. 
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patient 3
In 2016, a 63-year-old man received an EVAR for his recently identified aneurysm of the 
abdominal aorta and distal common iliac artery. Although he had an unremarkable medical 
history before surgery, he experienced night sweats and lost 15% of his initial weight after 
surgery. Anti-C. burnetii phase I IgG titer were found to be 1:1024 and an infected EVAR 
with abscesses was visualized on an FDG PET/CT scan, which was sufficient for diagnosis 
of chronic Q fever [50]. PCR on blood and drained pus from a perianal abscess remained 
negative for C. burnetii. He was started on doxycycline and hydroxychloroquine. Because 
the abscesses around the iliac artery were closely related to the rectosigmoid junction and 
cultured different intestinal bacteria, a fistula was suspected. In a routine screening, auto-
antibodies were determined and revealed positive ANA and anti-topoisomerase I antibod-
ies (anti-Scl-70). The patient appeared to have a new onset of Raynaud’s phenomenon and 
mild puffy fingers. Nailfold capillaroscopy showed aspecific changes consisting of a normal 
capillary density, micro-hemorrhages and broadening of the apexes. Giant capillaries were 
not present. Based on these clinical data, the patient was diagnosed with early SSc and is 
currently being monitored in the outpatient clinic.
patient 4
This 58-year-old woman presented with increasing complaints of discolored fingers and 
toes at the outpatient clinic of the Rheumatology department in 2007. Upon physical 
investigation, radial folds around the mouth were discovered. She evidently suffered from 
swollen fingers with sclerodactyly and thickened cuticles accounting for a mRSS of 2. 
Laboratory investigation showed a sedimentation rate of 24 mm/hr and the presence of 
ANA. She was diagnosed with LcSSc based on sclerodactyly, Raynaud’s phenomenon, 
ANA positivity, an early scleroderma pattern on nailfold capillaroscopy, and interstitial lung 
diseases. She was shortly prescribed methotrexate (20 mg weekly), but this was stopped 
due to disease progression under therapy. Prednisone 10mg daily was started, although 
this also failed to result in remission of the disease. In 2008, her mouth orifice was further 
limited, she presented with a polyarthritis of both knees, metacarpal phalanx (MCP) I, and 
PIP III and IV. Methotrexate 20 mg weekly was again started in September 2008 without 
any improvement. Therefore 120mg intramuscular methylprednisone injections every 6 
weeks were initiated.
Meanwhile, in 2008, she was admitted with a presumed acute Q fever infection based on 
positive anti-C. burnetii IgG, for which she was prescribed doxycyline 100mg twice daily 
for 2 weeks. In January 2009, IgG phase I titers were again tested and turned out to be 
1:8192. Retrospectively, IgG phase I titers from serum in 2007 were already 1:4096. She 
was diagnosed with probable chronic Q fever, according to the Dutch consensus guideline 
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on chronic Q fever diagnostics [50], based on high serology titers and the immune suppres-
sants she had used around 2007. A focus for the infection could not be identified.
With regard to the LcSSc, her condition gradually deteriorated, borderline pulmonary 
hypertension was diagnosed and methotrexate was prescribed in addition to prednisone, 
despite of the chronic infection. The serologic titers slowly declined fourfold with doxy-
cycline and hydroxychloroquine, which were stopped after 2 years of treatment in 2011, 
when anti-C. burnetii IgG phase I was 1:2048. 
discussion
The present study describes four chronic Q fever patients with concomitant LcSSc, differing 
in presentation and diagnostic process. In all four cases, the Q fever infection coincided 
with the beginning or worsening of SSc symptoms, although the disease entities were not 
diagnosed simultaneously. The Q fever outbreak in the Netherlands [23], which started in 
2007 and ended in 2010, offered a well-defined time frame in which Q fever was most 
likely contracted, as before and after the outbreak, incidence levels were neglectably low. 
Most patients however already had Raynaud’s phenomenon for a longer period of time, 
indicating that they likely had an increased susceptibility for SSc, the onset of which was 
possibly triggered by the chronic Q fever infection. The three male patients developed a 
relatively mild disease, which did not require immunosuppressive therapy. Furthermore, 
with adequate treatment of the chronic Q fever infection, the SSc remained present. 
The prevalence of systemic sclerosis in the Netherlands is 8.9 per 100,000 adults [271]. 
After the Q fever outbreak in the Netherlands, the prevalence of systemic sclerosis among 
proven and probable chronic Q fever patients is 4 in 322 individuals (unpublished data 
from Q fever database). Extrapolating these numbers (1242: 100,000), this indicates a 
possible association between chronic Q fever and systemic sclerosis. Although this is a 
highly selected group of individuals, bias based on population characteristics is unlikely. 
Supportive of this notion is that systemic sclerosis is usually more prevalent among women, 
while chronic Q fever is not, and systemic sclerosis is generally diagnosed earlier (median of 
50 years) [271], compared to chronic Q fever (median of 71 years) [64]. 
It is documented that chronic Q fever infection can trigger autoimmune diseases and other 
immunological syndromes [224, 245]. In favor of this is the typically older age of onset 
and the male gender of the cases, both features that are more commonly seen in chronic 
Q fever than SSc [8]. Furthermore, an increasing body of evidence suggests that infec-
tious agents can trigger SSc, for example, antibodies to cytomegalovirus, parvovirus B19, 
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hepatitis B, Toxoplasma and Helicobacter pylori are more common in SSc patients than in 
matched control groups [272-275]. The mechanisms for this have yet to be elucidated, but 
among others, molecular mimicry seems conceivable, as retroviral proteins show similarity 
to topo-isomerase antigen [276]. With regard to Q fever, intriguingly, C. burnetii infection 
and SSc both share the activation of the interferon type I pathway in dendritic cells [277, 
278]. Not excluding other theories, C. burnetii might also facilitate the progression of 
early systemic sclerosis, possibly through the induction of CXCL10 and CXCL11. These 
chemokines are abundantly produced by immune cells of chronic Q fever patients [129] 
and are biomarkers for disease progression of early SSc [279, 280]. Interesting in this 
notion is that CXCL10, induced by TNFα, interferons and fibroblasts, is anti-angiogenic and 
promotes vascular smooth muscle cell proliferation [128].
Differing from the other cases, case 4 evidently suffered from LcSSc with interstitial lung 
disease that required immunosuppressive therapy. Here, effective treatment of the infec-
tion did not noticeably improve the course of the SSc. Whether Q fever or SSc precedes the 
other is unclear, but both scenarios seem plausible. It is known that rheumatoid arthritis 
patients have an increased risk for the development of chronic Q fever, while anti-tumor 
necrosis factor (TNF) therapy was found not to be an independent risk factor [52]. 
These four cases likely represent an interplay between the immunological disturbances 
during a chronic Q fever infection and SSc and may be mediated by endothelial vasculopa-
thy and fibroblast dysfunction. The three male patients diagnosed after 60 years of age 
showed mild SSc in the absence of immunosuppressive therapy, while the female patient 
presented with a more aggressive course of SSc, possibly due to a non-Q fever related 
aetiology. By describing these four cases, we would like to raise awareness for concomitant 
chronic Q fever and systemic sclerosis and their clinical course. 
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Background: Chronic Q fever is caused by the intracellular bacterium Coxiella burnetii. 
This bacterium may cause infection of heart valves, aneurysms, or aortic prostheses. 
Immunological epiphenomena are not uncommon during Q fever and may complicate 
diagnosis and treatment. Here, we aim to identify immunological phenomena associated 
with chronic Q fever.
Methods: We collected data on immunological phenomena, including auto-antibodies, 
cryoglobulins and the presence of autoimmune diseases, from patients with proven chronic 
Q fever, who were treated at the outpatient clinic of the Radboud Expert Center for Q fever 
in Nijmegen, the Netherlands.
Results: Immunological data were available from 40 proven chronic Q fever patients. 
Twenty patients tested positive for auto-antibodies, such as anti-nuclear antibodies (39% 
of 36 patients), anti-smooth muscle antibodies (55% of 20 patients), anti-neutrophil cy-
toplasmic antibodies (26% of 19 patients) and anti-cardiolipin IgM and IgG (3% and 6% 
of 34 patients, respectively). During treatment or shortly before chronic Q fever diagnosis, 
patients were diagnosed with systemic sclerosis (3), systemic lupus erythematosus (2), au-
toimmune thyreoiditis (1) and myocarditis (1). Three patients needed immunosuppressive 
treatment in addition to treatment of their infection. Cryoglobulins were present in 26% 
of 31 patients. In one of the patients, these cryoglobulins masked appropriate serological 
monitoring of chronic Q fever, because anti-C. burnetii IgG phase I antibodies aggregated 
in the cryopreciptate and could not be detected in regularly processed serum. 
Conclusions: Auto-antibodies, autoimmune syndromes, and cryoglobulinemia, may occur 
in association with chronic Q fever. Their presence may complicate appropriate diagnostic 
and therapeutic decision making. 
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inTroducTion
Physicians in the Netherlands are still frequently faced with the consequences of the large 
Dutch Q fever outbreak of 2007 – 2010. During this period, over 4.000 cases of acute Q fe-
ver were reported [23], and it was estimated that around 40.000 individuals were infected. 
Chronic Q fever, or persistent focalizing Q fever infection [124], is a persistent infection 
with Coxiella burnetii that occurs following 1-5% of all C. burnetii infections, whether the 
acute infection was symptomatic or asymptomatic. Potentially, it is a lethal disease that 
usually presents as endocarditis, an infected vascular aneurysm and / or vascular prosthesis, 
or an osteoarticular infection [31]. The infection is hard to eradicate and therefore requires 
intensive and long lasting antibiotic treatment, often in addition to surgical interventions 
[31]. Diagnosing chronic Q fever is challenging since disease manifestations are often 
relatively mild with complaints such as general malaise with fatigue and low-grade fever, 
suddenly however, severe complications such as heart failure due to valvular dysfunction 
or ruptured aneurysms with high mortality may occur[69]. As an obligate intracellular bac-
terium C. burnetii will not grow in blood cultures, making diagnosis rely on a combination 
of adequate history taking, testing for specific anti-C. burnetii antibodies, PCR and imaging 
techniques such as echocardiography and Positron Emission Tomography – Computed 
Tomography (PET-CT) [50]. These difficulties make that 7 years after the outbreak, chronic 
Q fever still has a major impact on the Dutch healthcare system. 
During an infectious disease, the immune response is supposed to specifically target the 
intruding micro-organism, although immune activation may also constitute a response that 
is not only directed against the micro-organism, resulting in so-called immunological epi-
phenomena or heterologous responses. These immunological epiphenomena may include 
auto-antibody formation, autoimmune diseases or non-self-reactive immune responses, 
such as cryoglobulinemia or paraproteinaemia. 
In the Radboud Expert Center for Q fever, several patients with a chronic Q fever infection 
demonstrated such phenomena, which may obscure the already challenging diagnostic 
and therapeutic management of chronic Q fever. Therefore, we retrospectively studied the 
prevalence of autoimmunity and cryoglobulinemia in 40 proven chronic Q fever patients. 
We aim to create awareness of concomitant immunological phenomena during chronic Q 
fever. 
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subjects
The study population consisted of patients with a chronic Q fever infection treated at the 
Radboud university medical center for whom data on immunological phenomena were 
available. Patients were diagnosed with chronic Q fever if they had either a positive PCR on 
blood or tissue or had an IgG phase I of ≥ 1:1024 measured by immunofluoresence assay 
(IFA) and a definite endocarditis according to the modified Duke criteria [178] or proven 
large vessel or prosthesis infection by imaging studies [50]. One or more immunological 
parameters were tested in 40 patients.
immunological parameters
A panel of eight immunological markers was tested. These included: anti-nuclear antibod-
ies (ANA), extractable nuclear antibodies (ENA), anti-neutrophil cytoplasmic antibodies 
(ANCA), anti-smooth muscle antibodies (ASMA), anti-mitochrondrial antibodies (AMA), 
anti-cardiolipin IgG and IgM, cryoglobulins and M-proteins. When ANA was positive, the 
sample was further tested for anti-double strand DNA (anti-dsDNA). In case of a positive 
ANA or ENA, an immunoblot was used to further specify anti-SS-A, anti-SS-B, anti-RNP, 
anti-SM, anti-topoisomerase, anti-Jo, anti-centromere, anti-PM-SCL and anti-histones. 
ANCA positivity was confirmed with determination of antibodies to myeloperoxidase (anti-
MPO) and proteinase 3 (anti-PR3) measurements. Positive anti-cardiolipins were followed 
by a anti-β-2-Glyproteine (β2GPI) determination. 
immunological tests
ANA were tested by indirect immunofluorescence (IIF) on Hep-2000 cells transfected with 
SSA/Ro60 cDNA (ImmunoConcepts, Sacramento, CA, USA). Analysis of extractable nuclear 
antibodies (ENA) was performed by using the EliA Symphony screenings assay on the Im-
munocap 250 platform, according to manufacturer’s instructions (Thermo Fisher Scientific 
Inc, Waltham, MA, USA). The screen consists of antigen sources: SSA/Ro60+Ro52, SSB, 
Sm, RNP, Scl-70, Jo-1, Cenp-B. ENA specificity was determined by using the Euroline profile 
3 immunoblot (EuroImmun, Lübeck, Germany). The blot consists of recombinant antigens, 
synthetic peptides and natural antigens coated as separate lines on a nylon membrane. 
The antigens that are coated are: SSA/Ro60, SSA/Ro52, SSB, Sm, RNP, Scl-70, Jo-1, Cenp-B, 
Rib-P, PM-Scl, PCNA, dsDNA, Nucleosomes, and AMA-M2. Anti-dsDNA antibodies were 
determined by EliA method.
ANCA IgG was also determined by IIF on ethanol fixed slides and when possible, a distinc-
tion between cytoplasmic and perinuclear ANCA staining pattern was made (NOVA Lite® 
ANCA, Inova Diagnostics, San Diego, CA). When the immunofluorescence was considered 
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positive, it was followed by a subsequent enzyme immunoassay specific for anti-proteinase 
3 (anti-PR3) or anti-myeloperoxidase (anti-MPO) IgG using the EliA method. In case of 
the presence of ANA, we considered the ANCA undeterminable for reasons of possible 
interference. ASMA IgG and AMA IgG measurements were performed with IIF by using rat 
tissue (NOVA Lite® Rat Liver, Kidney, Stomach, INOVA Diagnostics). Anti-cardiolipin IgG and 
IgM were determined by EliA method. When anti-cardiolipin antibodies were detected also 
anti-β2GPI IgG antibodies were determined by EliA method. The presence of cryoglobulins 
was determined by drawing blood in two pre-heated serum tubes. Serum tubes were 
allowed to clot at 37⁰C after which the serum is separated by centrifugation at 37⁰C. 
Serum is collected and placed at 4⁰C for minimal 72 hours. After this time frame, tubes 
are visually inspected for cryoprecipitation. When present, the precipitate was washed in 
cold phosphate buffered saline, dissolved and the composition of the cryoprecipitate was 
immunotyped by using immunofixation electrophoresis techniques using antisera against 
intact immunoglobulins (IgG, IgM and IgA) and kappa and lambda light chains (Sebia, 
Lisses, France). Based on their composition, the cryoglobulins were classified according 
to the Brouet system [251]. The presence of M-proteins in serum was determined after 
protein electrophoresis on agarose gel. M-proteins were typed and quantified by means of 
immunofixation, as previously described.
ethics statement
This study was conducted according to the principles expressed in the declaration of 
Helsinki. According to our national law, this study was exempt from approval by an ethical 
review board, because of the retrospective characteristics of the study.
resulTs
In this cohort of 40 patients, 90% were males and the median age at diagnosis of chronic 
Q fever was 71 years. The clinical characteristics and summary of immune phenomena are 
depicted in Table 1.
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Table 1 Characteristics of 40 chronic Q fever patients
Clinical parameters Number, (%)
Gender 36 (90%) men
Age at diagnosis (median, range) 71 y, (22-81 y)
Focus of infection 28 (70%) vascular
9 (23%) valvular
3 (8%) unknown (PCR on blood positive, no 
signs of acute Q fever infection)
Aortic vascular prosthesis 24 (60%) present
PCR 15 (38%) positive on blood 
11 (28%) positive on tissue
3 (8%) positive blood and tissue
Treatment from start of diagnosis 38 (95%) doxycycline and 
hydroxychloroquine
1 (3%) cotrimoxazol and moxifloxacine
1 (3%) doxycycline
Anti-C. burnetii IgG I at diagnosis (median, range) 1:4096 (1:512 – 1:131072)
Anti-C. burnetii IgG II at diagnosis (median, range) 1:4096 (1:256 – 1:131072)
CRP at diagnosis 13 mg/dL (4 – 228)
Immunological parameters Number (%) of total patients tested
ANA 14 (39%) of 36
ENA 7 (21%) of 34
Anti-dsDNA† 4 (67%) of 6 
Anti-SS-A, anti-SS-B, anti-RNP, anti-SM, anti-
topoisomerase, anti-Jo, ACA, anti-PM, anti-histon††
4 (33%) of 12
ANCA* 5 (26%) of 19
Anti-MPO or anti-PR3‡ 0 (0%) of 3
Anti-cardiolipin 1 (3%) IgM and 2 (6) IgG of 34
β2GPI ‡‡ 1 (50%) of 2
ASMA 11 (55%) of 20
AMA 1 (5%) of 20
Cryoglobulins 8 (26%) of 31
M-proteins 6 (16%) of 38
Table 1. Patient characteristics and summary of immunological phenomena of 40 chronic Q fever patients. † 
anti-dsDNA was only determined with positive ANA. †† only determined with ANA or ENA positive. *ANCA was 
only determined with negative ANA ‡ only determined with positive ANCA. ‡‡ only determined with positive 
anticardiolipins. Abbreviations: CRP: C-reactive protein, ANA: anti-nuclear antibodies, ENA: extractable nuclear 
antibodies, anti-dsDNA: anti-double strand DNA, ACA: anti-centromere antibodies, ANCA: anti-neutrophil cy-
toplasmic antibodies, anti-MPO: anti-myeloperoxidase, anti-PR3: anti-proteinase 3, ASMA: anti-smooth muscle 
antibodies, AMA: anti-mitochrondrial antibodies, β2GPI: β-2-Glyprotein I.
Autoimmunity
The immunological parameters of each of the 40 patients are shown in Table 2. Twenty patients 
(50%) had one or more positive auto-antibodies, of those, six patients experienced immune-
related symptoms or syndromes (30%) : systemic sclerosis (3), myocarditis (1), thyreoiditis (1), 
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and systemic lupus erythematosus (SLE) (2). The three patients with systemic sclerosis had 
mild complaints for which immunosuppressive treatment was not necessary. Two of them 
were positive for ACA and one patient had anti-Scl70 antibodies. One patient presented 
with both autoimmune thyreoiditis and persistent myocarditis (biopsy Coxiella PCR negative), 
respectively one and two years after the diagnosis of chronic Q fever. This patient was still 
being treated for refractory chronic Q fever, tested positive for ANA, and was treated with my-
comofetil phenolate, intravenous immunoglobulins and prednisone. Additionally, this patient 
had a normocytic anemia of unknown origin and tested positive for parietal cell antibodies 
(PCA). Two patients exhibited SLE-like characteristics one and two years after being diagnosed 
with chronic Q fever, and were ANA and anti-dsDNA positive. One of these patients also 
tested positive for phospholipid antibodies. Together with pleural effusion, glomerulonephritis 
and an epileptic seizure, this was sufficient for diagnosing SLE. The other patient exhibited 
signs of a sarcoid-like reaction at the root of his lungs, pleural and pericardial effusion, and 
had signs of polyarthritis. Both patients were temporarily treated with immunosuppressive 
drugs. The former patient was treated with prednisone and mycomofetil phenolate, result-
ing in a decrease of complaints and a decrease of both ANA and anti-dsDNA positivity. The 
latter patient was treated with prednisone alone and showed a decrease in symptoms and 
a decrease in ANA positivity. One other patient exhibited signs of AA amyloidosis with renal 
involvement, confirmed by biopsy. This patient is currently being monitored and treated for 
both his chronic Q fever infection and concomitant nephrotic syndrome.
B-cell dyscrasia
Cryoglobulinemia was found in eight of 31 (26%) tested chronic Q fever patients. The mean 
time to test was 14 months after diagnosis and four patients were tested before diagnosis. 
None of the patients were diagnosed with actual cryoglobulinaemic syndrome, but some 
had complaints of skin lesions or vasculitis, which could not definitely be confirmed to be 
related to the cryoglobulinemia. In three patients, the cryoglobulins were initially judged to 
be only weakly positive and the composition was not further specified. Other cryoglobulins 
could be categorised according to the Brouet classification. One patient was diagnosed 
with mixed-type 2 cryoglobulinemia with a monoclonal IgM lambda and IgG lambda and a 
polyclonal IgG. One patient had a mixed-type 2 and 3 with a monoclonal IgM and polyclonal 
IgA, IgM and IgG. The other three patients all presented with a mixed-type 3 polyclonal 
IgM and IgG. In one of the cases, the cryoglobulinemia had severe clinical consequences for 
the monitoring of the chronic Q fever infection. After a sudden decrease in anti-C. burnetii 
IgG phase I, which could have been mistaken for a response to therapy if not for the 
alarming deterioration on imaging studies, the cryoglobulin precipitate was investigated for 
involvement of anti-C. burnetii antibodies. The anti-C. burnetii IgG titer recovered from this 
precipitate (1:16384) appeared to be much higher than the corresponding anti-C. burnetii 
phase I IgG from serum (1:16) and mirrored the deterioration seen on the imaging studies.
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In five of eight positive tested patients the cryoglobulin course was followed and it de-
clined during chronic Q fever treatment with the exception of one patient who remained 
weakly positive from start. In this patient, cryoglobulinemia was diagnosed 2 years after 
the diagnosis of chronic Q fever. 
M-proteins were measured in 38 patients and found to be present in six (16%). Immuno-
fixation revealed that IgG kappa was present in three individuals, IgG lambda in another 
three, and one individual had a IgA kappa monoclonal band. Another six individuals did 
not comply to the criteria for M-proteins, but had oligoclonal development of IgG or IgM. 
More than two bands on the agarose gel were called oligoclonal immunoglobulins. Three 
individuals had both cryoglobulinemia and M-proteins or oligoclonal development. One 
of the patients was simultaneously diagnosed with monoclonal gammopathy of unknown 
significance (MGUS) and chronic Q fever. During antibiotic treatment, the anti-C. burnetii 
IgG phase I antibodies declined, which were at maximum 1:131072, and concurrently, his 
M-proteins (maximum 7 g/L) declined as well. A slight oligoclonal development of IgG type 
lambda (<1 g/L) persisted after remission of the chronic Q fever. 
discussion
In this study, we describe the spectrum of immunological phenomena in 40 patients with 
proven chronic Q fever. We observed three patients with systemic sclerosis, two with 
SLE and strikingly, 50% of patients were positive for ANA, ANCA or ASMA antibodies, 
although the clinical significance remains undetermined. Twenty-six percent of patients 
had cryoglobulinemia. Symptoms of these immunological manifestations required immu-
nosuppressive drug treatment in three patients. Although not all laboratory abnormalities 
may result in overt clinical disease, they may be clinically significant as immunological 
phenomena can interfere with diagnosis, monitoring and or treatment of chronic Q fever.
Earlier published studies dating from 1989 described several immunological manifesta-
tions in Q fever patients, such as auto-antibodies, inflammatory diseases and autoimmune 
diseases [219-222, 224, 245]. The observations from our study partially match previous 
literature, regarding the prevalence of auto-antibodies and SLE. Myocarditis has been 
described before, mostly during acute Q fever, although not exclusively [281]. Although 
the pathogenesis of Q fever myocarditis has yet to be elucidated, it is conceivable that an 
immunopathogenesis and perhaps even autoimmunity contribute. Similar to other chronic 
infectious diseases, a striking presence of ANA (39%), ANCA (26%) and ASMA (55%) was 
observed in our cohort. Considering the ongoing immune activation, patients with chronic 
infectious diseases may be particularly prone to autoimmunity. In a prospective multicenter 
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cohort of 302 chronic hepatitis C patients, it was found that 70% of patients carried at 
least one auto-antibody; ANA (41%), cANCA (3%), anti-dsDNA (3%), and ASMA (9%) 
[282, 283]. Gender strongly influences the prevalence of auto-antibodies, an important 
consideration in our predominantly male cohort. ANA positivity for instance, was only 16% 
in a German cohort of healthy men (mean 58 years) whereas it was almost 40% in healthy 
women [284, 285]. The chronic Q fever patients in our study had a low CRP concentration 
(median 13 mg/dL, range 4-228) at diagnosis of their infection. This finding emphasizes 
careful consideration of the diagnostic work-up for chronic Q fever, especially in a (previ-
ously) Q fever endemic area, as autoimmune phenomena and a low CRP concentration can 
mask this lethal chronic infection. 
Although cryoglobulinemia has been described in six separate case reports before [245, 
248, 252-255], the high prevalence of cryoglobulinemia with chronic Q fever was an unex-
pected frequent finding in our study. Cryoglobulinemia can be associated with haemato-
logical malignancies, connective tissue disorders or infections. A well-known example of an 
infectious origin is chronic hepatitis C, which has a prevalence of cryoglobulinemia of up 
to 40% in Mediterranean countries [283]. Hepatitis C virus- associated cryoglobulinemia is 
believed to develop from continuous B-cell proliferation sustained by the hepatitis C virus. 
Clonal B-cells produce immunoglobulins with rheumatoid factor activity, which bind to viral 
core proteins and attract complement. It is assumed that B-cells support viral replication 
and thereby sustain the reaction. Other non HCV-related cryoglobulinemias of infectious 
origin were described by Terrier et al. [286]. Interestingly, most of these cryoglobulinemia-
associated infections (hepatitis B, Brucella, Leishmaniasis, bacterial endocarditis) induce a 
chronic disease with hypergammaglobulinemia [286]. 
The role of B-cells and immunoglobulins in Q fever is not well understood. Effective T-cell-
mediated immunity seems to be crucial for control of this intracellular bacterial infection. 
However, high anti-C. burnetii IgG phase I are a hallmark of chronic disease, indicating 
that B-cells are strongly activated without much evidence that they contribute to cure. 
We speculate that continuous activation of B-cells by C. burnetii or T-helper cells underlies 
clonal B-cell expansion that forms the basis of cryoglobulinemia. It is conceivable that C. 
burnetii-specific antibodies at least in some individuals constitute a part of the cryoglobu-
linaemic immune complexes, especially because of the disappearance of a measurable 
antibody titer in room-temperature drawn serum of one patient.
This study has some limitations such as the retrospective nature and the absence of an age-
matched control group. Of note, auto-antibodies may also be found in healthy individuals, 
depending on age, gender, geographic location, but also techniques and cut-off values 
used. Thus, comparison to healthy individuals or other chronic infectious diseases is prone 
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to bias. Underestimation of the autoimmunity prevalence is also probable, as some patients 
were treated for chronic Q fever for a considerable time before immunological markers 
were determined. Most patients had not been immunologically tested before diagnosis 
of chronic Q fever, whether the antibodies were already present before infection remains 
unknown. A more general concern is that cryoglobulin determination is particularly prone 
to errors in daily practice, because of its need for careful temperature handling during and 
after blood drawing. 
This study highlights the urge to keep concomitant autoimmunity in mind when consider-
ing, diagnosing, or treating chronic Q fever. The clinical significance of immunological 
phenomena in Q fever is highly variable, ranging from the presence of subclinical immune 
markers to overt clinical manifestations that may have severe impact on the diagnosis, 
course or treatment of chronic Q fever. In case of an autoimmune disease, immunosup-
pressive therapy should be carefully deliberated. Cryoglobulins are a common finding in 
chronic Q fever patients and in most cases become undetectable when the chronic Q fever 
is adequately treated. Cryoglobulins should be determined at least once at diagnosis and 
repeated if the IgG phase I titers decline unexpectedly. 
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Summary and General Discussion
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In the scientific endeavor of my thesis, I aimed to better understand the immune response 
to C. burnetii in chronic Q fever patients. In part one, I performed studies to understand 
the immunological mechanisms contributing to the progression to chronic Q fever and 
to improve the diagnosis of chronic Q fever. In part two, I described the immunological 
epiphenomena associated with chronic Q fever. The findings described in this thesis are 
summarized and discussed below. 
Hampered by the high infectivity of C. burnetii and thus the requirement of a Biosafety 
level 3 facility, researchers world-wide use inactivated C. burnetii when studying the im-
mune response in Q fever. It was unknown whether cytokine responses to heat-killed C. 
burnetii reflect the cytokine responses to viable C. burnetii, especially in relation to chronic 
Q fever. In chapter 2, we found that viable bacteria induced less production of TNF-α, IL-
1β, IL-6 and IL-10 in peripheral mononuclear compared to heat-killed C. burnetii. However, 
IFNγ, IL-17 and IL-22, cytokines involved in the interaction between NK-cells and T-cells 
with monocytes/macrophages were induced in equal amounts by viable and heat-killed C. 
burnetii. This finding implies that care must be taken when interpreting results of experi-
ments with heat-killed bacteria, especially when investigating the responsiveness of innate 
immune cells. It is reassuring that IFNγ production induced by C. burnetii is not influenced 
by viability with regard to the IFNγ production assay [28, 60], the claim of an intact IFNγ 
pathway in chronic Q fever [29] or for vaccine development. It would be compelling to 
investigate whether viable C. burnetii is able to manipulate host cytokine responses, by 
comparing cytokine production to viable C. burnetii to inactivated C. burnetii with similar 
cell wall structure, for instance chloramphenicol-inactivated C. burnetii or UV-inactivated 
C. burnetii. In this respect, IL-10 would be an interesting cytokine, to follow up on the 
observation that IL-10 was increased in the viable compared to heat-killed C. burnetii 
condition in four healthy volunteers in the absence of C. burnetii antibodies. As IL-10 has 
been implicated in the early pathogenesis of chronic Q fever [111, 118, 119], this observa-
tion deserves validation in another study.
Chronic Q fever patients have a high risk of acute complications, most frequently in the 
first months after diagnosis or as the first manifestation of disease [53, 69, 194]. The most 
common complication is an acute aneurysm (unpublished data, van Roeden, presented 
at ECCMID 2017). Aneurysms are defined by several histopathological features: inflam-
mation, vascular smooth muscle cell apoptosis, oxidative stress and extracellular matrix 
degeneration [287]. Loss of smooth muscle cells and extracellular matrix degeneration is 
established by proteases called Matrix Metalloproteinases (MMPs) that can cleave extracel-
lular matrix. MMPs are associated with formation and expansion of aneurysms. They may 
be seen as a double-edged sword in infection, MMPs facilitate immune cell migration, 
whereas superfluous activation assists pathogen spread and causes tissue damage [140]. 
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MMPs also modulate the activation of cytokines, chemokines and defensins [142]. As 
such, MMPs constitute a link between aneurysms and infection. In chapter 3, the role of 
MMPs in chronic Q fever was studied. We started with a transcriptome analysis of stimu-
lated peripheral immune cells. Intriguingly, when comparing responses to C. burnetii with 
LPS stimulation, a catabolic pathway was significantly enriched, which comprised MMP 
genes. Next, we investigated whether genetic variations in MMP genes were associated 
with progression to chronic Q fever. Indeed, in a large cohort of chronic Q fever patients, 
genetic variations in MMP genes were more common than in controls with resolved Q fever 
and similar risk factors. These findings were validated with cell stimulation experiments, 
which showed that chronic Q fever patients, resolved Q fever controls with cardiovascular 
risk factors and healthy controls produce various MMPs upon in vitro stimulation with C. 
burnetii. We further pursued this by determining circulating MMPs. Circulating MMP-7 
was observed to be higher in chronic Q fever patients than in cardiovascular controls. Doxy-
cycline, which is also a matrix metalloproteinase inhibitor, could partially reduce C. burnetii 
induced MMP production in-vitro, an interesting beneficial side-effect of the antibiotic that 
is used in the first-line treatment of chronic Q fever. 
Increased MMP production is not specific for Q fever, it has been described in many in-
fectious diseases, such as tuberculosis, HIV and Helicobacter pylori infection [140]. More 
specific for Q fever however, is the link of MMPs with the exacerbation of existing vascular 
lesions and persistent C. burnetii infection. MMP activity is tightly regulated by the produc-
tion of inactive pro-enzymatic forms and balanced by the production of tissue inhibitors of 
MMPs (TIMPs) [288]. It is unlikely that enhanced MMP production alone would explain the 
contribution to chronic Q fever pathogenesis, it is rather the sum of production, activity 
and inhibition that could tip the balance towards tissue destruction and damaging immune 
effects. 
Using peripheral blood has the advantage of accessibility, but in terms of pathogenesis, 
the local environment of the aneurysm would be much more informative. It is very likely 
that circulating lymphocytes and macrophages have different properties and cell surface 
markers than their aneurysm residing counterparts. For instance, local concentrations of 
(active) matrix metalloproteinases could be substantially higher than in circulating in blood. 
In future research into the pathogenesis of chronic Q fever, the local environment should 
have a prominent place. An interesting source of information may be derived from study-
ing excised aneurysm tissue from chronic Q fever patients. New PET-scan imaging tracers 
may also serve to visualize the local infection in more detail. 
Despite the limitations of the study, we have shown with multiple approaches that MMPs 
are induced by C. burnetii in chronic Q fever patients. Given the association of genetic 
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variations in MMP genes in chronic Q fever patients compared to the past Q fever individu-
als with cardiovascular risk factors, MMPs likely contribute to the pathogenesis of chronic 
Q fever. I speculate that, after induction of MMPs by C. burnetii, the environment becomes 
more permissive for C. burnetii by compromising the integrity of the vascular wall, espe-
cially in those individuals that are already genetically susceptible. 
Innate immune responses are of vital importance for effective clearance of C. burnetii. C. 
burnetii has a specific preference for cells of the myeloid lineage and has an obligate in-
tracellular life-style. Therefore, early survival at the time of the innate immune response, as 
opposed to the adaptive immune response, may be crucial in the persistence of C. burnetii. 
Ghigo et al. found that macrophages of chronic Q fever patients were not able to effectively 
kill C. burnetii, in contrast to individuals cured from acute Q fever. Limited recruitment of 
cathepsin D, a molecule that regulates the last maturation step of the phagolysosome, 
was involved in this [109]. We hypothesized that inefficient processing of C. burnetii inside 
macrophages would facilitate early survival and thus persistence and we investigated this 
in chapter 4 by determining if genetic variations in these mechanisms were more prevalent 
in chronic Q fever patients. We identified three processes that were involved in the killing 
of C. burnetii and for which it was known that interference with these processes would, at 
least in-vitro, affect C. burnetii replication or survival. The first process was phagolysosomal 
maturation, as was proposed to be defective by Ghigo et al. We chose several genes known 
to be crucially involved in phagolysosomal maturation of the Coxiella Containing Vacuole 
(CCV), such as Rabs, LAMPs, SNARE-proteins and cathepsins [80, 177, 289]. The second 
group was composed of genes in microbial killing, such as genes necessary for the forma-
tion of reactive oxygen species, nitric oxide, innate immune receptor P2RX7, and IDO. The 
final pathway was the autophagy pathway, a catabolic pathway for cell organelles and a 
defense mechanism for intracellular pathogens. In contrast to most pathogens, C. burnetii 
profits from the induction of the autophagy pathway and actively recruits autophagy mark-
ers to the CCV [84]. For every gene, several single nucleotide polymorphisms (SNPs) were 
selected based on localization and functional consequences. The prevalence of the SNPs 
in a group of chronic Q fever patients was compared to resolved Q fever controls with 
cardiovascular risk factors for chronic Q fever. In our study, the patient group was quite 
heterogeneous, with valvulopathy, vasculopathy and some immunosuppressed individuals. 
The control group was well matched for gender and their exposure to C. burnetii, but was 
slightly younger. The control individuals did have similar risk factors for chronic Q fever, 
except that the distribution of those risk factors was different within the groups. Of note, 
valvulopathy is less associated with progression to chronic Q fever than vasculopathy in 
the Netherlands. Despite these critical observations, the unique composition of the control 
group provided a chance to compare solely immunological factors between the groups. 
Two genetic variations were identified in every pathway: SNPs in RAB5A and RAB7A for 
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phagolysosomal maturation, two SNPs for the P2X7 receptor and a SNP in the genes 
MAP1LC3A and ATG5 of the autophagy pathway. The number of SNPs studied qualifies as 
multiple testing, but statistical measures to correct for these were not undertaken, instead, 
the results were validated by assessing the biological consequences of the identified SNPs. 
First, several SNPs were found to mediate the cytokine response to C. burnetii (RAB5A 
rs8682, RAB7A rs13081864 and MAP1LC3A rs1040747). In addition, several genes were 
up-regulated in chronic Q fever (ATG5) and differentially expressed by patients and controls 
in response to C. burnetii stimulation (P2RX7). 
Strikingly, there are many similarities with Mycobacterium tuberculosis, although several 
details are crucially different. First of all, a phagolysosomal maturation arrest is established 
by M. tuberculosis, mainly manifesting as defective conversion of Rab5 to Rab7 decorated 
phagolysosomes [290]. For C. burnetii, no such defect has been described, rather, Rab5 
and Rab7 participate in the formation of the CCV. The identified Rab5 and Rab7 poly-
morphisms in the chronic Q fever population may change the expression of the Rabs and 
thereby affect the efficiency of the phagolysosomal process. Secondly, of specific interest 
is the P2X7 receptor, an innate immune receptor gated by ATP, involved in inflamma-
some activation, apoptosis and reactive oxygen species production [291]. Loss-of-function 
rs3751143 in P2RX7 is a risk factor for the susceptibility to pulmonary tuberculosis [292] 
and leads to impaired killing capacity in individuals with the SNP [189]. The gain-of-
function SNP rs1718119 has been found to be associated with protection against ocular 
toxoplasmosis [190]. The third similarity is the involvement of the autophagy pathway 
in the defense against intracellular pathogens. Activation of autophagy in macrophages 
causes mycobacteria-containing phagosomes to mature into autolysosomes, which leads 
to reduced survival of the mycobacteria [293] and modulates cytokine responses of the 
host [294, 295]. A polymorphism in an autophagy gene, IRGM, was associated with M. 
tuberculosis susceptibility. In contrast, the Coxiella burnetii-mediated autophagosome 
trafficking towards the CCV and the acquisition of the autophagy marker LC3 lead to 
an increased survival of C. burnetii [84]. Polymorphisms in autophagy genes, MAP1LC3A 
rs1040747 and ATG5 rs2245214, were found more frequently in past Q fever controls 
and rs1040747 resulted in enhanced cytokine responses to C. burnetii by healthy controls. 
This study serves as a starting point for further research into these pathways, linking the 
previously found associations with C. burnetii survival to the development of chronic Q 
fever. The alternative validation methods, such as investigating the biological relevance 
of the found associations, strengthen the results. Replicating the results of this study in 
another cohort of chronic Q fever patients and controls would reinforce the associations 
tremendously. A topic of future studies could be to investigate the role of P2X7 receptor 
in the immune response to chronic Q fever and the role of autophagy in chronic Q fever. 
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Identifying patients with chronic Q fever is challenging. Seven to ten years after the 
epidemic, patients that were infected between 2007 and 2011 are still diagnosed with 
chronic Q fever. Many patients hardly have any symptoms of the infection, but suddenly 
present at the emergency department with a life-threatening complication. Therefore, 
screening asymptomatic patients that are known with aortic aneurysms, vascular prosthe-
ses, or prosthetic heart valves is a valuable method to detect chronically infected individuals 
[296]. Serology is the designated screening method, but other biomarkers that support the 
serology would be valuable [196]. Using an unbiased approach, we tried to identify new 
diagnostic biomarkers that reflect ongoing immunological activity in chapter 5. In a tran-
scriptome analysis, for which cells of chronic Q fever patients and controls were stimulated 
with heat-killed C. burnetii, we identified the top 4 genes that were most differentially 
expressed in chronic Q fever patients compared to controls. The first three genes (CXCL9, 
CXCL10, CXCL11) were found to be chemokines that were ligands for the CXCR3 receptor 
and all were induced by interferon-γ, the forth gene (CCL8) encoded another unrelated 
chemokine. The discriminatory capacity of the four chemokines was investigated in ex-vivo 
stimulated whole blood and (unstimulated) serum of chronic Q fever patients and various 
control groups, among which were acute Q fever patients, resolved Q fever individuals and 
healthy volunteers. One of the chemokines, CXCL9, was capable of discriminating resolved 
Q fever controls from chronic Q fever patients both after ex-vivo stimulation and in serum. 
The sensitivity and specificity of this test may be further validated in an independent cohort 
of patients and controls. 
In this study, we demonstrate another caveat in the diagnosis of chronic Q fever: chronic 
Q fever breaches the entrenched dogma of infection being accompanied with increased 
C-reactive protein (CRP). This is in sharp contrast to acute Q fever, where CRP is the only 
traditional infection marker that reflects disease activity and is associated with higher C. 
burnetii DNA loads [32, 297, 298]. Immunologically, this indicates that immune response 
for acute Q fever is different from immune mechanisms for chronic Q fever. In chronic Q 
fever, the acute IL-6 mediated inflammatory response may have ceded for IFNγ mediated 
immunity. Clinically, this implies that chronic Q fever should still be considered in patients 
with aneurysms or aortic prostheses suspected for an infection but without increased CRP 
concentration.
In addition to investigating the diagnostic capacity of CXCL9, we also followed a part 
of the patients prospectively, with the ultimate goal to use these markers for monitoring 
chronic Q fever during treatment. The markers did not correlate with treatment dura-
tion and only weakly with IgG phase I titers. However, most patients were not included 
at diagnosis, but at a variable time after start of treatment. It is debatable whether the 
immunological status of chronic Q fever patients after several months of treatment still 
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reflects the initial immunological constitution and whether IgG phase I titers represent 
treatment efficacy. An important matter of chronic Q fever research is therefore timing and 
multiple sequential measurements in contrast to only one measurement. For instance, the 
concentration of a circulating protein at time of diagnosis may vary per patient, but the 
decline rate could be similar. For chronic Q fever, time of diagnosis does not reflect time of 
disease initiation, as the delay in diagnosis is often substantial. Even time of infection does 
not necessarily reflect the time of progression to chronic Q fever, although the concept 
of a latent infection is probably incorrect for Q fever. Any delay in symptoms and signs 
could better be explained by clinical latency rather than microbiological latency, in other 
words, silent evolution. Evidence for this statement does not yet exist, but some reports 
give an indication that persistent infection slowly evolves rather than is characterized by 
reactivation of dormant bacteria [299]. 
The interaction of the immune system with C. burnetii is not a war, it is a hunt. A functional 
immune system is necessary to eradicate the bacterium. Generally, antibiotics aid in this 
natural immune-mediated eradication by depleting bacteria from essential nutrients, inhib-
iting bacterial protein synthesis, growth or replication. As outgrowth of bacteria increases 
exponentially, a timely immune response is of crucial importance. In this view, arguably, 
chronic Q fever can be seen as a failure of early immune responses, and antibiotic therapy 
can only slowly restore the balance, hence the long antibiotic therapy regimens. In the 
analogy of the hunt, the prey is slowed down by the antibiotic therapy as to give the hunter 
a chance to catch up. When this strategy fails, another approach would be to enhance the 
hunter. Immunotherapy can take multiple forms, from passive immunization to interferon-γ 
to treat a severe fungal infection or interferon-α in certain cases of hepatitis [300]. A 
persistent infectious disease such as chronic Q fever is the ideal candidate for immuno-
therapy. Two children with treatment resistant Q fever have been successfully treated with 
interferon-γ injections before [212, 213]. In chapter 6, we supplemented the first adult pa-
tient with chronic Q fever with interferon-γ. Although hampered by the insufficient means 
of monitoring the infection, no clear beneficial response could be detected. We concluded 
that, with the insights from the study performed by Schoffelen et al. in 2017 [29], IFNγ 
response is probably sufficient and addition of IFNγ does not improve the immune response 
to C. burnetii. That is, not in this patient who has been treated for 3 years already and is 
capable of mounting a robust IFNγ response to C. burnetii stimulation in-vitro. Although 
this first attempt was not encouraging, other immunotherapy strategies could potentially 
enhance the immune response to C. burnetii. Now that chronic Q fever is regarded as a local 
immunosuppressed state rather than an excess inflammatory state, parallels can be drawn 
with cancer treatment strategies, where immunotherapy has been given much attention. 
Reducing immunosuppressive mechanisms, for instance with immune checkpoint inhibitors 
instead of boosting pro-inflammatory signals could be another yet unexplored approach. 
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Part two of the thesis focused on immunological epiphenomena that are associated with 
C. burnetii infection. There are several scenario’s in which immunological epiphenomena 
become clinically relevant in Q fever. The first is at diagnosis. When individuals with un-
diagnosed chronic Q fever present with low-grade fever and several immunological phe-
nomena such as increased erythrocyte sedimentation rate and MGUS or autoantibodies, 
the differential diagnosis will be skewed into the direction of malignancies or autoimmune 
disease and it will lose the focus on infectious diseases. Secondly, we describe in chapter 7 
and chapter 9, that monitoring of the chronic Q fever infection was severely hampered by 
interference of cryoglobulins with anti-C. burnetii antibodies. Lastly, autoimmune diseases 
or immune-mediated disease that may occur with chronic Q fever, such as SLE or systemic 
sclerosis, can complicate the treatment of the infection. Because of the risk of disseminated 
chronic Q fever infection [301], immunosuppressive therapy should be prescribed with 
caution. Half of the chronic Q fever patients in chapter 9 had at least one auto-antibody 
and a third had B-cell dyscrasia. In chapter 8 we describe another immune-mediated 
disease that was unexpectedly common in chronic Q fever patients, systemic sclerosis or 
scleroderma. In clinical practice, the challenge of the coming years will be to deal with the 
complex interaction of appropriate and inappropriate immune responses. 
Another challenge in clinical practice will be to continue to monitor the treatment ef-
ficacy of chronic Q fever patients. Without better biomarkers and an understanding of 
the immune response against C. burnetii in chronic Q fever patients, guidance in critical 
decisions, such as on discontinuation of antibiotics is scarce. As in individuals with im-
munodeficiencies or check point inhibitors for cancer treatment, immunotherapy based 
on supplementing critical defects or inhibiting immunosuppressive regulatory mechanisms 
may aid those that do not respond to (antibiotic) therapy. Clues to understanding these im-
munological processes may lie in local immunological environment of C. burnetii infected 
aneurysms and heart-valves. 
There is much to learn about C. burnetii microbiology and infection. Peculiarly, this bacte-
rium has fooled scientists from the start. After the first outbreak in an abattoir, the infective 
agent was thought to be a virus, later it was classified in the group of Rickettsiae, before 
it was finally recognized as a γ proteobacterium. In an era of upcoming zoonotic diseases, 
we can learn from earlier outbreaks and anticipate on new outbreaks. The outbreak in the 
Netherlands provided the opportunity to study the response of chronic Q fever patients to 
C. burnetii. In future C. burnetii outbreaks, early identification of individuals at risk is crucial 
and thorough prospective immunological studies monitoring the evolution of chronic Q 
fever could provide new answers to old Queries. 
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wat is Q-koorts?
Q-koorts is een infectieziekte veroorzaakt door de bacterie Coxiella burnetii. De ziekte 
wordt overgedragen van dieren op mensen en verspreidt zich meestal via de lucht. Na 
inademing van bacteriën of sporen, kan men een griepachtig beeld ontwikkelen met 
koorts, een longontsteking of een leverontsteking. Dit ziektebeeld heet “Acute Q-koorts”. 
Hoewel acute Q-koorts meestal vanzelf geneest binnen een aantal weken, wordt soms 
kortdurend antibiotica voorgeschreven. Het grootste deel van de mensen dat besmet 
wordt, ervaart echter geen klachten en verwijdert de bacterie uit het lichaam zonder daar 
iets van te merken. Slechts bij vijf procent van de mensen gaat de infectie niet over en 
blijft de bacterie persisterend in het lichaam aanwezig; we spreken dan van “Chronische 
Q-koorts”. Mensen met chronische Q-koorts hebben doorgaans risicofactoren voor het 
ontwikkelen van een persisterende infectie. Deze risicofactoren zijn hartklepafwijkingen, 
een aneurysma van de aorta (dat is een verwijding van de grote lichaamsslagader) of een 
prothese van de aorta. Mensen met een verminderde afweer reactie of zwangere vrouwen 
hebben ook een grotere kans op het ontwikkelen van chronische Q-koorts. 
Tussen 2007 en 2011 vond er in Nederland de grootste Q-koorts epidemie ter wereld 
plaats, deze was vooral geconcentreerd in het Zuid-Oosten van het land. De bacteriën wer-
den uitgescheiden door besmette geiten tijdens het lammeren, waarna de bacteriën door 
de wind kon worden verspreid. De ligging van intensieve geitenhouderijen in de nabije 
omgeving van bewoond gebied heeft waarschijnlijk bijgedragen aan de grootschaligheid 
van de epidemie. Als gevolg van de epidemie zijn naar schatting ongeveer 40.000 mensen 
besmet (met of zonder klachten) en circa 300 mensen hebben een chronische infectie 
ontwikkeld. 
Een belangrijke vraag is waardoor sommige mensen een chronische infectie ontwikkelen 
terwijl de meeste mensen gewoon genezen van de acute Q-koorts. We weten dat hartkle-
paandoeningen en vaatwand afwijkingen de belangrijkste risicofactoren zijn, maar toch is 
een grote groep mensen met deze risico factoren die tijdens de epidemie acute Q-koorts 
kregen, hiervan normaal genezen. Er zijn dus waarschijnlijk, naast de al aanwezige hart-
klepaandoeningen en vaatwand afwijkingen, aanvullende risicofactoren nodig die de kans 
op chronische Q-koorts vergroten. Een verklaring zou kunnen zijn dat het afweer systeem 
(immuunsysteem) van chronische Q-koorts patiënten minder goed in staat is om Coxiella 
burnetii dood te maken. Het is nog onduidelijk welke immunologische processen hieraan 
ten grondslag liggen. 
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Het diagnosticeren van een chronische infectie wordt gedaan door middel van het aanto-
nen van antistoffen tegen Coxiella burnetii in het bloed, met behulp van een immuunflu-
orescentie test. Het aantonen van een lage concentratie IgG antistoffen betekent dat de 
patiënt de ziekte heeft gehad en is genezen. Een hoge concentratie (boven 1: 1024) kan 
wijzen op chronische ziekte. Het aantonen van de bacterie in bloed of in weefsel ná de 
acute ziekte, bewijst dat er chronische Q-koorts is. Dat gebeurt met de PCR techniek, waar-
bij DNA van de bacterie wordt aangetoond. De diagnose ‘bewezen’ chronische Q-koorts 
wordt pas gesteld als bij iemand, na de acute fase, Coxiella burnetii DNA is aangetoond of 
als iemand hoge antistoffen samen met een endocarditis (geïnfecteerde hartklep) of een 
geïnfecteerd aneurysma of aorta prothese heeft. Wanneer een patiënt niet geheel voldoet 
aan de criteria voor een ‘bewezen’ infectie, maar wel hoge antistoffen heeft in combinatie 
met risico factoren heeft, wordt de diagnose ‘waarschijnlijke’ chronische Q-koorts gesteld. 
Hoewel de hier genoemde diagnostische testen en criteria goede mogelijkheden bieden 
om chronische Q-koorts te diagnosticeren, zitten er ook nadelen aan en kunnen nieuwe 
aanvullende testen helpen om sneller en gemakkelijker de diagnose te stellen. 
De behandeling van chronische Q-koorts bestaat uit antibiotica gedurende minstens 
anderhalf jaar. Doxycycline in combinatie met het middel hydroxychloroquine, wat 
de werkzaamheid van de doxycycline op de plaats waar de bacterie zit vergroot, is de 
voorkeursbehandeling. Soms moet vanwege bijwerkingen of ineffectiviteit deze therapie 
gewisseld worden voor andere antibiotica. Vaak zijn hiernaast chirurgische ingrepen nodig 
om het geïnfecteerde materiaal te verwijderen of om bepaalde complicaties te behande-
len. Antibiotica vormen de hoeksteen van de behandeling van chronische Q-koorts, echter, 
sommige patiënten zouden kunnen profiteren van andere nieuwe aanvullende behande-
lingen, omdat zij veel bijwerkingen ervaren of omdat de antibiotica niet genoeg aanslaan. 
Het beloop van de chronische Q-koorts infectie wordt gemonitord met PET/CT-scans en 
bepalingen van de concentraties IgG-antistoffen. Dalende antistof concentraties in het 
bloed wijzen op het aanslaan van de therapie. Als de antistoffen voldoende zijn gedaald 
of onder een bepaalde grens komen kan de therapie gestaakt worden. Toch is het met de 
huidige methoden moeilijk te bepalen of de therapie daadwerkelijk gestaakt kan worden, 
bijvoorbeeld omdat sommige patiënten de afgesproken criteria niet bereiken. Er zijn dan 
ook extra testen nodig om de behandeling nauwkeuriger te kunnen vervolgen. 
Bij een aantal patiënten is bij de diagnose chronische Q-koorts ook een auto-immuunziekte 
vast gesteld. Het was nog niet duidelijk of er een verband is met chronische Q-koorts, wat 
de prevalentie (het voorkomen) is van auto-immuunziekten onder chronische Q-koorts 
patiënten en wat de consequenties zijn voor het beloop en voor de behandeling van 
chronische Q-koorts.
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wat is er onderzocht in dit proefschrift? 
Het onderzoek in dit proefschrift is gericht op de interactie tussen het afweer systeem en 
de Q-koorts bacterie tijdens chronische Q-koorts. 
Hierbij is geprobeerd een aantal vragen te beantwoorden: 
1. Wat zijn de immunologische factoren die bijdragen aan het ontwikkelen van chronische 
Q-koorts?
2. Welke immunologische markers worden specifiek door chronische Q-koorts patiënten 
tot expressie gebracht? Kunnen deze biomarkers worden gebruikt voor de diagnose dan 
wel het monitoren van het beloop van chronische Q-koorts?
3. Welke immunologische fenomenen komen voor bij chronische Q-koorts en wat is hun 
klinische relevantie?
1.  Wat zijn de immunologische factoren die bijdragen aan het ontwikkelen 
van chronische Q-koorts?
Omdat levende Coxiella burnetii bacteriën zeer besmettelijk zijn en bovendien geclas-
sificeerd zijn als potentieel biowapen, is het werken met deze levende bacterie niet 
zonder meer toegestaan. Daarom wordt voor onderzoek naar Q-koorts bijna altijd met 
hitte-geïnactiveerde Coxiella burnetii bacteriën gewerkt. Tot dusver was het echter niet 
bekend of er verschillen zijn in de afweerreactie tegen hitte-geïnactiveerde C. burnetii 
en levende C. burnetii, in het bijzonder bij chronische Q-koorts patiënten. In een speciaal 
daartoe uitgerust laboratorium in Lelystad (Wageningen Bioveterinary Research), vergele-
ken we daarom de immuun reacties op hitte-geïnactiveerde en levende C. burnetii. Het 
bleek nu dat immuuncellen van gezonde individuen en van chronische Q-koorts patiënten 
sommige signaalstoffen (cytokines) minder aanmaakten bij blootstelling aan levende C. 
burnetii dan na blootstelling aan hitte-geïnactiveerde C. burnetii. Een verklaring hiervoor 
zou kunnen zijn dat de afweercellen levende C. burnetii minder goed kunnen herkennen. 
De belangrijke cytokine interferon-γ, waarvan productie gemeten wordt in een eerder door 
ons ontwikkelde diagnostische test, werd echter wel evenveel aangemaakt na contact met 
hitte-geïnactiveerde en levende C. burnetii. De conclusie van dit onderzoek is echter dat 
resultaten van onderzoeken met geïnactiveerde C. burnetii niet eenvoudig vertaald kunnen 
worden naar levende bacteriën. 
Chronische Q-koorts patiënten hebben vaak een aneurysma, een verwijding van de grote 
lichaamsslagader. Coxiella burnetii is in staat om juist op deze verzwakte plek in de vaat-
wand te blijven overleven. Matrix metalloproteinases (MMPs) zijn stoffen die geassocieerd 
zijn met zowel aneurysmata als met infecties. MMPs zijn enzymen die de extracellulaire 
matrix ofwel de stof tussen de cellen (collageen, elastine) kunnen afbreken. MMPs zijn 
aanwezig in de aneurysmata, waar ze bijdragen aan het verzwakken van de vaatwand. Bij 
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een infectie zijn MMPs juist gunstig, omdat zij ervoor zorgen dat afweercellen de plaats 
van infectie kunnen bereiken. Bij een overschot aan MMP activiteit kunnen echter ook 
bacteriën zich gemakkelijker verspreiden. Wij onderzochten op vier manieren of MMPs 
een rol spelen bij de ontwikkeling van chronische Q-koorts. Eerst bekeken we kleine gene-
tische variaties in het DNA van patiënten en controle proefpersonen, deze kleine variaties 
in MMP-DNA kwamen vaker voor bij patiënten. Ten tweede bekeken we wat het effect 
was van het blootstellen van immuuncellen aan (hitte geïnactiveerde) Coxiella burnetii, 
dat leidt op gen niveau tot activatie van MMP-genen. Daarnaast is gemeten of er na 
contact met Coxiella burnetii ook daadwerkelijk MMP-eiwitten aangemaakt worden door 
de immuuncellen. Tenslotte bepaalden we in het bloed van chronische Q-koorts patiënten 
en bij controle groepen hoeveel MMPs er in het bloed circuleerden. Chronische Q-koorts 
patiënten hadden een grotere hoeveelheid MMPs in het bloed. Als interessante bijkomstig-
heid ontdekten we dat het antibioticum doxycycline, MMPs kan remmen. MMPs zouden 
dus een rol kunnen spelen bij het ontstaan of de progressie van chronische Q-koorts. 
Hoewel op het eerste gezicht het afweer systeem bij alle mensen hetzelfde lijkt te zijn, 
wordt niet iedereen op dezelfde manier ziek na blootstelling aan dezelfde bacterie. Een 
verklaring hiervoor, naast grote verschillen zoals geslacht, leeftijd, gewicht, en medicatie-
gebruik of ziekten, zijn kleine variaties in het DNA van de genen die coderen voor eiwitten 
die van belang zijn in de afweerreactie. Deze genetische variaties zijn meestal onschuldig, 
maar soms geven ze een klein voordeel of een klein nadeel bij blootstelling aan een bepaald 
pathogeen. Onze hypothese was dat dit ook voor Q-koorts zou kunnen gelden: sommige 
mensen met de gekende risico factoren zoals hartklep aandoeningen en vaatwand aandoe-
ningen, ontwikkelen – na infectie met Coxiella burnetii – wel chronische Q-koorts, terwijl 
anderen met dezelfde risicofactoren en dezelfde blootstelling geen chronische Q-koorts 
ontwikkelen. Wij onderzochten 66 genetische variaties in de genen die van belang zijn in 
de vroege afweer tegen Coxiella burnetii. We onderzochten of deze genetische variaties 
vaker voor komen bij 173 chronische Q-koorts patiënten, vergeleken met 184 mensen 
met een doorgemaakte Q-koorts infectie én dezelfde andere risicofactoren. Van zes ge-
netische variaties was inderdaad de prevalentie verschillend tussen beide groepen. Twee 
genetische variaties kwamen vaker voor bij chronische Q-koorts patiënten, het hebben van 
zo’n variatie levert dus een klein aanvullend risico op voor het ontwikkelen van chronische 
Q-koorts. Verrassend genoeg kwamen vier variaties juist vaker voor bij de mensen die 
ondanks hun risicofactoren geen chronische Q-koorts hadden ontwikkeld. Blijkbaar is het 
hebben van een van deze genetische variaties beschermend. Voor sommige genetische 
variaties konden we aantonen dat zij daadwerkelijk een effect hadden op de afweerreactie 
tegen Coxiella burnetii. Immuuncellen van mensen met deze genetische variaties maakten 
minder van sommige cytokines aan na contact met Coxiella burnetii. We concludeerden 
dan ook dat bepaalde genetische variaties in de afweer-genen tegen Coxiella burnetii kun-
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nen bijdragen aan het ontwikkelen van chronische Q-koorts. Daardoor kunnen we meer 
onderzoek naar deze genen gaan doen. Mogelijk zouden we in de toekomst, als meer 
van dit soort genetische variaties zijn aangetoond, kunnen voorspellen wie tijdens een 
epidemie meer én wie minder kans heeft op het krijgen van chronische Q-koorts. 
Een van de belangrijkste cytokines in de afweer tegen chronische Q-koorts is interferon-γ 
(IFNγ). Deze signaalstof kan de immuuncellen activeren en het doden van intracellulaire 
pathogenen verbeteren. Eerder zijn twee jonge kinderen met een langdurige (acute) Q-
koorts infectie succesvol behandeld met extra IFNγ, toegediend via injecties. Wij hebben 
een volwassen chronische Q-koorts patiënt, die veel bijwerkingen had van de huidige 
antibiotica, aanvullend behandeld met IFNγ injecties gedurende 6 maanden. Het bleek 
dat er na 6 maanden geen verbetering was opgetreden in de laboratorium waarden of 
de PET-scan. Hierna is de IFNγ therapie dan ook weer gestopt en is doorgegaan met het 
gebruikelijke antibiotica regime. Uit het behandelen van deze ene patiënt zijn nog geen 
goede conclusies te trekken, mogelijk is IFNγ therapie alleen succesvol als er een tekort 
is aan deze stof. De mogelijkheid voor andere immuuntherapieën zou wel onderzocht 
kunnen worden.
2.  Welke immunologische markers worden specifiek door chronische 
Q-koorts patiënten tot expressie gebracht? Kunnen deze biomarkers 
worden gebruikt voor de diagnose dan wel monitoring van chronische 
Q-koorts?
Het doel van hoofdstuk 4 was het identificeren van biomarkers voor chronische Q-koorts, 
stoffen die als test kunnen worden gebruikt bij het stellen van de diagnose én bij het 
monitoren van de behandeling van deze ziekte. We keken opnieuw naar hoe immuuncel-
len reageren op Coxiella burnetii en vergeleken daarbij chronische Q-koorts patiënten met 
gezonde vrijwilligers, en bepaalden de genexpressie van circa 32.000 genen waarbij werd 
bepaald voor welke genen de expressie het meest verschilde tussen patiënten en controles. 
Hieruit identificeerden we 4 chemokines, dat zijn stoffen die zorgen voor het aantrekken 
van immuuncellen. Drie van deze chemokines (genaamd CXCL9, CXCL10 en CXCL11) be-
hoorden tot dezelfde groep. Daarop is in het bloed van de patiënten en controle groepen 
de concentratie van deze chemokines bepaald. We vonden dat CXCL9 verschilde tussen 
chronische Q-koorts patiënten en mensen met doorgemaakte Q-koorts en dat we met 
behulp van deze CXCL9 voor circa 70% goed konden voorspellen wie er chronische Q-
koorts had en wie doorgemaakte Q-koorts. Deze chemokines bleken helaas niet geschikt 
om de behandeling van chronische Q-koorts te monitoren. We kunnen uit dit onderzoek 
concluderen dat CXCL9 een biomarker is voor het diagnosticeren van chronische Q-koorts. 
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3.  Welke immunologische fenomenen komen voor bij chronische Q-koorts 
en wat is hun klinische relevantie?
Auto-immuniteit ontstaat wanneer lichaamseigen componenten worden herkend door het 
verworven immuunsysteem, bijvoorbeeld doordat er zogenaamde auto-antistoffen worden 
aangemaakt. Er wordt gesproken van een auto-immuunziekte als dit leidt tot weefsel-
schade en klachten. Veel gezonde mensen hebben auto-antistoffen, maar dit hoeft niet te 
betekenen dat zij een auto-immuunziekte hebben. Auto-antistoffen ontstaan meestal bij 
mensen die daar genetisch kwetsbaar voor zijn in combinatie met bepaalde uitlokkende 
factoren, zoals een infectie. In dit opzicht is het niet verrassend dat chronische Q-koorts 
gepaard kan gaan met auto-immuniteit. Het is echter wel belangrijk om te bepalen of 
deze auto-immuniteit leidt tot klinische consequenties of dat het slechts om een passagère 
of bystander fenomeen gaat. Wij hebben eerst in de medische literatuur gezocht naar 
artikelen die Q-koorts patiënten met auto-immuniteit rapporteerden en deze systematisch 
beschreven in een review van de literatuur. We vonden dat bepaalde auto-antistoffen bij 
acute Q-koorts patiënten werden aangetoond, en andere auto-antistoffen bij chronische Q-
koorts patiënten. We vonden ook 5 beschrijvingen van een chronische Q-koorts patiënt met 
cryoglobulinemie, een antistof die bij koude temperatuur immuuncomplexen kan vormen 
wat kan neerslaan in weefsels. Na deze literatuur inventarisatie, hebben we auto-immuun 
fenomenen onderzocht in 40 patiënten die in het Radboudumc onder behandeling waren. 
De helft van de patiënten bleek auto-antistoffen in het bloed te hebben; 6 patiënten 
hadden ook een auto-immuunziekte. Een van de opvallende (auto-)immuun-gemedieerde 
ziekten was systemische sclerose, een zeldzame ernstige ziekte gepaard gaande met fibrose 
van de huid en interne organen. Patiënten met deze ziekte hebben we apart beschreven in 
een ander hoofdstuk. Van de chronische Q-koorts patiënten in het Radboudumc was er bij 
ongeveer een kwart cryoglobulinemie aanwezig. De auto-immuun fenomenen leidden in 
een aantal patiënten tot complexe situaties wat betreft de diagnose, het vervolgen van het 
beloop van de ziekte en/of de behandeling van de Q-koorts. We kunnen concluderen dat 
auto-immuniteit en cryoglobulinemie regelmatig voorkomen in associatie met chronische 
Q-koorts en dat zij diagnose, beloop en behandeling compliceren.
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